<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004314.pub3" GROUP_ID="MOVEMENT" ID="669503050516273135" MERGED_FROM="" MODIFIED="2016-10-11 14:23:46 +0100" MODIFIED_BY="Ema Roque" REVIEW_NO="" REVMAN_SUB_VERSION="5.2.7 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.3">
<COVER_SHEET MODIFIED="2016-10-11 14:10:26 +0100" MODIFIED_BY="Ema Roque">
<TITLE>Botulinum toxin type A versus botulinum toxin type B for cervical dystonia</TITLE>
<CONTACT>
<PERSON ID="FDF5556E82E26AA201D6C2758D661DA8" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>João</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Costa</LAST_NAME>
<SUFFIX>MD, PhD</SUFFIX>
<POSITION/>
<EMAIL_1>jncosta@medicina.ulisboa.pt</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Clinical Pharmacology Unit</DEPARTMENT>
<ORGANISATION>Instituto de Medicina Molecular</ORGANISATION>
<ADDRESS_1>Avenida Professor Egas Moniz</ADDRESS_1>
<ADDRESS_2/>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION/>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2016-10-11 14:10:26 +0100" MODIFIED_BY="Ema Roque">
<PERSON ID="z1307091141448665579807736261374" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Gonçalo</FIRST_NAME>
<MIDDLE_INITIALS>S</MIDDLE_INITIALS>
<LAST_NAME>Duarte</LAST_NAME>
<SUFFIX/>
<POSITION>Researcher</POSITION>
<EMAIL_1>gduarte@campus.ul.pt</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+351914662729</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Laboratório de Farmacologia Clínica e Terapêutica</DEPARTMENT>
<ORGANISATION>Faculdade de Medicina de Lisboa</ORGANISATION>
<ADDRESS_1>Avenida Professor Egas Moniz</ADDRESS_1>
<ADDRESS_2/>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION>Lisboa</REGION>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1>+351914662729</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE>These authors contributed equally to this work</FOOTNOTE>
</PERSON>
<PERSON ID="z1309131047147899672215461982225" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Mafalda</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Castelão</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>mcastelao@outlook.com</EMAIL_1>
<EMAIL_2/>
<URL>www.medicina.ulisboa.pt</URL>
<MOBILE_PHONE>+351969668033</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Laboratório de Farmacologia Clínica e Terapêutica</DEPARTMENT>
<ORGANISATION>Faculdade de Medicina de Lisboa</ORGANISATION>
<ADDRESS_1>Av. Prof. Egas Moniz</ADDRESS_1>
<ADDRESS_2/>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION/>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE>These authors contributed equally to this work</FOOTNOTE>
</PERSON>
<PERSON ID="z1408111518211702342261129499685" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Filipe</FIRST_NAME>
<MIDDLE_INITIALS>B</MIDDLE_INITIALS>
<LAST_NAME>Rodrigues</LAST_NAME>
<SUFFIX>MD</SUFFIX>
<POSITION>Researcher</POSITION>
<EMAIL_1>filipebrodrigues@gmail.com</EMAIL_1>
<EMAIL_2>f.rodrigues@ucl.ac.uk</EMAIL_2>
<URL/>
<MOBILE_PHONE>00447484169226</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Laboratório de Farmacologia Clínica e Terapêutica</DEPARTMENT>
<ORGANISATION>Faculdade de Medicina de Lisboa</ORGANISATION>
<ADDRESS_1>Avenida Professor Egas Moniz</ADDRESS_1>
<ADDRESS_2/>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION/>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE>These authors contributed equally to this work</FOOTNOTE>
</PERSON>
<PERSON ID="z1309131050199323179683584225320" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Raquel</FIRST_NAME>
<MIDDLE_INITIALS>E</MIDDLE_INITIALS>
<LAST_NAME>Marques</LAST_NAME>
<SUFFIX/>
<POSITION>Researcher</POSITION>
<EMAIL_1>amarques5@campus.ul.pt</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Laboratório de Farmacologia Clínica e Terapêutica</DEPARTMENT>
<ORGANISATION>Faculdade de Medicina de Lisboa</ORGANISATION>
<ADDRESS_1>Av. Professor Egas Moniz</ADDRESS_1>
<ADDRESS_2/>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION/>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE>These authors contributed equally to this work</FOOTNOTE>
</PERSON>
<PERSON ID="6005" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Joaquim</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Ferreira</LAST_NAME>
<SUFFIX/>
<POSITION>Director</POSITION>
<EMAIL_1>joaquimjferreira@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Laboratório de Farmacologia Clínica e Terapêutica</DEPARTMENT>
<ORGANISATION>Faculdade de Medicina de Lisboa</ORGANISATION>
<ADDRESS_1>Hospital de Santa Maria</ADDRESS_1>
<ADDRESS_2>Av. Prof. Egas Moniz</ADDRESS_2>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION/>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1>+ 351 21 797 3453</PHONE_1>
<PHONE_2/>
<FAX_1>+ 351 21 780 2129</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6111" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Cristina</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Sampaio</LAST_NAME>
<SUFFIX/>
<POSITION>Chief Medical Officer</POSITION>
<EMAIL_1>Cristina.Sampaio@chdifoundation.org</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>CHDI Foundation</ORGANISATION>
<ADDRESS_1>155 Village Boulevard</ADDRESS_1>
<ADDRESS_2>Suite 200</ADDRESS_2>
<CITY>Princeton</CITY>
<ZIP>08540</ZIP>
<REGION>NJ</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14820" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Austen</FIRST_NAME>
<MIDDLE_INITIALS>P</MIDDLE_INITIALS>
<LAST_NAME>Moore</LAST_NAME>
<SUFFIX>MD</SUFFIX>
<POSITION/>
<EMAIL_1>peter.moore@thewaltoncentre.nhs.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>The Walton Centre NHS Foundation Trust</ORGANISATION>
<ADDRESS_1>Lower Lane</ADDRESS_1>
<ADDRESS_2/>
<CITY>Liverpool</CITY>
<ZIP>L9 7LJ</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+ 44 151 225 3611</PHONE_1>
<PHONE_2/>
<FAX_1>+ 44 151 529 4638</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="FDF5556E82E26AA201D6C2758D661DA8" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>João</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Costa</LAST_NAME>
<SUFFIX>MD, PhD</SUFFIX>
<POSITION>Co-ordinating Editor</POSITION>
<EMAIL_1>jncosta@medicina.ulisboa.pt</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Laboratório de Farmacologia Clínica e Terapêutica</DEPARTMENT>
<ORGANISATION>Faculdade de Medicina de Lisboa</ORGANISATION>
<ADDRESS_1>Av. Prof. Egas Moniz</ADDRESS_1>
<ADDRESS_2/>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION/>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1>+351 217802120</PHONE_1>
<PHONE_2/>
<FAX_1>+351 21 7802129</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2016-10-11 12:11:45 +0100" MODIFIED_BY="João Costa">
<UP_TO_DATE>
<DATE DAY="26" MONTH="10" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="26" MONTH="10" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2005"/>
<LAST_CITATION_ISSUE ISSUE="10" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2016-10-07 00:10:44 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-10-07 00:10:44 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="6" MONTH="10" YEAR="2016"/>
<DESCRIPTION>
<P>Three new trials enrolling a total of 270 participants were included in the meta-analysis and systematic review (Comella 2005; Pappert 2008; Tintner 2005)</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2016-10-03 21:27:45 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="9" MONTH="5" YEAR="2016"/>
<DESCRIPTION>
<P>New authorship, accumulation of changes, reassessment and writing according to new quality standards, addition of a 'Summary of findings' table</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2016-05-09 19:13:51 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-05-09 19:13:51 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="5" MONTH="5" YEAR="2003"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Cochrane Movement Disorders Group</NAME>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>The Walton Centre for Neurology and Neurosurgery</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-10-11 14:11:13 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2016-10-05 23:08:33 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2016-02-19 20:34:01 +0000" MODIFIED_BY="[Empty name]">A comparison of botulinum toxin type A versus botulinum toxin type B for involuntary positioning of the head, or cervical dystonia</TITLE>
<SUMMARY_BODY MODIFIED="2016-10-05 23:08:33 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>The review question</B>
</P>
<P>We reviewed the evidence about the effect of botulinum toxin type A (BtA) compared to botulinum toxin type B (BtB) in people with involuntary positioning of the head, or cervical dystonia. This is an update of a previous Cochrane Review and we assessed the effectiveness (reduction in severity, disability and pain) and safety of BtA versus BtB in cervical dystonia.</P>
<P>
<B>Background</B>
</P>
<P>Cervical dystonia, also called spasmodic torticollis, is a disease that causes undesired, uncontrollable, often painful, abnormal placement of the head. It is a relatively uncommon condition (affecting 57 to 280 people per million) that can be very disabling and can affect a person's quality of life negatively. In most cases the cause is unknown and no cure exists. Since cervical dystonia is normally a long-term disease it requires long-term treatment.</P>
<P>Botulinum toxin (Bt) is a powerful, natural chemical that can cause severe paralysis (an inability to move in the part of the body where it is applied) in animals and humans<I>. </I>It can also be used to treat many conditions, in particular those with involuntary muscle contractions, such as cervical dystonia. Bt is delivered by injections into the muscles that contract to produce the disease. There are different types of Bt, not all are available for treating health conditions. BtA is typically the first-used treatment in cervical dystonia, but botulinum toxin type B (BtB) is an alternative option. The relative strength of each Bt formulation is variable, and the cost for 200 units varies from GBP 198 to GBP 308.</P>
<P>
<B>Study characteristics </B>
</P>
<P>We performed a rigorous search of the medical literature in October 2016 and found three studies that compared a single treatment session of BtA with BtB. These studies included a total of 270 participants, with on average a moderate disease impairment. The participants remained in the studies for a short period of time - between 16 and 20 weeks after the treatment. The average age of people in the studies was 53.3 years, and they had had cervical dystonia for an average of 6.6 to 7.9 years before taking part in the trials. Most, 63.3%, of the people in the studies were women. All three of the studies were funded by drug manufacturers with possible interests in the results of the studies.</P>
<P>
<B>Key results </B>
</P>
<P>The results show little or no difference between BtA and BtB in the main measures of overall improvement and safety, including the total number of adverse (unwanted or harmful) events. There was also little or no difference between BtA and BtB in the self-evaluations reported by the study participants. Based on the results we would expect that, out of 1000 people with cervical dystonia treated with BtB, there would be 362 more people who experience dry mouth/sore throat compared to 1000 people treated with BtA. The studies which looked at the duration of effect showed little or no difference between BtA and BtB. None of the studies examined the impact of either Bt on quality of life.</P>
<P>
<B>Quality of the evidence </B>
</P>
<P>All of the studies included participants that were different to the average person who suffers from cervical dystonia. To be included participants had to have a history of successful treatment with Bt. People with certain types of cervical dystonia, in particular the forms that make the head turn backward or forward, were not allowed to participate in the studies.</P>
<P>Not enough participants were included across the studies for us to be completely confident in the results for the total number of adverse events, the self-reported evaluations by participants or the pain assessment.</P>
<P>The quality of the evidence for overall improvement and total number of adverse events was low. The quality of the evidence for more sore throat/dry mouth in people receiving BtB is moderate. The quality of the evidence where participants gave their self-assessments is low.</P>
<P>No definite conclusions can be drawn regarding overall safety and long-term utility of BtA compared to BtB in cervical dystonia.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-10-05 23:08:17 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2016-10-03 21:16:11 +0100" MODIFIED_BY="[Empty name]">
<P>This is an update of a Cochrane review first published in 2003. Cervical dystonia is the most common form of focal dystonia and is a disabling disorder characterised by painful involuntary head posturing. There are two available formulations of botulinum toxin, with botulinum toxin type A (BtA) usually considered the first line therapy for this condition. Botulinum toxin type B (BtB) is an alternative option, with no compelling theoretical reason why it might not be as- or even more effective - than BtA.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2016-05-09 19:24:49 +0100" MODIFIED_BY="[Empty name]">
<P>To compare the efficacy, safety and tolerability of botulinum toxin type A (BtA) versus botulinum toxin type B (BtB) in people with cervical dystonia.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-10-05 23:08:17 +0100" MODIFIED_BY="[Empty name]">
<P>To identify studies for this review we searched the Cochrane Movement Disorders Group Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, reference lists of articles and conference proceedings. All elements of the search, with no language restrictions, were last run in October 2016.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2016-10-03 21:16:33 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blind, parallel, randomised, placebo-controlled trials (RCTs) comparing BtA versus BtB in adults with cervical dystonia.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2016-10-03 21:48:03 +0100" MODIFIED_BY="[Empty name]">
<P>Two independent authors assessed records, selected included studies, extracted data using a paper pro forma, and evaluated the risk of bias. We resolved disagreements by consensus or by consulting a third author. We performed meta-analyses using the random-effects model, for the comparison BtA versus BtB to estimate pooled effects and corresponding 95% confidence intervals (95% CI). No prespecified subgroup analyses were carried out. The primary efficacy outcome was improvement on any validated symptomatic rating scale, and the primary safety outcome was the proportion of participants with adverse events.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-10-03 23:42:59 +0100" MODIFIED_BY="[Empty name]">
<P>We included three RCTs, all new to this update, of very low to low methodological quality, with a total of 270 participants.</P>
<P>Two studies exclusively enrolled participants with a known positive response to BtA treatment. This raises concerns of population enrichment, with a higher probability of benefit from BtA treatment. None of the trials were free of for-profit bias, nor did they provide information regarding registered study protocols. All trials evaluated the effect of a single Bt treatment session, and not repeated treatment sessions, using doses from 100 U to 250 U of BtA (all onabotulinumtoxinA, or Botox, formulations) and 5000 U to 10,000 U of BtB (rimabotulinumtoxinB, or Myobloc/Neurobloc).</P>
<P>We found no difference between the two types of botulinum toxin in terms of overall efficacy, with a mean difference of -1.44 (95% CI -3.58 to 0.70) points lower on the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) for BtB-treated participants, measured at two to four weeks after injection. The proportion of participants with adverse events was also not different between BtA and BtB (BtB versus BtA risk ratio (RR) 1.40; 95% CI 1.00 to 1.96). However, when compared to BtA, treatment with BtB was associated with an increased risk of one adverse events of special interest, namely treatment-related sore throat/dry mouth (BtB versus BtA RR of 4.39; 95% CI 2.43 to 7.91). Treatment-related dysphagia (swallowing difficulties) was not different between BtA and BtB (RR 2.89; 95% CI 0.80 to 10.41). The two types of botulinum toxin were otherwise clinically non-distinguishable in all the remaining outcomes.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-10-03 21:17:59 +0100" MODIFIED_BY="[Empty name]">
<P>The previous version of this review did not include any trials, since these were still ongoing at the time. Therefore, with this update we are able to change the conclusions of this review. There is low quality evidence that a single treatment session of BtA (specifically onabotulinumtoxinA) and a single treatment session of BtB (rimabotulinumtoxinB) are equally effective and safe in the treatment of adults with certain types of cervical dystonia. Treatment with BtB appears to present an increased risk of sore throat/dry mouth, compared to BtA. Overall, there is no clinical evidence from these single-treatment trials to support or contest the preferential use of one form of botulinum toxin over the other.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-10-09 11:44:16 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2016-10-03 23:29:28 +0100" MODIFIED_BY="[Empty name]">
<P>This review is an update of a previously published review in the <I>Cochrane Database of Systematic Reviews</I> 2003, Issue 3 (<LINK REF="REF-Costa-2003" TYPE="REFERENCE">Costa 2003</LINK>), evaluating the efficacy and safety of botulinum toxin type A (BtA) versus botulinum toxin type B (BtB) in the treatment of cervical dystonia.</P>
<CONDITION MODIFIED="2016-10-03 23:29:28 +0100" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> for glossary of terms.</P>
<P>Dystonia is the third most common movement disorder, after Parkinson&#8217;s disease and essential tremor, with an overall prevalence of 164 per million (<LINK REF="REF-Steeves-2012" TYPE="REFERENCE">Steeves 2012</LINK>). Dystonia syndromes are a group of disabling, painful disorders characterised by involuntary sustained or intermittent muscle contractions that cause abnormal, often repetitive, movements or postures of the face, neck, trunk or limbs (<LINK REF="REF-Albanese-2013" TYPE="REFERENCE">Albanese 2013</LINK>). Dystonic movements are typically patterned or twisting, and are often initiated or worsened by voluntary action (<LINK REF="REF-Albanese-2013" TYPE="REFERENCE">Albanese 2013</LINK>). These neurological disorders can be classified on the basis of topographic distribution, including focal dystonia (one body region, e.g. cervical dystonia (involuntary movements of head and neck) and blepharospasm (involuntary closure of the eyes)), segmental dystonia (two or more adjacent regions), multifocal dystonia (two or more nonadjacent regions), hemidystonia (ipsilateral regions (same side of the body)) and generalised dystonia (trunk and two or more other regions) (<LINK REF="REF-Albanese-2013" TYPE="REFERENCE">Albanese 2013</LINK>; <LINK REF="REF-Tarsy-2006" TYPE="REFERENCE">Tarsy 2006</LINK>).</P>
<P>Focal dystonia is a highly disabling movement disorder, with serious functional and social impairment. Close to half of the dystonia patient population quits work by the age of forty or retires early due to the condition, and 10 years later, only 25% of people are working compared to 62% of the general population (<LINK REF="REF-Zoons-2012" TYPE="REFERENCE">Zoons 2012</LINK>). Moreover, health-related quality of life is significantly diminished, mainly due to depression and anxiety, with scores comparable to people with multiple sclerosis, Parkinson&#8217;s disease or stroke (<LINK REF="REF-Zoons-2012" TYPE="REFERENCE">Zoons 2012</LINK>).</P>
<P>Cervical dystonia, also called spasmodic torticollis, is the most common form of adult-onset focal dystonia, with estimates from population studies ranging from 57 per million in Europe (<LINK REF="REF-ESDE-2000" TYPE="REFERENCE">ESDE 2000</LINK>), to as high as 280 per million in the USA (<LINK REF="REF-Jankovic-2006" TYPE="REFERENCE">Jankovic 2006</LINK>). Typically, its onset occurs in the fifth decade of life (<LINK REF="REF-Albanese-2013" TYPE="REFERENCE">Albanese 2013</LINK>), and it affects more women than men (<LINK REF="REF-Defazio-2013" TYPE="REFERENCE">Defazio 2013</LINK>). This condition is characterised by abnormal movements of head, neck, and shoulder, resulting in posturing of the head away from its normal central position (<LINK REF="REF-Foltz-1959" TYPE="REFERENCE">Foltz 1959</LINK>). It may present predominantly with sustained abnormal posture, spasm, jerks, tremor, or a combination of these features. Neck or shoulder pain, or both, occur in more than 70% of individuals with cervical dystonia (<LINK REF="REF-Chan-1991" TYPE="REFERENCE">Chan 1991</LINK>; <LINK REF="REF-Tarsy-2006" TYPE="REFERENCE">Tarsy 2006</LINK>).</P>
<P>Cervical dystonia can be classified according to the dominant head position, with the most common type involving horizontal turning, the so-called rotatory (or simple) torticollis (<LINK REF="REF-Albanese-2013" TYPE="REFERENCE">Albanese 2013</LINK>; <LINK REF="REF-Chan-1991" TYPE="REFERENCE">Chan 1991</LINK>). Other common patterns include laterocollis (tilt to one side), retrocollis (tilt upwards resulting in neck extension) and anterocollis (tilt downwards resulting in neck flexion). Complex torticollis is a combination of these abnormal patterns, and is found relatively infrequently in clinical practice.</P>
<P>The aetiology of most forms of dystonia is still not fully understood, with the exception of early-onset dystonia, for which a hereditary aetiology is common (<LINK REF="REF-Balint-2015" TYPE="REFERENCE">Balint 2015</LINK>). In most cases of focal adult-onset dystonia, such as cervical dystonia, the pathophysiology is generally considered to result from inhibition of the central nervous system (CNS) at multiple levels (<LINK REF="REF-Hallett-1998" TYPE="REFERENCE">Hallett 1998</LINK>), resulting in abnormal sensorimotor integration. Cervical dystonia can also be secondary to brain injury, infections of the CNS, drugs (such as levodopa or antipsychotics), toxins, vascular or neoplastic disorders, and may also be psychogenic (i.e. have a psychological origin) (<LINK REF="REF-Albanese-2013" TYPE="REFERENCE">Albanese 2013</LINK>). Although most cases of cervical dystonia are currently classified as idiopathic (of unknown cause), it should be observed that some may come to be reclassified as inherited, since new gene discoveries are under investigation (<LINK REF="REF-Albanese-2013" TYPE="REFERENCE">Albanese 2013</LINK>; <LINK REF="REF-Balint-2015" TYPE="REFERENCE">Balint 2015</LINK>).</P>
<P>The natural course of cervical dystonia remains unclear. It usually develops gradually and worsens over the initial years. The clinical presentation in adults seldom progresses to generalised dystonia, although it often extends to contiguous body regions. For most individuals, cervical dystonia is a life-long disorder, with only about 10% undergoing spontaneous remissions (<LINK REF="REF-Jahanshani-1990" TYPE="REFERENCE">Jahanshani 1990</LINK>).</P>
<P>To date, no curative or disease-modifying treatments are available for cervical dystonia.</P>
</CONDITION>
<INTERVENTION MODIFIED="2016-10-03 21:20:25 +0100" MODIFIED_BY="[Empty name]">
<P>Botulinum toxin (Bt) is a powerful biological toxin produced by the bacterium <I>Clostridium botulinum</I>. The active form of botulinum toxin is a polypeptide composed of two chains: a heavy chain (100 kDa) and a light chain (50 kDa), and by associating with certain auxiliary proteins (haemagglutinins and non-haemagglutinins), the toxin forms a complex of variable size (<LINK REF="REF-Simpson-2004" TYPE="REFERENCE">Simpson 2004</LINK>). The nontoxic proteins aid the formation of neutralising antibodies, though beyond this their role is unclear (<LINK REF="REF-Frevert-2010" TYPE="REFERENCE">Frevert 2010</LINK>). Bt binds to peripheral cholinergic nerve terminals of the neuromuscular junction as well as sympathetic, parasympathetic and postganglionic terminals (<LINK REF="REF-Simpson-2004" TYPE="REFERENCE">Simpson 2004</LINK>). Bt, after binding to an acceptor protein, is endocytosed at the presynaptic membrane of acetylcholine nerve terminals (<LINK REF="REF-Pellizzari-1999" TYPE="REFERENCE">Pellizzari 1999</LINK>). Through the action of the N-terminal on the heavy-chain, a pore is formed on the endocytic membrane, which permits the release of the light-chain into the cytosol. This light chain, which is a zinc protease, performs the key action of botulinum toxin, by cleaving soluble N-ethylmaleimide sensitive factor attachment receptor proteins (SNARE proteins) (<LINK REF="REF-Pellizzari-1999" TYPE="REFERENCE">Pellizzari 1999</LINK>).</P>
<P>SNAREs are docking proteins for acetylcholine vesicles that allow for the release of acetylcholine into the synaptic cleft (<LINK REF="REF-Pellizzari-1999" TYPE="REFERENCE">Pellizzari 1999</LINK>). As the fusion of the vesicle membranes becomes inhibited, there is a temporary blockade of acetylcholine release at cholinergic synapses, causing a local chemodenervation. Temporary synapses are consequently formed via the process of axonal sprouting (<LINK REF="REF-Duchen-1971" TYPE="REFERENCE">Duchen 1971</LINK>; <LINK REF="REF-Holland-1981" TYPE="REFERENCE">Holland 1981</LINK>; <LINK REF="REF-Juzans-1996" TYPE="REFERENCE">Juzans 1996</LINK>).</P>
<P>There are seven immunologically distinct botulinum toxin serotypes (labelled A to G). These different Bt serotypes cleave specific SNARE proteins. Serotype A cleaves SNARE protein SNAP 25 located on the inner membrane, and serotype B targets synaptobrevin located on the vesicular membrane (<LINK REF="REF-Pellizzari-1999" TYPE="REFERENCE">Pellizzari 1999</LINK>).</P>
<P>Botulinum toxin is injected into the muscles involved in dystonia, with or without guidance by either electromyography (EMG) or ultrasound. As a general rule, the overall dose, the number of muscles injected and the number of injection sites per muscle are tailored to the severity of the case and the mass of the muscle. Within roughly three months after injection of botulinum toxin into skeletal muscle, the nerve terminal resumes exocytosis, and the muscle returns to its baseline clinical function, showing a wearing off of response from the Bt injection (<LINK REF="REF-Jankovic-2004" TYPE="REFERENCE">Jankovic 2004</LINK>). Eventually, the muscle paralysis subsides, and this is associated with the formation of new nerve sprouts capable of neurotransmission. Over time, synaptic activity resumes in the original nerve terminals, leading to sprout regression (<LINK REF="REF-de-Paiva-1999" TYPE="REFERENCE">de Paiva 1999</LINK>).</P>
<P>Currently there are two commercially available botulinum toxin serotypes (BtA and BtB). The following products are commonly available (three BtA and one BtB): onabotulinumtoxinA (Botox, Allergan Inc, Irvine, CA, USA), abobotulinumtoxinA (Dysport/Reloxin/Azzalure, Ipsen Pharma, Boulogne Billancourt, France), incobotulinumtoxinA (Xeomin/Bocoture Merz GmbH, Frankfurt, Germany), and rimabotulinumtoxinB (Myobloc/Neurobloc, Solstice Neurosciences Inc, Louisville, KY, USA). Other BtA formulations are available in more restricted markets and are yet to receive a generic name: Prosigne/Lantox (Lanzhou Institute of Biological Products, China), PurTox (Mentor Worldwide LLC, Santa Barbara, CA, USA), and Neuronox (Medy-Tox Inc, South Korea) (<LINK REF="REF-Walker-2014" TYPE="REFERENCE">Walker 2014</LINK>). Each type of Bt has its own relative potency and it is estimated that 1 U of onabotulinumtoxinA roughly corresponds to 1 U of incobotulinumtoxinA, 3 U to 5 U of abobotulinumtoxinA, and 50 U of rimabotulinumtoxinB (<LINK REF="REF-Bentivoglio-2015" TYPE="REFERENCE">Bentivoglio 2015</LINK>). The treatment cost per patient for each of the formulations is highly variable, and depends greatly on the country and individual characteristics of the people being treated, including responsiveness to Bt and number of muscles affected. Having in mind the 2016 prices per vial for each of the formulations currently available in the UK, and their relative potencies, 200 U of onabotulinumtoxinA cost GBP 276, 200 U of incobotulinumtoxinA cost GBP 260, 600 U to 1000 U of abobotulinumtoxinA cost GBP 184 to GBP 308, and 10,000 U of rimabotulinumtoxinB cost GBP 198 (<LINK REF="REF-BNF-2016a" TYPE="REFERENCE">BNF 2016a</LINK>; <LINK REF="REF-BNF-2016b" TYPE="REFERENCE">BNF 2016b</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2016-10-03 21:20:32 +0100" MODIFIED_BY="[Empty name]">
<P>The therapeutic potential of all Bt serotypes derives from their ability to inhibit the release of acetylcholine from the presynaptic nerve terminal into the synaptic cleft, causing local chemodenervation (<LINK REF="REF-Jankovic-2004" TYPE="REFERENCE">Jankovic 2004</LINK>). In addition to this, recent research has also suggested that Bt is active at multiple levels, namely sensory nerve terminals, and muscle spindles, which leads to a reduction in sensory input and fewer muscle contractions (<LINK REF="REF-Filippi-1993" TYPE="REFERENCE">Filippi 1993</LINK>; <LINK REF="REF-Matak-2014" TYPE="REFERENCE">Matak 2014</LINK>; <LINK REF="REF-Rosales-1996" TYPE="REFERENCE">Rosales 1996</LINK>; <LINK REF="REF-Rosales-2010" TYPE="REFERENCE">Rosales 2010</LINK>).</P>
<P>It has also been suggested that cortical reorganisation may result from changes in the spinal cord, brainstem and central nervous pathways (<LINK REF="REF-Palomar-2012" TYPE="REFERENCE">Palomar 2012</LINK>). Animal research has shown the presence of supra-therapeutic levels of Bt by way of retrograde axonal transport and penetration of the central nervous system (<LINK REF="REF-Antonucci-2008" TYPE="REFERENCE">Antonucci 2008</LINK>; <LINK REF="REF-Boroff-1975" TYPE="REFERENCE">Boroff 1975</LINK>). However, Bt has not been shown to penetrate the blood-brain barrier in humans.</P>
<P>Until recently, SNARE proteins were considered to be the only target-molecules of Bt. Thus, it was widely accepted that the therapeutic and toxic actions of Bt were exclusively mediated by SNARE cleavage preventing the release of synaptic neurotransmitters. However, recent studies have suggested that a number of Bt actions might not be mediated by SNARE cleavage, specifically regarding neuroexocytosis, cell cycle (division) and apoptosis (programmed cell death), neuritogenesis (formation of nerves) and gene expression (<LINK REF="REF-Matak-2015" TYPE="REFERENCE">Matak 2015</LINK>). The existence of unknown Bt molecular targets and modulation of unknown signalling pathways is a possibility that may prove to be relevant pharmacologically.</P>
</THEORY>
<IMPORTANCE MODIFIED="2016-10-03 21:52:01 +0100" MODIFIED_BY="[Empty name]">
<P>BtA is the toxin serotype that has been most intensively studied and approved for the treatment of a large number of focal dystonias. BtA is considered the first line therapy for cervical dystonia (<LINK REF="REF-Albanese-2013" TYPE="REFERENCE">Albanese 2013</LINK>). However, not all people with cervical dystonia have an adequate clinical response. Primary non-response to Bt is seen in cases where the first and subsequent treatment cycles do not elicit a response. Cases of secondary non-response, however, respond to initial treatment, but over the course of multiple treatment cycles, this effect wanes and is eventually lost. Secondary non-responsiveness is partially explained by the formation of neutralising antibodies, though it is worth noting that there are cases of secondary non-responders without positive antibody titers (<LINK REF="REF-Hanna-1998" TYPE="REFERENCE">Hanna 1998</LINK>; <LINK REF="REF-Lange-2009" TYPE="REFERENCE">Lange 2009</LINK>), as well as cases with positive titers with a maintained clinical response to Bt (<LINK REF="REF-Brin-2008" TYPE="REFERENCE">Brin 2008</LINK>; <LINK REF="REF-M_x00fc_ller-2009" TYPE="REFERENCE">Müller 2009</LINK>). An estimated 4% to 20% of people with cervical dystonia develop neutralising antibodies to the toxin (<LINK REF="REF-Brashear-2008" TYPE="REFERENCE">Brashear 2008</LINK>; <LINK REF="REF-Fabbri-2015" TYPE="REFERENCE">Fabbri 2015</LINK>), and if secondary non-responsiveness occurs, it is partially related to the protein load, with a higher protein load per dose generating higher antibody titers (<LINK REF="REF-Benecke-2012" TYPE="REFERENCE">Benecke 2012</LINK>; <LINK REF="REF-Frevert-2010" TYPE="REFERENCE">Frevert 2010</LINK>).</P>
<P>At the present time, BtB is the only approved non-BtA formulation available for the treatment of cervical dystonia in the European Union and North America. Both BtA and BtB have been shown to be efficacious in comparison to placebo in the treatment of adults with cervical dystonia (<LINK REF="REF-Costa-2005" TYPE="REFERENCE">Costa 2005</LINK>; <LINK REF="REF-Marques-2016" TYPE="REFERENCE">Marques 2016</LINK>), although with apparently different safety profiles. In the context of cervical dystonia, BtB is of particular interest as a treatment option for individuals who are non-responsive to BtA (<LINK REF="REF-Cullis-2000" TYPE="REFERENCE">Cullis 2000</LINK>; <LINK REF="REF-Eleopra-1997" TYPE="REFERENCE">Eleopra 1997</LINK>; <LINK REF="REF-Greene-1993" TYPE="REFERENCE">Greene 1993</LINK>).</P>
<P>Although different Bt subtypes have different molecular targets, to date we know of no evidence from systematic reviews or randomised controlled trials that presents conclusive evidence regarding the comparative effectiveness of BtA and BtB for treating cervical dystonia.</P>
<P>This is an update of a Cochrane systematic review that previously assessed this question. The original review failed to included any trials addressing clinical comparability of BtA versus BtB in cervical dystonia. Since the release of the original review, three trials have been published (<LINK REF="STD-Comella-2005" TYPE="STUDY">Comella 2005</LINK>; <LINK REF="STD-Pappert-2008" TYPE="STUDY">Pappert 2008</LINK>; <LINK REF="STD-Tintner-2005" TYPE="STUDY">Tintner 2005</LINK>). Furthermore, Cochrane&#8217;s criteria for evaluating studies' risk of bias and quality of evidence have evolved and been updated. Therefore, the authors consider it important to update this review.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2016-05-09 19:53:17 +0100" MODIFIED_BY="[Empty name]">
<P>To compare the efficacy, safety and tolerability of botulinum toxin type A versus botulinum toxin type B in people with cervical dystonia.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-10-07 00:10:52 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2016-10-03 23:27:27 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2016-10-03 21:27:44 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs), blinded, single or multiple dose, parallel-designed, of any duration, assessing the efficacy or safety, or both, of treatment with BtA versus BtB in adults with cervical dystonia were eligible for inclusion in this review. If trials had used inadequate randomisation or allocation concealment methods we would have included these only in the safety analyses. Non-parallel study designs, namely cross-over trials, were excluded in this updated version of the review, due to uncertainty about whether this type of study design was appropriate for studying people with cervical dystonia, as well as methodological concerns with regard to detection and performance bias.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2016-10-03 21:21:03 +0100" MODIFIED_BY="[Empty name]">
<P>Adults (i.e. 18 years of age and over), in any setting, with a clinical diagnosis, made by any physician, specialist or otherwise, of idiopathic cervical dystonia. We included trials that enrolled participants with any form of cervical dystonia, and additional or more widespread dystonias. Participants could have prior exposure to BtA or BtB, and could be taking any concomitant medications, if on stable regimens.</P>
<P>There were no restrictions regarding the number of participants recruited to trials, or the number of recruitment centres.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2016-06-07 20:43:57 +0100" MODIFIED_BY="[Empty name]">
<P>Intramuscular injections of BtA compared to BtB. We allowed all administration schedules and injection techniques, performed with or without guidance by either EMG or ultrasound.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-10-03 23:27:27 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2016-10-03 23:27:27 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Primary efficacy outcome</HEADING>
<P>Overall improvement on any validated symptomatic rating scale, such as Tsui scale, Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), and Cervical Dystonia Severity Scale (CDSS), measured between weeks 3 and 6 post-injection.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Primary safety outcome</HEADING>
<P>Proportion of participants with any adverse event, measured at any point during study follow-up.</P>
</SUBSECTION>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2016-10-03 23:27:23 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Change in subjective evaluation of clinical status evaluated by both patients and clinicians, as assessed with validated assessment tools such as the Patient Subjective Assessment of Change, Patient Global Assessment of Improvement, Patient Evaluation of Global Response (PEGR), Patient and Physician Global Assessment of Change, Investigator Global Assessment of Efficacy (IGAE), Physician Global Assessment of Change (PGAC), and visual analogue scale (VAS) for symptom severity, measured between weeks 3 and 6 post-injection.</LI>
<LI>Changes in pain scores, as assessed with validated assessment tools such as the Patient Assessment of Pain, TWSTRS-pain sub-scale score, and VAS Pain score, measured between weeks 2 and 6 post-injection.</LI>
<LI>Changes in quality of life assessments, as assessed with validated assessment tools such as the Short Form 36 (SF-36) quality-of-life questionnaire, measured at any point during study follow-up.</LI>
<LI>Numbers of participants with adverse events of special interest, such as dysphagia, sore throat, and local injection-site pain, measured at any point during study follow-up.</LI>
<LI>Duration of effect, assessed by the number of days until need for reinjection or effect waning.</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-10-07 00:10:52 +0100" MODIFIED_BY="[Empty name]">
<P>For this update, we expanded the search strategy to capture all the search terms for BtA and BtB formulations that were available at the time of the search. We designed the search strategy to include other botulinum toxin formulations and other dystonic disorders that were also under revision by our group.</P>
<ELECTRONIC_SEARCHES MODIFIED="2016-10-07 00:10:52 +0100" MODIFIED_BY="[Empty name]">
<P>We ran the final search for the original version of this review in June 2003, based on the search strategy developed for the Movement Disorders Group to identify all papers from 1977, the first year botulinum toxin was used therapeutically in any condition. The search for the current update was run for the last time in October 2016.</P>
<P>For the identification of studies considered for inclusion in this review, we developed detailed search strategies for each database searched. Please see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for the CENTRAL strategy, <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> for the MEDLINE search strategy, and <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> for the EMBASE strategy.</P>
<P>We assessed non-English language papers, translated them as necessary and evaluated them for inclusion.</P>
<P>We did not search trial registries.</P>
<SUBSECTION>
<HEADING LEVEL="5">Databases searched</HEADING>
<UL>
<LI>Cochrane Movement Disorders Group trials register (June 2003);</LI>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL; the Cochrane Library 2016, Issue 11);</LI>
<LI>MEDLINE (1977 to 6 October 2016);</LI>
<LI>Embase (1977 to 6 October 2016).</LI>
</UL>
</SUBSECTION>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2016-10-05 23:09:14 +0100" MODIFIED_BY="[Empty name]">
<P>The search strategy also included:</P>
<UL>
<LI>searches through reference lists of located trials and review articles concerning botulinum toxin;</LI>
<LI>handsearch of abstracts of international congresses relevant in the fields of movement disorders and botulinum toxins, i.e. American Academy of Neurology, Movement Disorders Society, International Association of Parkinsonism and Related Disorders, and International Neurotoxin Association (1985 to October 2016);</LI>
<LI>personal communication with other researchers in the field;</LI>
<LI>contact with drug manufacturers;</LI>
<LI>whenever necessary, we contacted authors of published trials for further information and unpublished data.</LI>
</UL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-10-03 23:27:10 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2016-10-03 21:27:44 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors independently screened all titles and abstracts identified from searches to determine which met the inclusion criteria. We retrieved in full text any papers identified as potentially relevant by at least one author, or those without an available abstract. Two review authors independently screened full text articles, with discrepancies resolved by discussion and by consulting a third author where necessary to reach consensus. We collated duplicate publications and present these by individual study. The screening and selection process is outlined in a PRISMA flow chart (<LINK REF="REF-Liberati-2009" TYPE="REFERENCE">Liberati 2009</LINK>), see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-10-03 23:27:10 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors extracted data independently from included studies using a piloted data extraction form. Any discrepancies were resolved by discussion until consensus was reached, or through consultation with a third author where necessary. The authors extracted data on the following items from each study.</P>
<UL>
<LI>Participants: inclusion and exclusion criteria, demographics and clinical baseline characteristics, number and reasons for withdrawals, exclusions and loss to follow-up, if any.</LI>
<LI>Interventions: full description of intervention, duration of treatment period and follow-up, providers, and co-interventions, if any.</LI>
<LI>Comparisons: number of participants randomised to each arm, compliance and dropouts, reasons for dropouts, and ability to perform an intention-to-treat analysis.</LI>
<LI>Outcomes: definition of outcomes, use of validated measurement tools, time point measurements, change from baseline or post-interventional measures, and missing outcomes, if any.</LI>
<LI>Study design: interventional, randomised, controlled, double-blind.</LI>
</UL>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-10-03 21:55:54 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed the risk of bias of included studies according to the domains described in the Cochrane tool for assessing risk of bias (<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>), and classified the risk of bias for each domain as high, unclear, or low, and the overall assessment as high or low. We assessed two further domains, which are described below: 'for-profit bias' and 'enriched population'. We used the following definitions for each domain in the 'Risk of bias' assessment.</P>
<SUBSECTION>
<HEADING LEVEL="4">Random sequence generation</HEADING>
<UL>
<LI>Low risk of bias: the study performed sequence generation using computer random number generation or a random number table. Drawing lots, tossing a coin, shuffling cards, and throwing dice were adequate if an independent person not otherwise involved in the study performed them.</LI>
<LI>Unclear risk of bias: the study authors did not report the sequence generation method.</LI>
<LI>High risk of bias: the sequence generation method was not random.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<UL>
<LI>Low risk of bias: participants and investigators enrolling participants could not foresee assignment because one of the following, or an equivalent method, was used to conceal allocation: central allocation, sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes.</LI>
<LI>Unclear risk of bias: insufficient information available to permit a judgement of &#8216;low risk&#8217; or &#8216;high risk&#8217;.</LI>
<LI>High risk of bias: participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias.</LI>
</UL>
<P>In addition to these criteria, we considered the implications of baseline imbalances in prognostic factors affecting the trial outcomes, as these may lead to selection bias (<LINK REF="REF-Corbett-2014" TYPE="REFERENCE">Corbett 2014</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding of participants and personnel</HEADING>
<UL>
<LI>Low risk of bias: either of the following: no blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding; or blinding of participants and key study personnel ensured, and it is unlikely that the blinding could have been broken.</LI>
<LI>Unclear risk of bias: any of the following: insufficient information available to permit a judgement of &#8216;low risk&#8217; or &#8216;high risk&#8217;; or the trial did not address this outcome.</LI>
<LI>High risk of bias: either of the following: no blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding; or blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinded outcome assessment</HEADING>
<P>We considered blinding separately for different outcomes, as appropriate, and, to aid in the process, divided the domain into two categories: subjective and objective assessment.</P>
<UL>
<LI>Low risk of bias: either of the following: no blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding; or blinding of outcome assessment ensured, and it is unlikely that the blinding could have been broken.</LI>
<LI>Unclear risk of bias: any of the following: insufficient information available to permit a judgement of &#8216;low risk&#8217; or &#8216;high risk&#8217;; or the trial did not address this outcome.</LI>
<LI>High risk of bias: either of the following: no blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding; or blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Incomplete outcome data</HEADING>
<UL>
<LI>Low risk of bias: missing data were unlikely to make treatment effects depart from plausible values. The study used sufficient methods, such as multiple imputation, to handle missing data.</LI>
<LI>Unclear risk of bias: there was insufficient information available to assess whether missing data in combination with the method used to handle missing data were likely to induce bias to the results.</LI>
<LI>High risk of bias: the results were likely to be biased due to missing data.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Selective outcome reporting</HEADING>
<UL>
<LI>Low risk: the trial reported the following predefined outcomes: if the original trial protocol was available, the outcomes reported by the trial were listed in that protocol; if the trial protocol was obtained from a trial registry, the outcomes reported by the trial should have been those enumerated in the original protocol if the trial protocol was registered before or at the time that the trial was begun.</LI>
<LI>Unclear risk: the study authors did not report all predefined outcomes fully, or it is unclear whether the study authors recorded data on outcomes or not.</LI>
<LI>High risk: the study authors did not report one or more predefined outcomes; if the trial protocol was registered after the trial was begun, we did not consider those outcomes to be reliable.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">For-profit bias</HEADING>
<P>In order to assess the study source of funding, this domain was added in place of the &#8216;other bias&#8217; domain.</P>
<UL>
<LI>Low risk of bias: the trial appears to be free of industry sponsorship or other type of for-profit support that may manipulate the trial design, conductance, or reporting of trial results.</LI>
<LI>Unclear risk of bias: the trial may or may not be free of for-profit bias as the trial does not provide any information about clinical trial support or sponsorship.</LI>
<LI>High risk of bias: the trial is sponsored by industry or received other type of for-profit support.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Enriched population</HEADING>
<P>Because the clinical effect of botulinum toxin treatment is easily perceived, Bt non-naive participants are likely to recognise the presence or absence of clinical effects, or frequent adverse events, or both, effectively revealing the respective allocation arm. It is also relevant that, by preferentially including responders to Bt or excluding non-responders to Bt, there is an increased likelihood that these participants respond more favourably to Bt than a naive population would. We opted to subdivide this domain in two: preferential enrolment of known positive responders to Bt; and exclusion of known poor responders to Bt.</P>
<UL>
<LI>Low risk of bias: at least 70% of trial participants were Bt-naive; the trial did not exclude any particular forms of cervical dystonia.</LI>
<LI>Unclear risk of bias: the trial did not make explicit the percentage of participants who were known responders to Bt.</LI>
<LI>High risk of bias: arbitrarily defined as more than 30% of participants non-naive to Bt; explicit exclusion of people with forms of cervical dystonia known to have a poor response to Bt, namely people with pure anterocollis and retrocollis.</LI>
</UL>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-10-03 23:27:02 +0100" MODIFIED_BY="[Empty name]">
<P>We compared disease symptoms at baseline to disease symptoms in weeks 2 to 4 post-injection in the BtA and BtB arms. We extracted continuous outcomes whenever possible. These data were then pooled from the studies, where adequate, and used for comparison.</P>
<SUBSECTION>
<HEADING LEVEL="4">Dichotomous data</HEADING>
<P>We based analysis of these data on the number of events and the number of people assessed in the intervention and comparison groups. We used these to calculate the risk ratio (RR) and 95% confidence interval (CI).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Continuous data</HEADING>
<P>We based analysis of these data on the mean, standard deviation (SD) and number of people assessed for both the intervention and comparison groups to calculate mean difference (MD) and 95% CI. Where the MD was reported without individual group data, we used this to report the study results. If more than one study measured the same outcome using different validated tools, we calculated the standardised mean difference (SMD), namely Hedges&#8217; (adjusted) <I>g </I>(<LINK REF="REF-Hedges-1985" TYPE="REFERENCE">Hedges 1985</LINK>), and 95% CI. For interpretation of effect sizes with SMDs, we used a rule of thumb to define a small effect (SMD = 0.2), a moderate effect (SMD = 0.5), or a large effect (SMD = 0.8) (<LINK REF="REF-Cohen-1988" TYPE="REFERENCE">Cohen 1988</LINK>). If necessary for comparison, we dichotomised rating scales using each study author's own criteria for improvement or no improvement.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Time-to-event data</HEADING>
<P>We planned to analyse these data based on log hazard ratios and standard errors obtained from results of Cox proportional hazards regression models. We had planned to use these in order to calculate a hazard ratio (HR) and 95% CI.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2016-10-03 21:22:29 +0100" MODIFIED_BY="[Empty name]">
<P>Whenever the included studies had multiple arms with different dosages of one or two of the botulinum toxins, we combined all groups to create a single pair-wise comparison, using the Review Manager 5 (RevMan 5) calculator (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>), according to the methods suggested by Cochrane (<LINK REF="REF-Higgins-2011c" TYPE="REFERENCE">Higgins 2011c</LINK>). We also would have opted to create a single pair-wise comparison in case of multiple treatment groups using different interventions (e.g. onabotulinumtoxinA and abobotulinumtoxinA) if these were compared to the same comparator.</P>
<P>This method combines all relevant experimental intervention groups of the study into a single group, and combines all relevant control intervention groups into a single control group. This approach avoided the duplication of the control group that would happen if multiple comparisons (e.g. BtX dose1 versus BtY; BtX dose2 versus BtY) were included in the meta-analysis, as well as the loss of information if one dosage group was chosen to the detriment of the others. If applicable, we planned to explore the effect of dosage in subgroup analysis.</P>
<P>For dichotomous outcomes, both the sample sizes and the numbers of people with events would have been summed across groups. For continuous outcomes, means and standard deviations could be combined using a pooled mean or SD (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>; <LINK REF="REF-Higgins-2011c" TYPE="REFERENCE">Higgins 2011c</LINK>).</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2016-10-03 21:22:29 +0100" MODIFIED_BY="[Empty name]">
<P>For missing outcome or summary data we used imputation methods to derive the missing data (where possible) and reported any assumptions in the review. These cases were investigated, through sensitivity analyses, to investigate the effects of any imputed data on pooled effect estimates.</P>
<P>As a first option we chose to use the available information (e.g. standard error (SE), 95% CI or exact P value) to recover the missing data algebraically (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>; <LINK REF="REF-Higgins-2011c" TYPE="REFERENCE">Higgins 2011c</LINK>; <LINK REF="REF-Wiebe-2006" TYPE="REFERENCE">Wiebe 2006</LINK>). When change from baseline SD was not reported or not possible to extract, as was the case in <LINK REF="STD-Tintner-2005" TYPE="STUDY">Tintner 2005</LINK>, we attempted to create a correlation coefficient based on another study in this review, and then used this correlation coefficient to impute a change from baseline SD (<LINK REF="REF-Abrams-2005" TYPE="REFERENCE">Abrams 2005</LINK>; <LINK REF="REF-Follmann-1992" TYPE="REFERENCE">Follmann 1992</LINK>; <LINK REF="REF-Higgins-2011c" TYPE="REFERENCE">Higgins 2011c</LINK>).</P>
<P>If this were to fail, and if at least one sufficiently large and similar study were to exist, we would use a method of single imputation (<LINK REF="REF-Furukawa-2006" TYPE="REFERENCE">Furukawa 2006</LINK>; <LINK REF="REF-Higgins-2011c" TYPE="REFERENCE">Higgins 2011c</LINK>).</P>
<P>Lastly, if a sufficient number of included studies with complete information were to exist, we would have used multiple imputation methods to derive missing data (<LINK REF="REF-Carpenter-2013" TYPE="REFERENCE">Carpenter 2013</LINK>; <LINK REF="REF-Rubin-1991" TYPE="REFERENCE">Rubin 1991</LINK>).</P>
<P>If none of these methods were to be successful we would have conducted a narrative synthesis for the data in question.<BR/>
</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2016-10-03 21:57:15 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed that studies were similar enough to allow pooling of data using meta-analysis. Where data was pooled using meta-analysis, we assessed the degree of heterogeneity by visual inspection of forest plots and by examining the Chi<SUP>2</SUP> test for heterogeneity. We quantified heterogeneity using the I<SUP>2</SUP> statistic. We considered an I<SUP>2 </SUP>value of 50% or more to represent substantial levels of heterogeneity, but interpreted this value in light of the size and direction of effects and the strength of the evidence for heterogeneity, based on the P value from the Chi<SUP>2 </SUP>test (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2016-10-03 21:22:29 +0100" MODIFIED_BY="[Empty name]">
<P>We included too few studies in this review , namely fewer than 10, to allow construction of a funnel plot (<LINK REF="REF-Sterne-2001" TYPE="REFERENCE">Sterne 2001</LINK>), and formal testing of asymmetry (<LINK REF="REF-Peters-2006" TYPE="REFERENCE">Peters 2006</LINK>), which may indicate publication bias. Should enough studies be included in future updates of this review, we plan to undertake these analyses.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2016-10-03 21:58:06 +0100" MODIFIED_BY="[Empty name]">
<P>We performed the analyses with RevMan 5 version 5.3 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>), Stata version 14 (<LINK REF="REF-Stata-2015" TYPE="REFERENCE">Stata 2015</LINK>) and TSA (<LINK REF="REF-Thorlund-2011" TYPE="REFERENCE">Thorlund 2011</LINK>; <LINK REF="REF-TSA-2011" TYPE="REFERENCE">TSA 2011</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Meta-analysis</HEADING>
<P>We based the decision whether or not to meta-analyse data on an assessment of whether the interventions in the included trials were similar enough in terms of participants, settings, intervention, comparison and outcome measures to ensure meaningful conclusions from a statistically pooled result. We conducted data synthesis using a random-effects model.</P>
<P>We pooled effect measures by applying the Mantel-Haenszel method for dichotomous outcomes, and applying the inverse-variance or generic inverse-variance method for continuous outcomes. In addition, we had planned to pool time-to-event data using the generic inverse-variance method. We presented all results with 95% CI.</P>
<P>We calculated the number of participants needed to treat for an additional beneficial outcome (NNTB) and for an additional harmful outcome (NNTH) from meta-analysis estimates, rather than treating data as if they came from a single trial, as the latter approach is more prone to bias, especially when there are significant imbalances between groups within one or more trials in the meta-analysis (<LINK REF="REF-Altman-2002" TYPE="REFERENCE">Altman 2002</LINK>). However, caution is needed in the interpretation of these findings since they may be misleading because of variation in the event rates in each trial, differences in the outcomes considered, and differences in clinical setting (<LINK REF="REF-Smeeth-1999" TYPE="REFERENCE">Smeeth 1999</LINK>).</P>
<P>Where there were no data that could be combined into a meta-analysis we undertook a narrative approach to result synthesis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Trial sequential analysis</HEADING>
<P>In order to explore whether the cumulative data were of adequate power to evaluate the primary outcomes of this review, we performed a trial sequential analysis (<LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>), and calculated a required information size (also known as the <I>heterogeneity-adjusted required information size</I>) (<LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>). Trial sequential analysis aims to evaluate whether statistically significant results of meta-analysis are reliable by accounting for the required information size (i.e. the number of participants in the meta-analysis required to accept or reject an intervention effect). The technique is analogous to sequential monitoring boundaries in single trials. Trial sequential analysis adjusts the threshold of statistical significance and has been shown to reduce the risk of random errors due to repetitive testing of accumulating data (<LINK REF="REF-Imberger-2016" TYPE="REFERENCE">Imberger 2016</LINK>).</P>
<P>We calculated the required information size and computed the trial sequential monitoring boundaries using the O&#8217;Brien-Fleming approach (<LINK REF="REF-O_x0027_Brien-1979" TYPE="REFERENCE">O'Brien 1979</LINK>). The required information size was based on the event proportion or standard deviation in the control group; assumption of a plausible relative risk reduction (RRR) of 10%; a 5% risk of type I error; a 20% risk of type II error (power = 80%); and the observed heterogeneity of the meta-analysis (<LINK REF="REF-Jakobsen-2014" TYPE="REFERENCE">Jakobsen 2014</LINK>; <LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessing the quality of the evidence</HEADING>
<P>As recommended by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group methodology (<LINK REF="REF-Sch_x00fc_nemann-2011" TYPE="REFERENCE">Schünemann 2011</LINK>), two reviewers independently assessed all of the outcomes in the following domains: study limitations, inconsistency, indirectness, imprecision and publication bias. In case of disagreement the authors attempted to reach consensus, consulting an independent third reviewer if necessary. For this purpose, we used the GRADEprofiler (GRADEpro GDT) software tool (<LINK REF="REF-GRADEpro-GDT-2014" TYPE="REFERENCE">GRADEpro GDT 2014</LINK>), which we then used to export a 'Summary of findings' table for inclusion in the review manuscript.</P>
<P>To ensure the consistency and reproducibility of GRADE judgements, we applied the following criteria to each domain for all key comparisons of the critical outcomes.</P>
<UL>
<LI>Study limitations: we downgraded once if more than 30% of participants were from studies classified as being at a high risk of bias across any domain, with the exception of 'for-profit bias'.</LI>
<LI>Inconsistency: we downgraded once if heterogeneity was statistically significant or if the I<SUP>2</SUP> value was more than 40%. When a meta-analysis was not performed we downgraded once if trials did not show effects in the same direction.</LI>
<LI>Indirectness: we downgraded once if more than 50% of the participants were outside the target group.</LI>
<LI>Imprecision: we downgraded once if the optimal information size criterion was not met or, alternatively, if it was met but the 95% CI fails to exclude important benefit or important harm (<LINK REF="REF-Guyatt-2011" TYPE="REFERENCE">Guyatt 2011</LINK>).</LI>
<LI>Publication bias: we downgraded once where there was direct evidence of publication bias or if estimates of effect based on small scale, industry-sponsored studies raised a high index of suspicion of publication bias.</LI>
</UL>
<P>We applied the following definitions to the quality of evidence (<LINK REF="REF-Balshem-2011" TYPE="REFERENCE">Balshem 2011</LINK>):</P>
<UL>
<LI>high quality: we are very confident that the true effect lies close to that of the estimate of the effect;</LI>
<LI>moderate quality: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different;</LI>
<LI>low quality: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect;</LI>
<LI>very low quality: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">'Summary of findings' table</HEADING>
<P>As has become standard practice in Cochrane Reviews, we have included a 'Summary of findings' table to present the main findings of this review in a simple tabular format, based on the results of the GRADE analysis. In particular, we included key information concerning the quality of evidence, the magnitude of effect of the interventions examined, and the sum of available data on the outcome overall cervical dystonia improvement, proportion of participants with adverse events, subjective change as assessed by the patient, cervical dystonia associated pain, sore throat/dry mouth, and dysphagia (difficulty swallowing).</P>
</SUBSECTION>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2016-10-03 21:22:29 +0100" MODIFIED_BY="[Empty name]">
<P>We planned to conduct subgroup analyses according to the dosages of Bt used, though this was not possible given the paucity of results. In particular, we included key information concerning the quality of evidence, the magnitude of effect of the interventions examined, and the sum of the available data on the outcome.</P>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-10-07 00:09:01 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2016-10-07 00:09:01 +0100" MODIFIED_BY="[Empty name]">
<P>We identified three new studies for inclusion in this update: <LINK REF="STD-Comella-2005" TYPE="STUDY">Comella 2005</LINK>; <LINK REF="STD-Pappert-2008" TYPE="STUDY">Pappert 2008</LINK>; <LINK REF="STD-Tintner-2005" TYPE="STUDY">Tintner 2005</LINK>. </P>
<SEARCH_RESULTS MODIFIED="2016-10-07 00:09:01 +0100" MODIFIED_BY="[Empty name]">
<P>See: <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>, flow diagram of study selection.</P>
<P>We last ran the electronic search in October 2016. The search returned 1646 records (208 through CENTRAL; 182 though MEDLINE; 1256 through Embase), resulting in 1599 records after removing all duplicates. After title and abstract screening, three articles were assessed for full-text screening, with all three being included for both the qualitative and quantitative syntheses. We did not retrieve any unpublished trials.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-10-03 23:26:43 +0100" MODIFIED_BY="[Empty name]">
<P>We have listed all the included studies in this review in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table.<BR/>
</P>
<P>The three studies included in this review are parallel-group RCTs comparing BtA and BtB for adults (i.e. 18 years of age or over) with cervical dystonia. Trial size varied from 20 to 139 participants. Two of the included RCTs were multi-centre studies conducted in North America and Europe (<LINK REF="STD-Comella-2005" TYPE="STUDY">Comella 2005</LINK>; <LINK REF="STD-Pappert-2008" TYPE="STUDY">Pappert 2008</LINK>), while the remaining trial was a single-centred study conducted in the USA (<LINK REF="STD-Tintner-2005" TYPE="STUDY">Tintner 2005</LINK>). All trials were conducted in the 2000s.</P>
<P>Overall, 270 participants were enrolled, 171 of whom were female (63.3%). A total of 141 participants included in this review were randomised to the BtA arm of their respective studies, with the remaining 129 participants randomised to the BtB arm. The average age of participants among the three trials was 53.3 years. The baseline mean cervical dystonia symptoms were moderate to severe in all participants, and well matched between study arms, with baseline TWSTRS total scores of 41.8 and 45.6 for participants in <LINK REF="STD-Comella-2005" TYPE="STUDY">Comella 2005</LINK> and <LINK REF="STD-Pappert-2008" TYPE="STUDY">Pappert 2008</LINK>, respectively, which may be interpreted as representing a moderate overall disease impairment. <LINK REF="STD-Tintner-2005" TYPE="STUDY">Tintner 2005</LINK> did not provide data for baseline TWSTRS total score. The mean duration of cervical dystonia was 7.9 years and 6.6 years for participants in <LINK REF="STD-Comella-2005" TYPE="STUDY">Comella 2005</LINK> and <LINK REF="STD-Pappert-2008" TYPE="STUDY">Pappert 2008</LINK>, respectively. <LINK REF="STD-Tintner-2005" TYPE="STUDY">Tintner 2005</LINK> did not provide data for the number of years since diagnosis of dystonia. <LINK REF="STD-Pappert-2008" TYPE="STUDY">Pappert 2008</LINK> enrolled exclusively Bt-naive participants (no prior exposure to any form of Bt), while the remaining studies enrolled participants with a known positive response to BtA exclusively (<LINK REF="STD-Comella-2005" TYPE="STUDY">Comella 2005</LINK>; <LINK REF="STD-Tintner-2005" TYPE="STUDY">Tintner 2005</LINK>). Overall, 58.9% of the participants included in this review had a known positive response to BtA. None of the included trials described the method of participant referral and recruitment prior to study enrolment. Within each study, as well as when considered together, participants were well matched for clinical and demographic characteristics between BtA and BtB arms at baseline.</P>
<P>All studies were designed to evaluate only a single treatment session. Two studies used doses from 100 U to 250 U of BtA - both onabotulinumtoxinA formulations - and 5000 U to 10,000 U of BtB (<LINK REF="STD-Comella-2005" TYPE="STUDY">Comella 2005</LINK>; <LINK REF="STD-Pappert-2008" TYPE="STUDY">Pappert 2008</LINK>), while the remaining study referred only to botulinum doses being administered at a 1:50 ratio of BtA (onabotulinumtoxinA formulation) to BtB (<LINK REF="STD-Tintner-2005" TYPE="STUDY">Tintner 2005</LINK>). In all studies, and within these limits, the Bt doses administered were left at the discretion of the clinician. Techniques and schema of Bt administration did not vary a great deal among studies. In all trials, the toxin was injected into the muscles involved in cervical dystonia selected by the investigator, with the use of electromyography left to the discretion of the clinician performing the injection.</P>
<P>
<LINK REF="STD-Comella-2005" TYPE="STUDY">Comella 2005</LINK> and <LINK REF="STD-Pappert-2008" TYPE="STUDY">Pappert 2008</LINK> both used TWSTRS total score at week 4 post-injection as the primary efficacy outcome. <LINK REF="STD-Tintner-2005" TYPE="STUDY">Tintner 2005</LINK> was designed with the specific objective of comparing the autonomic effects of Bt, reporting only TWSTRS sub-scores at baseline and at week 3 post-injection. <LINK REF="STD-Comella-2005" TYPE="STUDY">Comella 2005</LINK> and <LINK REF="STD-Pappert-2008" TYPE="STUDY">Pappert 2008</LINK> also studied subjective response as assessed by participants and clinicians. Regarding safety outcomes, all studies reported treatment-associated adverse events. <LINK REF="STD-Comella-2005" TYPE="STUDY">Comella 2005</LINK> reported data using an intention-to-treat (ITT) principle. One study specified the method of data analysis used (<LINK REF="STD-Pappert-2008" TYPE="STUDY">Pappert 2008</LINK>), stating that data was analysed using both per-protocol (PP) and ITT principles. However, only PP data were reported, with the claim by the authors that no difference existed between PP and ITT results. None of the included trials had an available protocol register.</P>
<P>All trials were short-term, with a follow-up period lasting 16 to 20 weeks post-injection or until such time as reinjection was required.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2016-02-18 18:52:58 +0000" MODIFIED_BY="[Empty name]">
<P>All reports that were entered for full-text screening were assessed as eligible for inclusion in this review.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-10-03 21:59:13 +0100" MODIFIED_BY="[Empty name]">
<P>See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>: 'Risk of bias' table.</P>
<P>The included studies were evaluated using a modified version of the Cochrane 'Risk of bias' tool. See <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> for the 'Risk of bias' summary graphs. These assessments were based on the information available in the primary report data.</P>
<P>We considered that none of the included studies had a high risk of bias in all domains, though we rated the 'for-profit bias' domain at a high risk of bias in all studies, and considered the 'selective reporting' domain at a high risk of bias in one study (<LINK REF="STD-Tintner-2005" TYPE="STUDY">Tintner 2005</LINK>). We additionally rated all studies to as having a low risk of bias with regard to the incomplete outcome data domain.</P>
<ALLOCATION MODIFIED="2016-10-03 21:22:29 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Comella-2005" TYPE="STUDY">Comella 2005</LINK> adequately described the method of randomisation (permuted block allocation scheme), though made no specific description of allocation concealment. We chose to rate <LINK REF="STD-Comella-2005" TYPE="STUDY">Comella 2005</LINK> as having a low risk of selection bias. We considered that the remaining studies had an unclear risk of bias (<LINK REF="STD-Pappert-2008" TYPE="STUDY">Pappert 2008</LINK>; <LINK REF="STD-Tintner-2005" TYPE="STUDY">Tintner 2005</LINK>), as no specific and reproducible descriptions were made regarding the methods of randomisation and allocation concealment.</P>
</ALLOCATION>
<BLINDING MODIFIED="2016-10-03 21:22:28 +0100" MODIFIED_BY="[Empty name]">
<P>Two studies adequately reported the methods of guaranteeing blinding, being correctly executed, double-blind controlled trials, so we rated them as having a low risk of bias (<LINK REF="STD-Comella-2005" TYPE="STUDY">Comella 2005</LINK>; <LINK REF="STD-Pappert-2008" TYPE="STUDY">Pappert 2008</LINK>). We rated the remaining study as having an unclear risk of bias (<LINK REF="STD-Tintner-2005" TYPE="STUDY">Tintner 2005</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2016-10-03 21:22:28 +0100" MODIFIED_BY="[Empty name]">
<P>Two studies adequately reported the number and reasons for participant exclusions in both treatment arms (<LINK REF="STD-Comella-2005" TYPE="STUDY">Comella 2005</LINK>; <LINK REF="STD-Tintner-2005" TYPE="STUDY">Tintner 2005</LINK>), these were evenly distributed across both treatment arms, and so we rated them as having a low risk of bias. <LINK REF="STD-Pappert-2008" TYPE="STUDY">Pappert 2008</LINK> did not provide data according to an ITT principle, so we chose to grade this study as being at an uncertain risk of attrition bias.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2016-10-03 21:22:28 +0100" MODIFIED_BY="[Empty name]">
<P>We considered that the more clinically relevant outcomes that are usually evaluated in intervention trials for this condition were reported in both <LINK REF="STD-Comella-2005" TYPE="STUDY">Comella 2005</LINK> and <LINK REF="STD-Pappert-2008" TYPE="STUDY">Pappert 2008</LINK>, which is why they were considered to be at low risk of bias for reporting data. We rated the remaining study as having a high risk of bias for this domain (<LINK REF="STD-Tintner-2005" TYPE="STUDY">Tintner 2005</LINK>). This is because it referred in the methods section to having selected several outcomes, though only two of these were reported in the results. Additionally, none of the included studies had a registered trial protocol available.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2016-10-03 21:59:13 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">For-profit bias</HEADING>
<P>All studies were supported, wholly or in part, by pharmaceutical companies (Allergan, Inc and Soltice Neurosciences, Inc) (<LINK REF="STD-Comella-2005" TYPE="STUDY">Comella 2005</LINK>; <LINK REF="STD-Pappert-2008" TYPE="STUDY">Pappert 2008</LINK>; <LINK REF="STD-Tintner-2005" TYPE="STUDY">Tintner 2005</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Enriched population</HEADING>
<P>We believe that all included studies potentially had a form of enriched population. Two studies exclusively enrolled positive responders to treatment with BtA (<LINK REF="STD-Comella-2005" TYPE="STUDY">Comella 2005</LINK>; <LINK REF="STD-Tintner-2005" TYPE="STUDY">Tintner 2005</LINK>), meaning that there was a potential risk of population enrichment in 159 of the 270 participants (59%) included in this review. These two studies also excluded people known to have poorer responses to treatment with botulinum toxin (<LINK REF="STD-Comella-2005" TYPE="STUDY">Comella 2005</LINK>; <LINK REF="STD-Pappert-2008" TYPE="STUDY">Pappert 2008</LINK>), namely people with pure anterocollis and retrocollis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Publication bias</HEADING>
<P>We intended to use funnel plots to explore publication bias. However, due to the small number of included studies, the power of this analysis was considered to be inadequate (<LINK REF="REF-Sterne-2011" TYPE="REFERENCE">Sterne 2011</LINK>).</P>
</SUBSECTION>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-10-03 23:53:40 +0100" MODIFIED_BY="[Empty name]">
<P>The key results of this review can be found in &#8216;<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>&#8217;.</P>
<SUBSECTION>
<HEADING LEVEL="3">Preceding data analysis</HEADING>
<P>See <LINK TAG="MISSING_DATA" TYPE="SECTION">Dealing with missing data</LINK>.</P>
<P>In this review we derived the values of the change from baseline SD for each of the TWSTRS sub-scales (pain, severity and disability) in <LINK REF="STD-Tintner-2005" TYPE="STUDY">Tintner 2005</LINK>. In this case we created a correlation coefficient for each sub-scale based on <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1603290105300954794594189801078&amp;format=REVMAN#STD-Pappert-2008">Pappert 2008</A>, and then used this to impute the change from baseline SD for each sub-scale, for both BtA and BtB. Since <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1603290105300954794594189801078&amp;format=REVMAN#STD-Pappert-2008">Pappert 2008</A> did not report the final SD for each intervention group we opted to substitute it with the baseline SD, as it is reasonable to assume that the intervention does not alter the variability of the outcome measure (<LINK REF="REF-Higgins-2011c" TYPE="REFERENCE">Higgins 2011c</LINK>). In all cases the correlation coefficient was greater than 0.5, which provides added security to our imputation.</P>
<P>We had no further need to use imputation methods.</P>
<P>We conducted sensitivity analyses for each case in which imputation methods were applied.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Overall improvement on any validated symptomatic rating scale for cervical dystonia</HEADING>
<P>The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) is currently the most common clinical validated tool to assess and document the status of people with cervical dystonia (<LINK REF="REF-Consky-1994" TYPE="REFERENCE">Consky 1994</LINK>). The TWSTRS (total score range, 0 to 85) is composite of three sub-scales that evaluate different features of cervical dystonia, namely severity (range, 0 to 35), disability (range, 0 to 30) and pain (range, 0 to 20). The higher the score, the greater the level of morbidity. In the absence of a validated value for a clinically meaningful change in TWSTRS total score, we have considered a 10% change from participants' baseline status as representing a clinically meaningful change.</P>
<P>Two studies (n = 231) reported data for the mean change from baseline in TWSTRS total score (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1603290105300954794594189801078&amp;format=REVMAN#STD-Comella-2005">Comella 2005</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1603290105300954794594189801078&amp;format=REVMAN#STD-Pappert-2008">Pappert 2008</A>), with no difference between the BtA and BtB treatment groups, mean difference (MD) -1.44 (95% CI -3.58 to 0.70; I<SUP>2 </SUP>= 0%; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
<P>In relation to the trial sequential analysis, the cumulative evidence overcame the information size generated by a conventional sample size calculation, assuming a baseline TWSTRS of 40 points and a required change of 10% from baseline, with an SD of 8.3. The cumulative evidence also overcame the heterogeneity-adjusted required information size of 138 participants.</P>
<P>We were able to use data from all three included studies to calculate the improvement on TWSTRS sub-scales, with there being no difference between the BtA and BtB groups with regard to both TWSTRS severity (MD -0.26; 95% CI -1.27 to 0.75; I<SUP>2 </SUP>= 0%; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>) and TWSTRS disability (MD -0.17; 95% CI -1.19 to 0.86; I<SUP>2 </SUP>= 0%; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Proportion of participants with adverse events</HEADING>
<P>One study (n = 111) reported data concerning the proportion of participants with adverse events (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1603290105300954794594189801078&amp;format=REVMAN#STD-Pappert-2008">Pappert 2008</A>). In this study BtA and BtB treatment were not associated with different risks for adverse events (RR 1.40; 95% CI 1.00 to 1.96; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
<P>We were not able to calculate a heterogeneity-adjusted required information size for this outcome since it was only reported in one study. However, the total number of participants included in this trial was less than the number generated by a conventional sample size calculation for a single adequately powered equivalence trial. Therefore, the cumulative evidence was not adequately powered for evaluation of the proportion of participants with adverse events.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Change in subjective evaluation of clinical status evaluated both by patients and clinicians</HEADING>
<P>One study (138 participants) reported data with regard to subjective assessments by both clinicians and patients at week 4 after treatment. (<LINK REF="STD-Comella-2005" TYPE="STUDY">Comella 2005</LINK>) The instruments used to measure this outcome were the Patient Global Assessment (PGA) and Subjective Global Assessment (SGA) scales. The PGA and SGA ratings ranged from -4 (marked worsening of cervical dystonia signs) to 4 (complete abolishment of cervical dystonia signs).</P>
<P>Both forms of subjective assessment, measured as mean change from baseline in PGA and SGA, were not different between BtA and BtB groups, (PGA MD 0.20; 95% CI -0.17 to 0.57; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>; SGA MD 0.20; 95% CI -0.20 to 0.60; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P>
<P>
<LINK REF="STD-Pappert-2008" TYPE="STUDY">Pappert 2008</LINK> also mentioned having studied subjective evaluation of clinical status by both patients and clinicians, though the final report did not include any data for this analysis, referring only to the fact that all evaluations were similar between treatment arms.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Changes in pain scores, as assessed with validated assessment tools</HEADING>
<P>All included trials provided data in the form of mean change from baseline on TWSTRS pain sub-scale (range, 0 to 20); there was no difference between the intervention groups for this outcome (MD -0.83; 95% CI -1.75 to 0.09; I<SUP>2 </SUP>= 0%; <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Changes in quality of life assessments</HEADING>
<P>None of the included trials studied the effect of BtA or BtB on the quality of life of people with cervical dystonia.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Proportion of participants with adverse events of special interest</HEADING>
<P>The most frequently reported adverse events were sore throat/dry mouth (24.5%) (<LINK REF="STD-Comella-2005" TYPE="STUDY">Comella 2005</LINK>; <LINK REF="STD-Pappert-2008" TYPE="STUDY">Pappert 2008</LINK>), and dysphagia (18.2%) (<LINK REF="STD-Comella-2005" TYPE="STUDY">Comella 2005</LINK>; <LINK REF="STD-Pappert-2008" TYPE="STUDY">Pappert 2008</LINK>; <LINK REF="STD-Tintner-2005" TYPE="STUDY">Tintner 2005</LINK>). Dysphagia was equally likely in BtA and BtB-treated participants (RR 2.89; 95% CI 0.80 to 10.41; I<SUP>2</SUP>=74%; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>). Sore throat/dry mouth was more likely among BtB-treated participants in comparison to BtA-treated ones, with a RR of 4.39 (95% CI 2.43 to 7.91; I<SUP>2</SUP>=0%; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>). The NNTH in BtB-treated participants compared to BtA-treated participants for sore throat/dry mouth was 3 (95% CI 4 to 2).</P>
<P>For all other reported adverse events, including pain at injection site, no difference was found between groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Duration of effect, or number of days until need for reinjection or effect waning</HEADING>
<P>This item was reported in two studies (n = 231) (<LINK REF="STD-Comella-2005" TYPE="STUDY">Comella 2005</LINK>; <LINK REF="STD-Pappert-2008" TYPE="STUDY">Pappert 2008</LINK>), though we opted not to combine the data through a quantitative synthesis (meta-analysis) due to this outcome being reported as survival time for the median of each arm with the inherent limitations that entails (<LINK REF="REF-Michiels-2005" TYPE="REFERENCE">Michiels 2005</LINK>).</P>
<P>
<LINK REF="STD-Pappert-2008" TYPE="STUDY">Pappert 2008</LINK> reported that among its 93 participants both formulations of Bt did not differ from one another - median treatment duration of effect was 13.1 weeks in the BtA arm and 13.7 weeks in the BtB arm (hazard ratio (HR) 0.95; 95% CI 0.56 to 1.59; log rank P = 0.833). The trialists performed a subgroup analysis for participants who showed an improvement from baseline at week 4 (n = 83) was also conducted, without a difference between the groups (HR 0.79; 95% CI 0.45 to 1.41; log rank P = 0.414).</P>
<P>Similarly, <LINK REF="STD-Comella-2005" TYPE="STUDY">Comella 2005</LINK> reported that among its 138 participants both formulations of Bt did not differ from one another - median treatment duration of effect was 13.0 weeks in the BtA arm and 11.7 weeks in the BtB arm (HR 95% CI 0.55 to 1.07). A subgroup analysis for participants who showed an improvement from baseline at week 4 was also conducted, with a median time to loss of benefit of 14 weeks for BtA and 12.1 weeks for BtB. The trialists presented the results of a log rank test for this subgroup reporting a difference in the two distributions (HR 95% CI 0.43 to 0.98).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-10-09 11:44:16 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2016-10-03 23:54:44 +0100" MODIFIED_BY="[Empty name]">
<P>This updated review included three randomised, parallel-designed trials, that enrolled 270 participants with cervical dystonia, of whom 62.3% had been previously treated with botulinum toxin type A (BtA). As can be seen in the <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>, BtA (onabotulinumtoxinA) and botulinum toxin type B (BtB; rimabotulinumtoxinB) were equally effective in reducing overall disease impairment, including disease severity, disability, and pain. Subjective assessments by both participants and clinicians were likewise not different between BtA and BtB. The comparative impacts of both forms of botulinum toxin on other domains of participants&#8217; quality of life, such as social functioning or mental health, have not been addressed in the included trials.</P>
<P>Overall adverse event rates were not different between groups, though this may be due to the small sample that was analysed for this outcome. The short duration of the trials, as well as the reduced sample size, precluded the drawing of strong conclusions regarding the lack of differences between BtA and BtB. The most common adverse events of special interest related to treatment were sore throat/dry mouth and dysphagia. Of these, only the risk of sore throat/dry mouth was different between the treatment groups, with BtB-treated participants experiencing an increased risk of this adverse event, with a number needed to treat for one additional harmful event of 3 after a single botulinum toxin (Bt) injection. No fatalities or serious adverse events were considered to be related to either treatment in any of the trials. Data for special subpopulations, such as people with certain types of cervical dystonia known to respond poorly to Bt treatment, as well as for children and pregnant women, were not available.</P>
<P>We found low-to-moderate statistical heterogeneity for most efficacy and safety outcome estimates, the exception being dysphagia.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2016-10-03 21:22:28 +0100" MODIFIED_BY="[Empty name]">
<P>All included trials addressed the primary research question directly, using the same assessment tool, the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS). However, data were not fully reported for all outcomes, and in some cases results could not be pooled and compared across studies. This limited the amount of data available and, consequently, our confidence in the overall conclusions.</P>
<P>The participants included in the studies were not fully representative of the overall population of people with cervical dystonia. The effects of population enrichment and the moderate overall disease impairment (as assessed by the baseline TWSTRS scores) preclude definite conclusions concerning all people with this condition.</P>
<P>Since the included trials use only onabotulinumtoxinA, there are no data regarding the efficacy and safety profile of BtB versus other forms of BtA, namely abobotulinumtoxinA and incobotulinumtoxinA.</P>
<P>Four noteworthy factors challenge the implementation of the evidence derived from this review. Firstly, a limited number of centres conducted the research, and these were heterogeneous in terms of their regional distribution, with all trials being conducted in Europe or North America. Differences in clinical practice, training of experts, and local guidelines in other regions of the world may conceivably present an obstacle to application of the evidence summarised here. Secondly, the total number of participants across several outcomes was less than the number of participants calculated by a standard sample size calculation for a single adequately powered equivalence study. As such, presenting only trends in the results, more studies are needed to provide robust evidence with regards to these trends. Thirdly, it is common for people with cervical dystonia to have concomitant medications for their condition, such as muscle relaxants and benzodiazepines. Reasonably, in trials, participants are required to be on a stable dose of these medications for many weeks to avoid confounding factors. As a result, little is known at present about the impact of these drug regimens with regard to implementation of the evidence in this review. Fourthly, several outcomes of interest were either poorly reported or entirely omitted. Specifically, no quality of life assessments were reported in any of the included studies; subjective assessments by both participants and clinicians were not reported in two of the included studies; the proportion of participants with adverse events was also not reported in two of the included studies; and the time to effect was not reported in any of the included trials, which is of interest as this is clinically relevant for both participants and clinicians, as well as a potentially important differentiating factor between BtA and BtB.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2016-10-03 21:22:28 +0100" MODIFIED_BY="[Empty name]">
<P>See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>, 'Risk of bias' tables, and 'Risk of bias' summary tables (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
<P>We considered all studies to be at high risk of bias due to for-profit bias. We additionally considered <LINK REF="STD-Tintner-2005" TYPE="STUDY">Tintner 2005</LINK> to be at a high risk of reporting bias, since it did not report outcomes that were collected, without providing any explanation for this omission. Additionally, we judged <LINK REF="STD-Tintner-2005" TYPE="STUDY">Tintner 2005</LINK> to be at an unclear risk of bias for all 'Risk of bias' domains with the exception of attrition bias. We considered the risk of bias due to an enriched population to be high in <LINK REF="STD-Comella-2005" TYPE="STUDY">Comella 2005</LINK> and <LINK REF="STD-Tintner-2005" TYPE="STUDY">Tintner 2005</LINK>, and unclear in <LINK REF="STD-Pappert-2008" TYPE="STUDY">Pappert 2008</LINK>. Finally, statistical heterogeneity was low for all outcomes with the exception of the proportion of participants with sore throat/dry mouth.</P>
<P>Some outcomes could not be compared across studies, as some studies lacked reporting of relevant data. Imbalances between baseline characteristics of the participants and incomplete description of the variables prevented confident imputation of values for missing data, which further reduced the amount of combinable data, and therefore the precision of the results.</P>
<P>The included trials enrolled between 20 and 139 participants, each individually enrolling fewer participants than the total number that would be required for a single adequately-powered equivalence trial of BtA versus BtB. Collectively however, only the following outcomes were under-powered: overall proportion of participants with adverse events, change in subjective evaluation of clinical status evaluated by patients, and changes in pain scores.</P>
<P>Taken together, as can be seen in <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>, we consider that there is low quality evidence that a single treatment session of BtA and a single treatment session of BtB, in certain types of cervical dystonia, are equally efficacious in reducing disease impairment, including severity, disability, and pain. The quality of evidence supporting the higher occurrence of sore throat/dry mouth among BtB-treated individuals is moderate. There is also low-quality evidence that dysphagia occurs at the same rate in people treated with BtA and BtB. The quality of evidence assessing the change in subjective evaluation of clinical status evaluated by patients is low. Regarding the overall safety and tolerability comparison, the quality of the evidence is low, meaning that we are unable to draw any robust conclusions. Additionally, we can draw no conclusions regarding continued responsiveness and long-term efficacy, which are important aspects to consider in a chronic condition such as cervical dystonia.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2016-10-04 00:12:10 +0100" MODIFIED_BY="[Empty name]">
<P>Although we followed the methods recommended by Cochrane in order to minimise bias in the review process, certain areas do deserve attention. Despite having contacted experts in the area extensively, not having searched all available clinical trial registries opens the current review to two potential problems: firstly, the possibility of having missed trials and also the possibility of introducing publication bias. We opted not to search trial registries as the trials that have been conducted are well-known in the area, and this form of search was not included in the review protocol.</P>
<P>An additional bias was that we could not obtain data for all outcomes in the included trials. A further limitation of this review is the small number of participants contributing data to each outcome. Therefore, the results of the pooled analysis should be viewed with caution, especially in the presence of statistical heterogeneity, as further studies may have an important impact in effect size estimations.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2016-10-09 11:44:16 +0100" MODIFIED_BY="[Empty name]">
<P>The current review is, to our knowledge, the first systematic review with data that address the question of whether one type of botulinum toxin is superior to another or not. We have included all randomised controlled trials that addressed this question in the current review.</P>
<P>
<LINK REF="STD-Comella-2005" TYPE="STUDY">Comella 2005</LINK> reported a very large proportion of BtB-treated participants with dysphagia and sore throat/dry mouth at week 4, particularly when compared to the available evidence from RCTs (dysphagia in <LINK REF="STD-Comella-2005" TYPE="STUDY">Comella 2005</LINK>: 80%; dysphagia in <LINK REF="REF-Marques-2016" TYPE="REFERENCE">Marques 2016</LINK>: 16%; sore throat/dry mouth in <LINK REF="STD-Comella-2005" TYPE="STUDY">Comella 2005</LINK>: 48%; sore throat/dry mouth in <LINK REF="REF-Marques-2016" TYPE="REFERENCE">Marques 2016</LINK>: 17%). However, the participants with these adverse events at baseline was likewise very high (baseline dysphagia in <LINK REF="STD-Comella-2005" TYPE="STUDY">Comella 2005</LINK>: 14%; baseline sore throat/dry mouth in <LINK REF="STD-Comella-2005" TYPE="STUDY">Comella 2005</LINK>: 37%), as the study exclusively enrolled people already being treated with BtA for cervical dystonia. For this reason, we opted to study the proportion of newly-developed cases of each adverse event in comparison to baseline, with the results being more in-line with both the available evidence and clinical practice (See <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> for a comparison of dysphagia and sore throat/dry mouth in <LINK REF="STD-Comella-2005" TYPE="STUDY">Comella 2005</LINK>, <LINK REF="REF-Marques-2016" TYPE="REFERENCE">Marques 2016</LINK>, and the current review).<BR/>
</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-10-03 22:09:24 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2016-10-03 21:22:28 +0100" MODIFIED_BY="[Empty name]">
<P>In this updated Cochrane Review we found that a single treatment session of BtA and a single treatment session of BtB are equally effective and well tolerated in the treatment of adults with certain types of cervical dystonia. Treatment with BtB is associated with an increased risk of sore throat/dry mouth when compared to treatment with BtA. Overall, there is no clinical evidence to support or not support the preferential use of one form of botulinum toxin over another. No conclusions can be drawn regarding individuals with predominant retrocollis or anterocollis, as these were mostly excluded from the clinical trials.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-10-03 22:09:24 +0100" MODIFIED_BY="[Empty name]">
<P>We have had access only to published research data from trials of botulinum toxin type A (BtA) versus BtB in cervical dystonia. It is difficult to determine which and how many resources should be invested in future research.</P>
<P>It would be of interest if future studies comparing BtA and BtB were to use different formulations of BtA, namely abobotulinumtoxinA or incobotulinumtoxinA, or both, as the trials included in this review used only onabotulinumtoxinA.</P>
<P>The net benefit of both a single BtA and BtB injection in the treatment of cervical dystonia has been established in the published trials. Nonetheless, further studies are needed to establish the relative effectiveness of different doses of specific botulinum toxin formulations, assessing efficacy, safety, duration of effect and quality of life across regimes. Because therapy typically requires optimising a dose for each patient rather than administering a fixed dose of botulinum toxin, such a line of research would be important to support physicians' management of doses and allow for a more solid and safe individualisation of patient treatment. Also to be determined is the added value, if any, of guidance methods (e.g. electromyography) in injecting botulinum toxin into the cervical muscles.</P>
<P>The time to effect of BtA and BtB were not studied in any of the included studies, and as this may be a clinically relevant and differentiating factor between the two formulations, future research should endeavour to study this outcome.</P>
<P>Future research concerning all formulations of botulinum neurotoxin should endeavour to establish clinical effectiveness not only based on changes from baseline, but also, preferably, based on validated measures of Minimal Clinically Important Difference/Change (<LINK REF="REF-Bro_x017c_ek-2006" TYPE="REFERENCE">Bro&#380;ek 2006</LINK>). Research is required in order to establish such a parameter for the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), currently the most widely used and disseminated clinical scale in the field. We are, however, aware of an effort to create a new clinical scale in dystonia - the Comprehensive Cervical Dystonia Rating Scale (<LINK REF="REF-Comella-2015" TYPE="REFERENCE">Comella 2015</LINK>), which will include a revision of the TWSTRS, to be named TWSTRS-2, with a Minimal Clinically Important Change validation being planned.</P>
<P>It is currently uncertain whether or not the clinical effectiveness of botulinum toxin decays over time, with repeated treatment sessions, and whether a possible loss of effectiveness occurs in all clinical domains. Another related aspect is the possible development of BtB-non-responsiveness, as there is no plausible theoretical reason why this would not occur, as it does for BtA. Future studies comparing BtA and BtB should address the comparative proportion of participants who develop clinical secondary non-responsiveness to treatment.</P>
<P>Finally, in conducting this systematic review we were faced with the fact that there is no defined core outcome set in cervical dystonia research, as there are for other areas (<LINK REF="REF-Tugwell-2007" TYPE="REFERENCE">Tugwell 2007</LINK>). The definition of a set of core outcome measures to be included in future research, via well-established methodology to determine the inclusion of patient-reported outcomes (<LINK REF="REF-Macefield-2014" TYPE="REFERENCE">Macefield 2014</LINK>), would be relevant to promote research in this field, as well as to support the clinical effectiveness of botulinum toxin.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-10-03 21:27:44 +0100" MODIFIED_BY="[Empty name]">
<P>We would like to thank Ema Roque (Cochrane Movement Disorders Review Group), Daisy Abreu (Clinical Pharmacology Unit, Faculty of Medicine, University of Lisbon), and Francesca Fiorentino (CEMBE, Faculty of Medicine, University of Lisbon) sincerely for their contributions to this review. Additionally, we would like to thank the internal peer-reviewers, who greatly added to the quality of this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2016-10-11 14:11:13 +0100" MODIFIED_BY="[Empty name]">
<P>Costa J, Ferreira JJ, and Sampaio C were investigators in clinical trials in botulinum toxin A and B use in dystonia sponsored by Elan (manufacturer of BtB), Allergan (manufacturer of BtA), and Ipsen (manufacturer of BtA). Searching for studies, selection of studies, data extraction and analysis (including risk of bias), and GRADE assessment were performed by authors (FRB, GSD, MC, REM) that are not trialists. Ferreira JJ and Sampaio C were speakers in symposiums promoted by Elan, Allergan, and Ipsen.<BR/>Moore AP has received royalties from Ipsen for the use 'LIVEchart' scoring system for botulinum toxin treatment efficacy. He has additionally received consulting fees from Ipsen, Merz (manufacturer of BtA), Eisai (manufacturer of BtB), and Allergan. The same companies have provided for support for travel to meetings for studies or other purposes.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2016-10-03 21:22:40 +0100" MODIFIED_BY="[Empty name]">
<P>A Peter Moore - APM; Cristina Sampaio - CS; Filipe Brogueira Rodrigues - FBR; Gonçalo S Duarte - GSD; João Costa - JC; Joaquim Ferreira - JJF; Mafalda Castelão - MC; Raquel E Marques - REM.</P>
<P>Concieving the review - APM, CS, JC, JJF</P>
<P>Designing the review - APM, CS, JC, JJF</P>
<P>Co-ordinating the review - JC</P>
<P>Designing search strategies &#8211; FBR, GSD, JC</P>
<P>Undertaking searches &#8211; FBR, GSD</P>
<P>Screening search results &#8211; FRB, GSD, MC, REM</P>
<P>Organising retrieval of papers - FRB, GSD, JC, MF, REM</P>
<P>Screening retrieved papers against eligibility criteria - FRB, GSD, MC, REM</P>
<P>Appraising quality of papers - FRB, GSD, JC, MC, REM</P>
<P>Extracting data from papers - FRB, GSD, JC, MC, REM</P>
<P>Writing to authors of papers for additional information &#8211; GSD, JC, REM</P>
<P>Data management for the review &#8211; FRB, GSD, MC, REM</P>
<P>Entering data into RevMan - FRB, GSD, MC, REM</P>
<P>Analysis of data - FRB, GSD, JC, MC, REM</P>
<P>Interpretation of data - APM, CS, FRB, GSD, JC, JJF, MC, REM</P>
<P>Writing the review - FRB, GSD, JC, MC, REM</P>
<P>GRADE assessment - GSD, JC</P>
<P>Providing general advice on the review &#8211; APM, CS, JC, JJF</P>
<P>Performing previous work that was the foundation of the current review &#8211; Ana Borges, Claudia Espírito Santo, Miguel Coelho.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2016-10-05 23:07:34 +0100" MODIFIED_BY="[Empty name]">
<P>For this updated review the study designs accepted were restricted to parallel-group. No changes were made in the type of participants included or in the interventions allowed.</P>
<P>Adverse events, which were originally a secondary outcome, were included in this updated review as a primary safety outcome. Also, in this safety analysis we considered the proportion of participants with the most frequent adverse events, which was not stated in the original protocol. An assessment of the duration of effect was included as a new secondary outcome measure.</P>
<P>The search strategy was prolonged from the inception to October 2016.</P>
<P>New approaches were assumed to deal with missing data and unit of analysis issues.</P>
<P>The latest recommended Cochrane tool for assessing risk of bias was used in this review, which was expanded to include two additional criteria, added by the review authors. Blinding of outcome assessment was analysed in two new subcategories: subjective and objective assessment.</P>
<P>The trial sequential analysis was not in the original review protocol.</P>
<P>A &#8216;Summary of findings' table was also added.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-10-11 14:23:46 +0100" MODIFIED_BY="Ema Roque">
<STUDIES MODIFIED="2016-10-03 21:42:35 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2016-10-03 21:42:35 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Comella-2005" MODIFIED="2016-10-03 21:42:21 +0100" MODIFIED_BY="[Empty name]" NAME="Comella 2005" YEAR="2005">
<REFERENCE MODIFIED="2016-10-03 21:42:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Comella CL, Jankovic J, Shannon KM, Tsui J, Swenson M, Leurgans S, et al</AU>
<TI>Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia</TI>
<SO>Neurology</SO>
<YR>2005</YR>
<VL>65</VL>
<PG>1423-9</PG>
<IDENTIFIERS MODIFIED="2014-10-04 23:36:04 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4393336"/><IDENTIFIER MODIFIED="2014-10-04 23:36:04 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1212/01.wnl.0000183055.81056.5c"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-10-04 23:16:49 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414040"/><IDENTIFIER MODIFIED="2014-10-04 23:16:49 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1212/01.wnl.0000183055.81056.5c"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pappert-2008" MODIFIED="2016-10-03 21:42:28 +0100" MODIFIED_BY="[Empty name]" NAME="Pappert 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-10-03 21:42:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pappert EJ, Germanson T</AU>
<TI>Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: randomized double-blind, noninferiority trial</TI>
<SO>Movement Disorders</SO>
<YR>2008</YR>
<VL>23</VL>
<PG>510-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4393337"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-10-05 11:52:41 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414042"/><IDENTIFIER MODIFIED="2014-10-05 11:52:41 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/mds.21724"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tintner-2005" MODIFIED="2016-10-03 21:42:35 +0100" MODIFIED_BY="[Empty name]" NAME="Tintner 2005" YEAR="2005">
<REFERENCE MODIFIED="2016-10-03 21:42:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tintner R, Gross R, Winzer UF, Smalky KA, Jankovic J</AU>
<TI>Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial</TI>
<SO>Neurology</SO>
<YR>2005</YR>
<VL>65</VL>
<PG>765-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4393338"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-10-05 14:25:02 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414044"/><IDENTIFIER MODIFIED="2014-10-05 14:25:02 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1212/01.wnl.0000174433.76707.8c"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES/>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2014-10-08 17:05:24 +0100" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-10-07 00:19:56 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2016-10-07 00:19:56 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Abrams-2005" MODIFIED="2016-02-18 19:21:16 +0000" MODIFIED_BY="[Empty name]" NAME="Abrams 2005" TYPE="JOURNAL_ARTICLE">
<AU>Abrams KR, Gillies CL, Lambert PC</AU>
<TI>Meta-analysis of heterogeneously reported trials assessing change from baseline</TI>
<SO>Statistics in Medicine</SO>
<YR>2005</YR>
<VL>24</VL>
<PG>3823-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Albanese-2013" MODIFIED="2016-09-29 16:17:05 +0100" MODIFIED_BY="[Empty name]" NAME="Albanese 2013" TYPE="JOURNAL_ARTICLE">
<AU>Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, et al</AU>
<TI>Phenomenology and classification of dystonia: a consensus update</TI>
<SO>Movement Disorders</SO>
<YR>2013</YR>
<VL>28</VL>
<NO>7</NO>
<PG>863-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-2002" MODIFIED="2016-01-04 08:07:07 +0000" MODIFIED_BY="[Empty name]" NAME="Altman 2002" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Deeks JJ</AU>
<TI>Meta-analysis, Simpson's paradox, and the number needed to treat</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2002</YR>
<VL>2</VL>
<NO>1</NO>
<PG>3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Antonucci-2008" MODIFIED="2016-05-18 17:00:14 +0100" MODIFIED_BY="[Empty name]" NAME="Antonucci 2008" TYPE="JOURNAL_ARTICLE">
<AU>Antonucci F, Rossi C, Gianfranceschi L, Rossetto O, Caleo M</AU>
<TI>Long-distance retrograde effects of botulinum neurotoxin</TI>
<SO>Journal of Neuroscience</SO>
<YR>2008</YR>
<VL>28</VL>
<PG>3689&#8211;96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Balint-2015" MODIFIED="2016-10-03 21:39:10 +0100" MODIFIED_BY="[Empty name]" NAME="Balint 2015" TYPE="JOURNAL_ARTICLE">
<AU>Balint B, Bhatia KP</AU>
<TI>Isolated and combined dystonia syndromes - an update on new genes and their phenotypes</TI>
<SO>European Journal of Neurology</SO>
<YR>2015</YR>
<VL>22</VL>
<NO>4</NO>
<PG>610-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Balshem-2011" MODIFIED="2016-08-22 10:20:16 +0100" MODIFIED_BY="[Empty name]" NAME="Balshem 2011" TYPE="JOURNAL_ARTICLE">
<AU>Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al</AU>
<TI>GRADE guidelines: 3. Rating the quality of evidence</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>401-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Benecke-2012" MODIFIED="2016-10-03 21:39:00 +0100" MODIFIED_BY="[Empty name]" NAME="Benecke 2012" TYPE="JOURNAL_ARTICLE">
<AU>Benecke R</AU>
<TI>Clinical Relevance of Botulinum Toxin Immunogenicity</TI>
<SO>BioDrugs</SO>
<YR>2012</YR>
<VL>26</VL>
<NO>2</NO>
<PG>e1-e9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bentivoglio-2015" MODIFIED="2016-10-03 21:38:54 +0100" MODIFIED_BY="[Empty name]" NAME="Bentivoglio 2015" TYPE="JOURNAL_ARTICLE">
<AU>Bentivoglio AR, Del Grande A, Petracca M, Tamara Ialongo T, Ricciardi L</AU>
<TI>Clinical differences between botulinum neurotoxin type A and B</TI>
<SO>Toxicon</SO>
<YR>2015</YR>
<VL>107</VL>
<PG>77-84</PG>
<IDENTIFIERS MODIFIED="2016-06-12 19:37:25 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-06-12 19:37:16 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="http://dx.doi.org/10.1016/j.toxicon.2015.08.001"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-BNF-2016a" MODIFIED="2016-06-12 19:57:09 +0100" MODIFIED_BY="[Empty name]" NAME="BNF 2016a" TYPE="OTHER">
<AU>British National Formulary</AU>
<TI>Botulinum toxin type A</TI>
<SO>National Institute for Health and Care Excellence</SO>
<YR>May 2016</YR>
<IDENTIFIERS MODIFIED="2016-06-12 19:56:50 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-06-12 19:56:50 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="http://www.evidence.nhs.uk/formulary/bnf/current/4-central-nervous-system/49-drugs-used-in-parkinsonism-and-related-disorders/493-drugs-used-in-essential-tremor-chorea-tics-and-related-disorders/torsion-dystonias-and-other-involuntary-movements/botulinum-toxin-type-a"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-BNF-2016b" MODIFIED="2016-06-12 19:59:09 +0100" MODIFIED_BY="[Empty name]" NAME="BNF 2016b" TYPE="OTHER">
<AU>British National Formulary</AU>
<TI>Botulinum toxin type B</TI>
<SO>National Institute for Health and Care Excellence</SO>
<YR>May 2016</YR>
<IDENTIFIERS MODIFIED="2016-06-12 19:59:09 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-06-12 19:59:09 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="http://www.evidence.nhs.uk/formulary/bnf/current/4-central-nervous-system/49-drugs-used-in-parkinsonism-and-related-disorders/493-drugs-used-in-essential-tremor-chorea-tics-and-related-disorders/torsion-dystonias-and-other-involuntary-movements/botulinum-toxin-type-b"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Boroff-1975" MODIFIED="2016-09-29 16:18:32 +0100" MODIFIED_BY="[Empty name]" NAME="Boroff 1975" TYPE="JOURNAL_ARTICLE">
<AU>Boroff DA, Chen GS</AU>
<TI>On the question of permeability of the blood&#8211;brain barrier to botulinum toxin</TI>
<SO>International Archives of Allergy and Applied Immunology</SO>
<YR>1975</YR>
<VL>48</VL>
<PG>495&#8211;504</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brashear-2008" MODIFIED="2016-10-03 21:38:39 +0100" MODIFIED_BY="[Empty name]" NAME="Brashear 2008" TYPE="JOURNAL_ARTICLE">
<AU>Brashear A</AU>
<TI>Botulinum toxin serotype A for cervical dystonia&#8212;an assessment</TI>
<SO>US Neurology</SO>
<YR>2008</YR>
<VL>4</VL>
<NO>2</NO>
<PG>58-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brin-2008" MODIFIED="2016-10-03 21:38:31 +0100" MODIFIED_BY="[Empty name]" NAME="Brin 2008" TYPE="JOURNAL_ARTICLE">
<AU>Brin MF, Comella CL, Jankovic J, Lai F, Naumann M; CD-017 BoNTA Study Group.</AU>
<TI>Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay</TI>
<SO>Movement Disorders</SO>
<YR>2008</YR>
<VL>23</VL>
<NO>10</NO>
<PG>1353-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bro_x017c_ek-2006" MODIFIED="2016-02-18 19:21:16 +0000" MODIFIED_BY="[Empty name]" NAME="Bro&#380;ek 2006" TYPE="JOURNAL_ARTICLE">
<AU>Bro&#380;ek JL, Guyatt GH, Schünemann HJ</AU>
<TI>How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure</TI>
<SO>Health and Quality of Life Outcomes</SO>
<YR>2006</YR>
<VL>4</VL>
<PG>69</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carpenter-2013" MODIFIED="2016-09-08 13:51:45 +0100" MODIFIED_BY="[Empty name]" NAME="Carpenter 2013" TYPE="BOOK">
<AU>Carpenter J, Kenward M</AU>
<SO>Multiple Imputation and its Application</SO>
<YR>2013</YR>
<PB>Wiley</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chan-1991" NAME="Chan 1991" TYPE="JOURNAL_ARTICLE">
<AU>Chan J, Brin MF, Fanh S</AU>
<TI>Idiopathic cervical dystonia: clinical characteristics</TI>
<SO>Movement Disorders</SO>
<YR>1991</YR>
<VL>6</VL>
<PG>119-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohen-1988" MODIFIED="2016-10-03 21:38:23 +0100" MODIFIED_BY="[Empty name]" NAME="Cohen 1988" TYPE="BOOK">
<AU>Cohen J</AU>
<SO>Statistical Power Analysis in the Behavioral Sciences</SO>
<YR>1988</YR>
<EN>2nd</EN>
<PB>Hillsdale (NJ): Lawrence Erlbaum Associates, Inc</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Comella-2015" MODIFIED="2016-10-03 21:38:05 +0100" MODIFIED_BY="[Empty name]" NAME="Comella 2015" TYPE="JOURNAL_ARTICLE">
<AU>Comella CL, Fox SH, Bhatia KP, Perlmutter JS, Jinnah HA, Zurowski M, et al</AU>
<TI>Development of the comprehensive Cervical Dystonia Rating Scale: methodology</TI>
<SO>Movement Disorders</SO>
<YR>2015</YR>
<VL>2</VL>
<NO>2</NO>
<PG>135-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Consky-1994" MODIFIED="2016-10-03 21:37:47 +0100" MODIFIED_BY="[Empty name]" NAME="Consky 1994" TYPE="BOOK_SECTION">
<AU>Consky ES, Lang AE</AU>
<TI>Clinical assessments of patients with cervical dystonia</TI>
<SO>Therapy with Botulinum Toxin</SO>
<YR>1994</YR>
<PG>211-37</PG>
<ED>Jankovic J, Hallett M</ED>
<PB>Marcel Dekker, Inc</PB>
<CY>New York (NY)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Corbett-2014" MODIFIED="2016-10-03 21:37:57 +0100" MODIFIED_BY="[Empty name]" NAME="Corbett 2014" TYPE="JOURNAL_ARTICLE">
<AU>Corbett MS, Higgins JP, Woolacott NF</AU>
<TI>Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool</TI>
<SO>Research Synthesis Methods</SO>
<YR>2014</YR>
<VL>5</VL>
<NO>1</NO>
<PG>79-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Costa-2005" MODIFIED="2016-10-03 21:37:36 +0100" MODIFIED_BY="[Empty name]" NAME="Costa 2005" TYPE="COCHRANE_REVIEW">
<AU>Costa J, Espírito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, et al</AU>
<TI>Botulinum toxin type A therapy for cervical dystonia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2016-03-17 08:34:48 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-03-17 08:34:37 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003633.pub2"/><IDENTIFIER MODIFIED="2016-03-17 08:34:48 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15674910"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cullis-2000" MODIFIED="2016-10-03 21:37:28 +0100" MODIFIED_BY="[Empty name]" NAME="Cullis 2000" TYPE="JOURNAL_ARTICLE">
<AU>Cullis PA, Barnes M, Duane D, Chen RE, Freeman A, Fross R, et al</AU>
<TI>Safety and tolerability of repeated doses of Neurobloc (Botulinum toxin type B) in patients with cervical dystonia: an open-label, dose-escalation study</TI>
<SO>Movement Disorders</SO>
<YR>2000</YR>
<VL>15 (Suppl 2)</VL>
<PG>29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Paiva-1999" MODIFIED="2016-09-29 16:23:22 +0100" MODIFIED_BY="[Empty name]" NAME="de Paiva 1999" TYPE="JOURNAL_ARTICLE">
<AU>de Paiva A, Meunier FA, Molgó J, Aoki KR, Dolly JO</AU>
<TI>Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals</TI>
<SO>Proceedings of the National Academy of Sciences of the United States of America</SO>
<YR>1999</YR>
<VL>96</VL>
<PG>3200&#8211;5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Defazio-2013" MODIFIED="2016-10-03 21:35:34 +0100" MODIFIED_BY="[Empty name]" NAME="Defazio 2013" TYPE="JOURNAL_ARTICLE">
<AU>Defazio G, Jankovic J, Giel JL, Papapetropoulos S</AU>
<TI>Descriptive epidemiology of cervical dystonia</TI>
<SO>Tremor and Other Hyperkinetic Movements</SO>
<YR>2013</YR>
<VL>3</VL>
<PG>tre-03-193-4374-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duchen-1971" MODIFIED="2016-10-03 21:35:20 +0100" MODIFIED_BY="[Empty name]" NAME="Duchen 1971" TYPE="JOURNAL_ARTICLE">
<AU>Duchen LW</AU>
<TI>An electron microscopic study of the changes induced by botulinum toxin in the motor end-plates of slow and fast skeletal muscle fibres of the mouse</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1971</YR>
<VL>14</VL>
<PG>47-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eleopra-1997" MODIFIED="2016-10-03 21:35:14 +0100" MODIFIED_BY="[Empty name]" NAME="Eleopra 1997" TYPE="JOURNAL_ARTICLE">
<AU>Eleopra R, Tugnoli V, Rossetto O, Montecucco C, De Grandis D</AU>
<TI>Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human</TI>
<SO>Neuroscience Letters</SO>
<YR>1997</YR>
<VL>224</VL>
<NO>2</NO>
<PG>91-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ESDE-2000" MODIFIED="2016-10-03 23:29:28 +0100" MODIFIED_BY="[Empty name]" NAME="ESDE 2000" TYPE="JOURNAL_ARTICLE">
<AU>Epidemiological Study of Dystonia in Europe (ESDE) Collaborative Group</AU>
<TI>A prevalence study of primary dystonia in eight European countries</TI>
<SO>Journal of Neurology</SO>
<YR>2000</YR>
<VL>247</VL>
<PG>787-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fabbri-2015" MODIFIED="2016-10-07 00:18:28 +0100" MODIFIED_BY="[Empty name]" NAME="Fabbri 2015" TYPE="JOURNAL_ARTICLE">
<AU>Fabbri M, Leodori G, Fernandes RM, Bhidayasiri R, Marti MJ, Colosimo C, et al</AU>
<TI>Neutralizing antibody and botulinum toxin therapy: a systematic review and meta-analysis</TI>
<SO>Neurotoxicity Research</SO>
<YR>2015</YR>
<VL>29</VL>
<PG>105-17</PG>
<IDENTIFIERS MODIFIED="2016-02-19 22:54:38 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-02-19 22:54:38 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="26467676"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Filippi-1993" MODIFIED="2016-09-29 16:27:30 +0100" MODIFIED_BY="[Empty name]" NAME="Filippi 1993" TYPE="JOURNAL_ARTICLE">
<AU>Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E</AU>
<TI>Botulinum A toxin effects on rat jaw muscle spindles</TI>
<SO>Acta Oto-laryngologica</SO>
<YR>1993</YR>
<VL>113</VL>
<PG>400&#8211;4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Follmann-1992" MODIFIED="2016-02-18 19:21:16 +0000" MODIFIED_BY="[Empty name]" NAME="Follmann 1992" TYPE="JOURNAL_ARTICLE">
<AU>Follmann D, Elliott P, Suh I, Cutler J</AU>
<TI>Variance imputation for overviews of clinical trials with continuous response</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1992</YR>
<VL>45</VL>
<PG>769-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Foltz-1959" NAME="Foltz 1959" TYPE="JOURNAL_ARTICLE">
<AU>Foltz EL, Knopp LM, Ward AA</AU>
<TI>Experimental spasmodic torticollis</TI>
<SO>Journal of Neurosurgery</SO>
<YR>1959</YR>
<VL>16</VL>
<PG>55-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Frevert-2010" MODIFIED="2016-02-18 19:35:09 +0000" MODIFIED_BY="[Empty name]" NAME="Frevert 2010" TYPE="JOURNAL_ARTICLE">
<AU>Frevert J, Dressler D</AU>
<TI>Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?</TI>
<SO>Biologics: Targets &amp; Therapy</SO>
<YR>2010 Dec</YR>
<VL>4</VL>
<PG>325-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Furukawa-2006" MODIFIED="2016-09-08 13:52:27 +0100" MODIFIED_BY="[Empty name]" NAME="Furukawa 2006" TYPE="JOURNAL_ARTICLE">
<AU>Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N</AU>
<TI>Imputing missing standard deviations in meta-analyses can provide accurate results</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2006</YR>
<VL>59</VL>
<NO>1</NO>
<PG>7-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro-GDT-2014" MODIFIED="2016-10-04 00:09:11 +0100" MODIFIED_BY="[Empty name]" NAME="GRADEpro GDT 2014" TYPE="COMPUTER_PROGRAM">
<TI>GRADEpro GDT</TI>
<YR>2014</YR>
<EN>Date accessed: September 2016</EN>
<PB>GRADE Working Group, McMaster University</PB>
<CY>Hamilton (ON)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Greene-1993" MODIFIED="2016-02-18 19:21:16 +0000" MODIFIED_BY="[Empty name]" NAME="Greene 1993" TYPE="JOURNAL_ARTICLE">
<AU>Greene PE, Fahn S</AU>
<TI>Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A</TI>
<SO>Movement Disorders</SO>
<YR>1993</YR>
<VL>8(4)</VL>
<PG>479-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011" MODIFIED="2016-09-29 16:30:08 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al</AU>
<TI>GRADE guidelines 6. Rating the quality of evidence - imprecision</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1283-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hallett-1998" MODIFIED="2016-10-03 21:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Hallett 1998" TYPE="JOURNAL_ARTICLE">
<AU>Hallett M</AU>
<TI>The neurophysiology of dystonia</TI>
<SO>Archives of Neurology</SO>
<YR>1998</YR>
<VL>55</VL>
<NO>5</NO>
<PG>601-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hanna-1998" MODIFIED="2016-10-03 21:34:34 +0100" MODIFIED_BY="[Empty name]" NAME="Hanna 1998" TYPE="JOURNAL_ARTICLE">
<AU>Hanna PA, Jankovic J</AU>
<TI>Mouse bioassay versus western blot assay for botulinum toxin antibodies: correlation with clinical response</TI>
<SO>Neurology</SO>
<YR>1998</YR>
<VL>50</VL>
<NO>6</NO>
<PG>1624-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hedges-1985" MODIFIED="2016-08-29 09:25:00 +0100" MODIFIED_BY="[Empty name]" NAME="Hedges 1985" TYPE="BOOK">
<AU>Hedges LV, Olkin I</AU>
<SO>Statistical Methods for Meta-Analysis</SO>
<YR>1985</YR>
<PB>Academic Press, Inc</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2016-07-20 17:37:26 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557&#8211;60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011a" MODIFIED="2016-10-03 21:34:24 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011a" TYPE="OTHER">
<AU>Higgins JP, Deeks JJ editor(s)</AU>
<TI>Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011b" MODIFIED="2016-10-03 21:34:17 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011b" TYPE="OTHER">
<AU>Higgins JPT, Altman DG, Sterne JAC editor(s)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011c" MODIFIED="2016-10-03 21:34:06 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011c" TYPE="OTHER">
<AU>Higgins JPT, Deeks JJ, Altman DG editor(s)</AU>
<TI>Chapter 16: Special topics in statistics. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Holland-1981" MODIFIED="2016-10-07 00:19:56 +0100" MODIFIED_BY="[Empty name]" NAME="Holland 1981" TYPE="JOURNAL_ARTICLE">
<AU>Holland RL, Brown MC</AU>
<TI>Nerve growth in botulinum toxin poisoned muscles</TI>
<SO>Neuroscience</SO>
<YR>1981</YR>
<VL>6</VL>
<PG>1167&#8211;79</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Imberger-2016" MODIFIED="2016-09-08 14:00:35 +0100" MODIFIED_BY="[Empty name]" NAME="Imberger 2016" TYPE="JOURNAL_ARTICLE">
<AU>Imberger G, Thorlund K, Gluud C, Wetterslev J</AU>
<TI>False-positive findings in Cochrane meta-analyses with and without application of trial sequential analysis: an empirical review</TI>
<SO>BMJ Open</SO>
<YR>2016</YR>
<VL>6</VL>
<NO>8</NO>
<PG>e011890</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jahanshani-1990" MODIFIED="2016-02-18 18:38:50 +0000" MODIFIED_BY="[Empty name]" NAME="Jahanshani 1990" TYPE="JOURNAL_ARTICLE">
<AU>Jahnanshani M, Marion M-H, Marsden CD</AU>
<TI>Natural history of adult-onset idiopathic torticollis</TI>
<SO>Archives of Neurology</SO>
<YR>1990</YR>
<VL>47</VL>
<PG>548-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jakobsen-2014" MODIFIED="2016-09-08 14:00:10 +0100" MODIFIED_BY="[Empty name]" NAME="Jakobsen 2014" TYPE="JOURNAL_ARTICLE">
<AU>Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud C</AU>
<TI>Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2014</YR>
<VL>14</VL>
<NO>1</NO>
<PG>120</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jankovic-2004" MODIFIED="2016-09-29 16:41:36 +0100" MODIFIED_BY="[Empty name]" NAME="Jankovic 2004" TYPE="JOURNAL_ARTICLE">
<AU>Jankovic J</AU>
<TI>Botulinum toxin in clinical practice</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>2004</YR>
<VL>75</VL>
<NO>7</NO>
<PG>951-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jankovic-2006" MODIFIED="2016-10-03 21:33:59 +0100" MODIFIED_BY="[Empty name]" NAME="Jankovic 2006" TYPE="JOURNAL_ARTICLE">
<AU>Jankovic J, Tsui J, Bergeron C</AU>
<TI>Prevalence of cervical dystonia and spasmodic torticollis in the United States general population</TI>
<SO>Parkinsonism &amp; Related Disorders</SO>
<YR>October 2007</YR>
<VL>13</VL>
<NO>7</NO>
<PG>411-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Juzans-1996" MODIFIED="2016-10-03 21:33:34 +0100" MODIFIED_BY="[Empty name]" NAME="Juzans 1996" TYPE="JOURNAL_ARTICLE">
<AU>Juzans P, Comella J, Molgo J, Faille L, Angaut-Petit D</AU>
<TI>Nerve terminal sprouting in botulinum type-A treated mouse levator auris longus muscle</TI>
<SO>Neuromuscular Disorders</SO>
<YR>1996</YR>
<VL>6</VL>
<NO>3</NO>
<PG>177-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lange-2009" MODIFIED="2016-10-07 00:17:36 +0100" MODIFIED_BY="[Empty name]" NAME="Lange 2009" TYPE="JOURNAL_ARTICLE">
<AU>Lange O, Bigalke H, Dengler R, Wegner F, deGroot M, Wohlfarth K</AU>
<TI>Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing?</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>2009</YR>
<VL>32</VL>
<NO>4</NO>
<PG>213-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liberati-2009" MODIFIED="2016-10-07 00:17:24 +0100" MODIFIED_BY="[Empty name]" NAME="Liberati 2009" TYPE="JOURNAL_ARTICLE">
<AU>Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al</AU>
<TI>The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration</TI>
<SO>PLOS Medicine</SO>
<YR>2009</YR>
<VL>6</VL>
<PG>e1000100</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Macefield-2014" MODIFIED="2016-02-18 19:21:16 +0000" MODIFIED_BY="[Empty name]" NAME="Macefield 2014" TYPE="JOURNAL_ARTICLE">
<AU>Macefield RC, Jacobs M, Korfage IJ, Nicklin J, Whistance RN, Brookes ST, et al</AU>
<TI>Developing core outcomes sets: methods for identifying and including patient-reported outcomes (PROs)</TI>
<SO>Trials</SO>
<YR>2014</YR>
<VL>15</VL>
<PG>49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marques-2016" MODIFIED="2016-10-03 21:33:22 +0100" MODIFIED_BY="[Empty name]" NAME="Marques 2016" TYPE="COCHRANE_REVIEW">
<AU>Marques RE, Duarte GS, Rodrigues FB, Castelão M, Ferreira J, Sampaio C, et al</AU>
<TI>Botulinum toxin type B for cervical dystonia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2016</YR>
<VL>13</VL>
<NO>5</NO>
<IDENTIFIERS MODIFIED="2016-10-03 21:33:22 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-03 21:33:22 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004315.pub3"/><IDENTIFIER MODIFIED="2016-05-18 15:13:35 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="27176573"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Matak-2014" MODIFIED="2016-10-03 21:32:06 +0100" MODIFIED_BY="[Empty name]" NAME="Matak 2014" TYPE="JOURNAL_ARTICLE">
<AU>Matak I, Lackovi&#263; Z</AU>
<TI>Botulinum toxin A, brain and pain</TI>
<SO>Progress in Neurobiology</SO>
<YR>2014</YR>
<VL>119-20</VL>
<PG>39&#8211;59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Matak-2015" MODIFIED="2016-10-03 21:31:51 +0100" MODIFIED_BY="[Empty name]" NAME="Matak 2015" TYPE="JOURNAL_ARTICLE">
<AU>Matak I, Lackovi&#263; Z</AU>
<TI>Botulinum neurotoxin type A: actions beyond SNAP-25?</TI>
<SO>Toxicology</SO>
<YR>2015</YR>
<VL>335</VL>
<PG>79-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Michiels-2005" MODIFIED="2016-09-29 16:44:08 +0100" MODIFIED_BY="[Empty name]" NAME="Michiels 2005" TYPE="JOURNAL_ARTICLE">
<AU>Michiels S, Piedbois P, Burdett S, Syz N, Stewart L, Pignon JP</AU>
<TI>Meta-analysis when only the median survival times are known: a comparison with individual patient data results</TI>
<SO>International Journal of Technology Assessment in Health Care</SO>
<YR>2005</YR>
<VL>21</VL>
<NO>1</NO>
<PG>119-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-M_x00fc_ller-2009" MODIFIED="2016-10-03 21:31:40 +0100" MODIFIED_BY="[Empty name]" NAME="Müller 2009" TYPE="JOURNAL_ARTICLE">
<AU>Müller K, Mix E, Adib Saberi F, Dressler D, Benecke R</AU>
<TI>Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity</TI>
<SO>Journal of Neural Transmission</SO>
<YR>2009</YR>
<VL>116</VL>
<NO>5</NO>
<PG>579-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Brien-1979" MODIFIED="2016-09-08 13:58:50 +0100" MODIFIED_BY="[Empty name]" NAME="O'Brien 1979" TYPE="JOURNAL_ARTICLE">
<AU>O&#8217;Brien PC, Fleming TR</AU>
<TI>A multiple testing procedure for clinical trials</TI>
<SO>Biometrics</SO>
<YR>1979</YR>
<VL>35</VL>
<PG>549-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Palomar-2012" MODIFIED="2016-10-03 21:29:54 +0100" MODIFIED_BY="[Empty name]" NAME="Palomar 2012" TYPE="JOURNAL_ARTICLE">
<AU>Palomar FJ, Mir P</AU>
<TI>Neurophysiological changes after intramuscular injection of botulinum toxin</TI>
<SO>Clinical Neurophysiology</SO>
<YR>2012</YR>
<VL>123</VL>
<NO>1</NO>
<PG>54&#8211;60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pellizzari-1999" MODIFIED="2016-09-29 16:45:56 +0100" MODIFIED_BY="[Empty name]" NAME="Pellizzari 1999" TYPE="JOURNAL_ARTICLE">
<AU>Pellizzari R, Rossetto O, Schiavo G, Montecucco C</AU>
<TI>Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses</TI>
<SO>Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences</SO>
<YR>1999</YR>
<VL>354</VL>
<PG>259&#8211;68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peters-2006" MODIFIED="2016-10-07 00:17:02 +0100" MODIFIED_BY="[Empty name]" NAME="Peters 2006" TYPE="JOURNAL_ARTICLE">
<AU>Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L</AU>
<TI>Comparison of two methods to detect publication bias in meta-analysis</TI>
<SO>JAMA</SO>
<YR>2006</YR>
<VL>295</VL>
<NO>6</NO>
<PG>676-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2016-05-09 20:41:04 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rosales-1996" MODIFIED="2016-09-29 16:46:25 +0100" MODIFIED_BY="[Empty name]" NAME="Rosales 1996" TYPE="JOURNAL_ARTICLE">
<AU>Rosales RL, Arimura K, Takenaka S, Osame M</AU>
<TI>Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>1996</YR>
<VL>19</VL>
<PG>488&#8211;96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rosales-2010" MODIFIED="2016-09-29 16:46:44 +0100" MODIFIED_BY="[Empty name]" NAME="Rosales 2010" TYPE="JOURNAL_ARTICLE">
<AU>Rosales RL, Dressler D</AU>
<TI>On muscle spindles, dystonia and botulinum toxin</TI>
<SO>European Journal of Neurology</SO>
<YR>2010</YR>
<VL>17</VL>
<PG>71&#8211;80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rubin-1991" MODIFIED="2016-09-08 13:55:12 +0100" MODIFIED_BY="[Empty name]" NAME="Rubin 1991" TYPE="JOURNAL_ARTICLE">
<AU>Rubin DB, Schenker N</AU>
<TI>Multiple imputation in health-care databases: an overview and some applications</TI>
<SO>Statistics in Medicine</SO>
<YR>1991</YR>
<VL>10</VL>
<PG>585&#8211;98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2011" MODIFIED="2016-10-03 21:29:38 +0100" MODIFIED_BY="[Empty name]" NAME="Schünemann 2011" TYPE="OTHER">
<AU>Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH</AU>
<TI>Chapter 11: Presenting results and &#8216;Summary of findings' tables. In: Higgins JPT, Green S editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-2004" MODIFIED="2016-09-29 16:47:45 +0100" MODIFIED_BY="[Empty name]" NAME="Simpson 2004" TYPE="JOURNAL_ARTICLE">
<AU>Simpson LL</AU>
<TI>Identification of the major steps in botulinum toxin action</TI>
<SO>Annual Review of Pharmacology and Toxicology</SO>
<YR>2004</YR>
<VL>44</VL>
<PG>167-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smeeth-1999" MODIFIED="2016-02-18 19:21:16 +0000" MODIFIED_BY="[Empty name]" NAME="Smeeth 1999" TYPE="JOURNAL_ARTICLE">
<AU>Smeeth L, Haines A, Ebrahim S</AU>
<TI>Numbers needed to treat derived from meta-analysis - sometimes informative, usually misleading</TI>
<SO>BMJ</SO>
<YR>1999</YR>
<VL>318(7197)</VL>
<PG>1548-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stata-2015" MODIFIED="2016-10-04 00:09:33 +0100" MODIFIED_BY="[Empty name]" NAME="Stata 2015" TYPE="COMPUTER_PROGRAM">
<AU>StataCorp</AU>
<TI>Stata Statistical Software: release 14</TI>
<YR>2015</YR>
<EN>Date accessed: September 2016</EN>
<PB>StataCorp</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Steeves-2012" MODIFIED="2016-10-07 00:16:41 +0100" MODIFIED_BY="[Empty name]" NAME="Steeves 2012" TYPE="JOURNAL_ARTICLE">
<AU>Steeves TD, Day L, Dykeman J, Jette N, Pringsheim T</AU>
<TI>The prevalence of primary dystonia: a systematic review and meta&#8208;analysis</TI>
<SO>Movement Disorders</SO>
<YR>2012</YR>
<VL>27</VL>
<NO>14</NO>
<PG>1789-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2001" MODIFIED="2016-09-29 16:48:57 +0100" MODIFIED_BY="[Empty name]" NAME="Sterne 2001" TYPE="JOURNAL_ARTICLE">
<AU>Sterne JA, Egger M</AU>
<TI>Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2001</YR>
<VL>54</VL>
<NO>10</NO>
<PG>1046-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2011" MODIFIED="2016-10-03 21:29:09 +0100" MODIFIED_BY="[Empty name]" NAME="Sterne 2011" TYPE="OTHER">
<AU>Sterne JAC, Egger M, Moher D editor(s)</AU>
<TI>Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tarsy-2006" MODIFIED="2016-10-03 21:28:51 +0100" MODIFIED_BY="[Empty name]" NAME="Tarsy 2006" TYPE="JOURNAL_ARTICLE">
<AU>Tarsy D, Simon D</AU>
<TI>Dystonia</TI>
<SO>New Egyptian Journal of Medicine</SO>
<YR>2006</YR>
<VL>355</VL>
<PG>818-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2011" MODIFIED="2016-09-30 09:46:40 +0100" MODIFIED_BY="[Empty name]" NAME="Thorlund 2011" TYPE="OTHER">
<AU>Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C</AU>
<TI>User manual for trial sequential analysis (TSA)</TI>
<SO>ctu.dk/tsa/files/tsa &#775;manual.pdf 2011</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-TSA-2011" MODIFIED="2016-10-04 00:09:41 +0100" MODIFIED_BY="[Empty name]" NAME="TSA 2011" TYPE="COMPUTER_PROGRAM">
<AU>Copenhagen Trial Unit</AU>
<TI>Trial Sequential Analysis. Version 0.9 Beta</TI>
<YR>2011</YR>
<EN>Date accessed: September 2016</EN>
<PB>Copenhagen Trial Unit</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tugwell-2007" MODIFIED="2016-02-18 19:21:16 +0000" MODIFIED_BY="[Empty name]" NAME="Tugwell 2007" TYPE="JOURNAL_ARTICLE">
<AU>Tugwell P, Boers M, Brooks P, Simon L, Strand V, Idzerda L</AU>
<TI>OMERACT: an international initiative to improve outcome measurement in rheumatology</TI>
<SO>Trials</SO>
<YR>2007</YR>
<VL>8</VL>
<PG>38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walker-2014" MODIFIED="2016-10-03 21:28:31 +0100" MODIFIED_BY="[Empty name]" NAME="Walker 2014" TYPE="JOURNAL_ARTICLE">
<AU>Walker TJ, Dayan SH</AU>
<TI>Comparison and overview of currently available neurotoxins</TI>
<SO>Journal of Clinical and Aesthetic Dermatology</SO>
<YR>2014</YR>
<VL>7</VL>
<NO>2</NO>
<PG>31-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2008" MODIFIED="2016-09-08 13:55:55 +0100" MODIFIED_BY="[Empty name]" NAME="Wetterslev 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Thorlund K, Brok J, Gluud C</AU>
<TI>Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2008</YR>
<VL>61</VL>
<PG>64-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2009" MODIFIED="2016-09-08 13:56:16 +0100" MODIFIED_BY="[Empty name]" NAME="Wetterslev 2009" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Thorlund K, Brok J, Gluud C</AU>
<TI>Estimating required information size by quantifying diversity in random-effects model meta-analyses</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2009</YR>
<VL>9</VL>
<PG>86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wiebe-2006" MODIFIED="2016-09-08 13:54:53 +0100" MODIFIED_BY="[Empty name]" NAME="Wiebe 2006" TYPE="JOURNAL_ARTICLE">
<AU>Wiebe N, Vandermeer B, Platt RW, Klassen TP, Moher D, Barrowman NJ</AU>
<TI>A systematic review identifies a lack of standardization in methods for handling missing variance data</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2006</YR>
<VL>59</VL>
<NO>4</NO>
<PG>342-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zoons-2012" MODIFIED="2016-10-03 21:28:22 +0100" MODIFIED_BY="[Empty name]" NAME="Zoons 2012" TYPE="JOURNAL_ARTICLE">
<AU>Zoons E, Dijkgraaf MG, Dijk JM, van Schaik IN, Tijssen MA</AU>
<TI>Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value</TI>
<SO>Neurology</SO>
<YR>2012</YR>
<VL>259</VL>
<NO>12</NO>
<PG>2519&#8211;26</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2016-02-18 18:38:03 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Costa-2003" MODIFIED="2016-02-18 18:38:03 +0000" MODIFIED_BY="[Empty name]" NAME="Costa 2003" TYPE="COCHRANE_REVIEW">
<AU>Costa J, Borges AA, Espírito-Santo CC, Ferreira J, Coelho MM, Moore P, Sampaio C</AU>
<TI>Botulinum toxin type A versus botulinum toxin type B for cervical dystonia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2016-02-18 18:38:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-02-18 18:38:03 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004314.pub2"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-10-04 00:20:43 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-10-04 00:20:43 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2016-10-03 23:37:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Comella-2005">
<CHAR_METHODS MODIFIED="2016-10-03 23:37:42 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, controlled study; randomisation in permuted block allocation schemes.</P>
<P>Data were collected at baseline, week 4, and every 2 weeks thereafter up to 20 weeks post-injection.</P>
<P>Data were analysed on a ITT basis.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-03 21:23:49 +0100" MODIFIED_BY="[Empty name]">
<P>The study was conducted in the outpatient offices of unspecified dystonia study centres.</P>
<P>139 randomised participants</P>
<P>Mean age of participants was 56.7 years; 68% were female; the combined duration of cervical dystonia was 7.9 years. The mean TWSTRS total score was 41.8.</P>
<P>All participants had previously been exposed to a form of botulinum neurotoxin, and were required to have moderate severity CD, as well as a minimum of 15 on the TWSTRS motor severity subsection, for inclusion.</P>
<P>Exclusion criteria: predominant anterocollis and retrocollis</P>
<P>.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-03 21:23:43 +0100" MODIFIED_BY="[Empty name]">
<P>139 participants were randomised into 2 groups: BtA group (n = 74); BtB group (n = 65)</P>
<P>BtA group: BtA was obtained in vials containing 100 U <I>Clostridium botulinum</I> toxin type A, 0.5 mg albumin (human), and 0.9 mg sodium chloride in a sterile vacuum-dried form without a preservative. BtA was stored at a temperature at or below -5°C and reconstituted within 4 h of administration with 1 mL of 0.9% sterile unpreserved saline to provide a final concentration of 100 U/mL. Subjects randomised to BtA received a maximal dose of 250 U (2.5 mL). Subjects were injected with a volume of the appropriate study drug based on previous injection amounts. Muscle selection, dosing into each muscle, number of injection sites, and use of electromyography were at the discretion of the injecting physician.</P>
<P>BtB group: BtB was obtained in vials containing at least 5000 U <I>Clostridium botulinum</I> toxin type B, 0.05% albumin (human), 0.01 M sodium succinate, and 0.1 M sodium chloride buffer at a pH of 5.6. Commercially available vials of BtB contain overfill of approximately 0.1 mL to 0.2 mL or 500 U to 1000 U BtB. The BtB was stored at a temperature between 2°C and 8°C. Each vial of BtB was diluted with 0.25 mL of 0.9% sterile unpreserved saline to provide a concentration of at least 4000 U/mL. Subjects randomised to BtB received a maximal dose of 10,000 U (2.5 mL).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-03 21:23:07 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcomes:</B>
</P>
<UL>
<LI>Change in total TWSTRS score at week 4</LI>
<LI>Duration of clinical effect (the time in days until the target TWSTRS score was reached)</LI>
<LI>Adverse effects evaluated by spontaneous report and adverse events interviews</LI>
</UL>
<P>
<B>Secondary outcomes: </B>
</P>
<UL>
<LI>Physician Global Assessment of Change (-4 is very marked worsening, 0 is no change and +4 is complete remission)</LI>
<LI>Patient Global Assessment and pain and discomfort at baseline injection</LI>
</UL>
<P>No neutralising antibody testing was performed.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-03 21:23:21 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-03 23:38:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pappert-2008">
<CHAR_METHODS MODIFIED="2016-10-03 23:38:12 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, controlled trial; randomisation was done via a Interactive Voice Response system, which created a subject randomisation number which was then forwarded to the site pharmacist who prepared the study drug.</P>
<P>Data were collected at baseline, week 4 post-injection and every 4 weeks until there was a further need for botulinum therapy.</P>
<P>Both PP and ITT analyses were performed, but the study reported only the PP analysis.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-03 21:52:45 +0100" MODIFIED_BY="[Empty name]">
<P>Multi-centre trial conducted in 24 sites in Europe (Poland, Hungary, UK, Italy, Spain, Germany, Slovakia, France and Portugal).</P>
<P>111 randomised participants</P>
<P>Mean age = 48.9 years; 55.9% were female; and the average duration of CD was 6.6 years.</P>
<P>Exclusion criteria: people with pure anterocollis and retrocollis, as well as previous treatment with botulinum toxin</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-03 22:25:46 +0100" MODIFIED_BY="[Empty name]">
<P>Participants were randomised into 2 groups: BtA group (n = 56); BtB group (n = 55)</P>
<P>BtA group: BtA was obtained by the pharmacy (100 U of vacuum-dried BtA neurotoxin complex) and stored at or below -5°C. The final concentration of BtA was 75 U/mL. Electromyography was used at the discretion of the investigator providing the injection.</P>
<P>BtB group: BtB supplied by the manufacturer in insulated shipping boxes, and maintained at 2°C to 8°C. BtB is a clear, colourless to light yellow, sterile injectable solution containing 5000 U of BtB per mL in an isotonic solution of 0.05% human serum albumin/0.01M succinate/0.1M sodium chloride buffer at an approximate pH of 5.6. The final concentration of BtB was 5,000 U/mL. Electromyography was used at the discretion of the investigator providing the injection.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-03 23:38:30 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome:</B>
</P>
<UL>
<LI>Change in total TWSTRS score at 4 weeks post-injection</LI>
</UL>
<P>
<B>Secondary outcomes:</B>
</P>
<UL>
<LI>Change in TWSTRS sub-scores (i.e. pain, severity and disability)</LI>
<LI>Subject pain assessment on VAS</LI>
<LI>Primary Investigator and Patient Global Assessment (5-point scales for both frequency and intensity) on VAS at week 4</LI>
<LI>Adverse events by spontaneous reporting and on investigation</LI>
</UL>
<P>No neutralising antibody testing was performed.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-03 21:25:52 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-04 00:20:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tintner-2005">
<CHAR_METHODS MODIFIED="2016-10-03 23:38:37 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, controlled trial; randomisation method not explained.</P>
<P>Data were collected at baseline and at week 2 post-injection.</P>
<P>It is unclear wether the data were analysed PP or by an ITT method.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-03 21:53:01 +0100" MODIFIED_BY="[Empty name]">
<P>The location of the study was not mentioned.</P>
<P>20 randomised participants</P>
<P>Mean age: BtA group = 55 years; BtB group = 64 years; 14 participants were female. The duration of CD in the participants is unknown.</P>
<P>Participants were required to have a previous response to BtA within the last year of sufficient magnitude for functional improvement.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-04 00:20:43 +0100" MODIFIED_BY="[Empty name]">
<P>BtA group: n = 11</P>
<P>BtB group: n = 9</P>
<P>No information was provided about the specific dosages or frequency of administration of Bt therapy. No information was provided about length of follow-up. </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-03 21:27:07 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome:</B>
</P>
<UL>
<LI>TWSTRS sub-score at week 2 post-injection</LI>
</UL>
<P>
<B>Secondary outcomes:</B>
</P>
<UL>
<LI>Heart rate</LI>
<LI>Blood pressure</LI>
<LI>Orthostatic heart rate regulation</LI>
<LI>Heart rate variation with respiration</LI>
<LI>Saliva production</LI>
<LI>Ocular autonomic testing</LI>
<LI>Composite Autonomic Scoring Scale</LI>
<LI>Visual Functional Questionnaire</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-09-30 09:40:02 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>
<B>Abbreviations</B>
</P>
<P>AI: assistant investigator<BR/>AEs: adverse events<BR/>Bt: botulinum toxin<BR/>BtA: botulinum toxin type A (onabotulinumtoximA only in this systematic review)<BR/>BtB: botulinum toxin type B (rimabotulinumtoxinB)<BR/>CD: cervical dystonia<BR/>h: hour(s)<BR/>ITT: intention-to-treat analysis<BR/>PI: principal investigator<BR/>PP: per protocol<BR/>TWSTRS: Toronto Western Spasmodic Torticollis Rating Scale<BR/>
<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2014-10-08 17:05:24 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-10-03 23:38:07 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-10-03 21:53:10 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-03 21:25:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Comella-2005">
<DESCRIPTION>
<P>Quote: &#8220;Random assignments were generated by the study biostatistician, were stratified by center, and used permuted block allocation schemes with blocks of randomly allocated lengths of two or four. The study biostatistician ensured that the initial assignments were balanced across centers. The permuted block approach prevented imbalances in the numbers randomized to each treatment arm...&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-03 21:26:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pappert-2008">
<DESCRIPTION>
<P>Quote: &#8220;Subjects were randomized in a 1:1 ratio of BoNT-A [BtA] to BoNT-B [BtB]. The site Principal Investigator (PI) contacted an Interactive Voice Response system for a Subject Randomization Number.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-03 21:53:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tintner-2005">
<DESCRIPTION>
<P>The text refers to this trial being randomised, though method of randomisation was not specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-10-03 21:26:14 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-03 21:25:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Comella-2005">
<DESCRIPTION>
<P>Quote: &#8220;Random assignments were generated by the study biostatistician, were stratified by center, and used permuted block allocation schemes with blocks of randomly allocated lengths of two or four. The study biostatistician ensured that the initial assignments were balanced across centers. The permuted block approach prevented imbalances in the numbers randomized to each treatment arm...&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-03 21:26:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pappert-2008">
<DESCRIPTION>
<P>Quote: &#8220;Treatment allocation for the randomization number was forwarded to the site pharmacist who prepared the study drug and had no contact with the subject or injector. All other study personnel were blinded.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-30 09:42:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tintner-2005">
<DESCRIPTION>
<P>Method of allocation concealment not specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-10-05 11:29:54 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2016-10-03 21:27:44 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.04" NO="4">
<NAME>Outcome group:Independent Drug Preparer</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>Outcome group: Principal Investigator (PI)</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.02" NO="2">
<NAME>Outcome group: Rating Investigator (RI)</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.03" NO="3">
<NAME>Outcome group: Study Coordinator</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-10-03 21:25:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Comella-2005">
<DESCRIPTION>
<P>Quote: &#8220;The principal/treating investigator (PI) enrolled the subjects, assessed the inclusion and exclusion criteria, obtained informed consent, applied and evaluated the UBI [unilateral brow injection], performed the injection of study drug (BoNTA or BoNTB), reported complications associated with injection, assessed adverse events, and determined when subjects reached the defined end point of the study. (&#8230;) The PI, RI, and coordinator were blinded to serotype administered to each subject.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2016-10-03 21:25:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Comella-2005">
<DESCRIPTION>
<P>Quote: &#8220;The rating investigator (RI) reviewed the TWSTRS teaching tape to ensure uniform ratings and assessed subjects using the TWSTRS (motor severity, disability, and pain) and the physician&#8217;s global assessment (PGA). The RI did not perform other study procedures. (&#8230;) The PI, RI, and coordinator were blinded to serotype administered to each subject.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.03" MODIFIED="2016-10-03 21:25:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Comella-2005">
<DESCRIPTION>
<P>Quote: &#8220;The study coordinator scheduled study visits, recorded concomitant medications, obtained the subjective global assessment (SGA), and completed study-related questionnaires. (&#8230;) The PI, RI, and coordinator were blinded to serotype administered to each subject.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-10-03 21:25:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Comella-2005">
<DESCRIPTION>
<P>Quote: &#8220;The drug preparer obtained the randomization code for each subject from the study biostatistician and prepared the BoNTA or BoNTB.&#8221;</P>
<P>The drug preparer was not involved in other study procedures.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-10-03 21:26:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pappert-2008">
<DESCRIPTION>
<P>Quote: &#8220;At screening (&#8804;21 days prior to baseline visit), the PI performed a history, examination, and confirmed inclusion/exclusion criteria. At baseline, prior to injection, the PI performed the TWSTRS (&#8230;). At week 4 and all subsequent visits, the PI performed the TWSTRS and Investigator Global VAS [0 mm (much worse) to 100 mm (much better) at the time of evaluation compared to baseline].&#8221;</P>
<P>Quote: &#8220;All other study personnel were blinded&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2016-10-03 21:26:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pappert-2008">
<DESCRIPTION>
<P>Quote: &#8220;At baseline, prior to injection, (&#8230;) the AI administered the subject Pain Visual Analogue Scale (VAS) [0 mm (worst pain ever) to 100 mm (no pain)].</P>
<P>The Administrative Investigator conducted the remaining visits including collection of AEs and the administration of the Subject Pain VAS and Subject Global VAS [ranging from 0 mm (much worse) to 100 mm (much better) at the time of evaluation compared to baseline].&#8221;</P>
<P>Quote: &#8220;All other study personnel were blinded&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.03" MODIFIED="2016-10-03 21:26:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pappert-2008">
<DESCRIPTION>
<P>Quote: &#8220;At baseline, prior to injection, (&#8230;) the AI administered the subject Pain Visual Analogue Scale (VAS) [0 mm (worst pain ever) to 100 mm (no pain)].</P>
<P>The Administrative Investigator conducted the remaining visits including collection of AEs and the administration of the Subject Pain VAS and Subject Global VAS [ranging from 0 mm (much worse) to 100 mm (much better) at the time of evaluation compared to baseline].&#8221;</P>
<P>Quote: &#8220;All other study personnel were blinded&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-10-03 21:26:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pappert-2008">
<DESCRIPTION>
<P>Quote: &#8220;An unblinded pharmacist prepared the study drug&#8221;.</P>
<P>Quote: &#8220;pharmacist who prepared the study drug and had no contact with the subject or injector&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-09-30 09:42:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tintner-2005">
<DESCRIPTION>
<P>The text refers to this trial being double-blind, though no evidence of adequate participant blinding was provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2016-09-30 09:41:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tintner-2005">
<DESCRIPTION>
<P>The text refers to this trial being double-blind, though no evidence of adequate participant blinding was provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.03" MODIFIED="2016-10-03 21:27:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tintner-2005">
<DESCRIPTION>
<P>The text refers to this trial being double-blind, though no evidence of adequate participant blinding was provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-10-03 21:27:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tintner-2005">
<DESCRIPTION>
<P>The text refers to this trial being double-blind, though no evidence of adequate participant blinding was provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2016-10-03 22:14:31 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>Outcome group: Objective Outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.02" NO="2">
<NAME>Outcome group: Subjective Outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-03 21:25:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Comella-2005">
<DESCRIPTION>
<P>Quote: &#8220;The PI, RI, and coordinator were blinded to serotype administered to each subject.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-02-03 08:16:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Comella-2005">
<DESCRIPTION>
<P>All participants had previous successful treatment with BtA, which could have led to the recognition of the expected effect, or to the lack of it. However, this would presumably not have an effect as the comparison arm was also a botulinum toxin formulation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-03 21:26:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pappert-2008">
<DESCRIPTION>
<P>Quote: &#8220;All other study personnel were blinded.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-10-03 22:14:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pappert-2008">
<DESCRIPTION>
<P>All participants were toxin-naive. However, this would presumably not have an effect as the comparison arm was also a botulinum toxin formulation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-09-30 09:42:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tintner-2005">
<DESCRIPTION>
<P>The text refers to this trial being double-blind, though no evidence of adequate investigator blinding was provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-09-30 09:42:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tintner-2005">
<DESCRIPTION>
<P>The text refers to this trial being double-blind, though no evidence of adequate investigator blinding was provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-10-03 23:38:07 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-03 23:38:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Comella-2005">
<DESCRIPTION>
<P>Only one post-randomisation withdrawal occurred, in the BtA group (inability to travel to the study site).</P>
<P>The ITT analysis of the primary outcome variables for the TWSTRS and adverse events was done for all participants examined at week 4.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-03 22:40:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pappert-2008">
<DESCRIPTION>
<P>Postrandomisation exclusions were low and roughly distributed evenly between groups (BtA group = 8; BtB group = 10).</P>
<P>The reasons for exclusion were presented. Five of the exclusions in the BtB group, and all of them (8) in the BtB group, were due to ;protocol violations', which were not specified. However, the authors describe that &#8220;all 13 subjects that were excluded for protocol violations in the PP population were from one site where the study personnel had not been appropriately trained.&#8221;</P>
<P>The data reported included only those according to the PP principle, despite the authors claiming that there were no differences between PP and ITT.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-09-30 09:42:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tintner-2005">
<DESCRIPTION>
<P>Quote: &#8220;20 subjects with cervical dystonia responsive to BTX-A were randomized and completed the study&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2016-10-03 23:24:15 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-05 11:34:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Comella-2005">
<DESCRIPTION>
<P>The expected outcomes that are usually evaluated in intervention trials for this condition were reported in this study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-05 14:49:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pappert-2008">
<DESCRIPTION>
<P>The expected outcomes that are usually evaluated in intervention trials for this condition were reported in this study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-03 23:24:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tintner-2005">
<DESCRIPTION>
<P>Although the report refers, in the methods section, to having selected several outcomes, only 2 of these were reported in the results. Moreover, due to inherent BtA properties the outcome assessment usually lasted at least until the week 16 after the treatment section.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2016-01-06 19:14:44 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="STUDY" MODIFIED="2016-10-03 21:27:19 +0100" MODIFIED_BY="[Empty name]" NO="11">
<NAME>For-profit bias</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-03 21:25:36 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Comella-2005">
<DESCRIPTION>
<P>Quote: &#8220;Supported primarily by an unrestricted research grant from Allergan Inc., Irvine, CA.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-03 21:26:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pappert-2008">
<DESCRIPTION>
<P>Quote: &#8220;Eric J. Pappert, MD and Terry Germanson, PhD for The Myobloc/Neurobloc European Cervical Dystonia Study Group&#8221;</P>
<P>Quote: &#8220;The first named author (EJP) is an employee of Solstice Neurosciences, Inc. maker of MYOBLOC® (BoNT-B) and took charge of the publication and analysis after the study was completed. (&#8230;) The statistical consultant (TG) is an independent contractor paid for her analytic time by Solstice Neurosciences, Inc. and has nothing further to disclose.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-03 21:27:19 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tintner-2005">
<DESCRIPTION>
<P>Trial report refers to this study having been supported by a grant from Allergan Inc.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2016-10-03 21:26:35 +0100" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Enriched population - exclusive enrolment of positive responders</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-03 21:25:36 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Comella-2005">
<DESCRIPTION>
<P>Quote: &#8220;All subjects were followed up in outpatient clinics and had previous successful treatment with BoNTA, with a subjective report of at least 30% benefit.&#8221;</P>
<P>Quote: &#8220;At the baseline visit, the PI evaluated the UBI [unilateral brow injection], and excluded subjects with UBI indicating clinical resistance (no effacement of brow wrinkling). Subjects were then randomized to either BoNTA or BoNTB&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-03 21:26:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pappert-2008">
<DESCRIPTION>
<P>Quote: &#8220;Exclusion criteria included: (&#8230;) previous treatment with BoNT&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-30 09:42:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tintner-2005">
<DESCRIPTION>
<P>Subjects were required to be known responders to the effects of BTA within the past year.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2016-10-03 21:27:44 +0100" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Enriched population - exclusion of poor responders</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-03 21:25:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Comella-2005">
<DESCRIPTION>
<P>Quote: &#8220;Subjects were also excluded if they had predominant anterocollis or retrocollis&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-03 21:26:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pappert-2008">
<DESCRIPTION>
<P>Quote: &#8220;Exclusion criteria included: pure antero- or retrocollis&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-03 21:27:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tintner-2005">
<DESCRIPTION>
<P>No reference made to exclusion of poor responders.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2016-10-03 23:37:04 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2016-10-03 23:37:04 +0100" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2016-09-06 14:03:49 +0100" MODIFIED_BY="[Empty name]">Botulinum toxin type A versus botulinum toxin type B for adults with cervical dystonia</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Botulinum toxin type A compared to botulinum toxin type B for adults with cervical dystonia</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Patient or population: </B>adults with cervical dystonia<BR/>
<B>Settings: </B>hospital-based, movement disorders clinics<BR/>
<B>Intervention: </B>botulinum toxin type A<BR/>
<B>Comparison: </B>botulinum toxin type B</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="3" ROWSPAN="1" VALIGN="TOP">
<P>Anticipated absolute effects<SUP>*</SUP> (95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>What happens</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>With botulinum toxin type A</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>With botulinum toxin type B</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Difference</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Overall cervical dystonia improvement:</B> change from baseline to week 4 assessed with TWSTRS total score<BR/>Scale (range, 0 to 85; more is worst)<BR/>&#8470; of participants: 231<BR/>(2 RCTs)</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>9.1 TWSTRS units decrease</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>10.5 TWSTRS units decrease</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>The mean change from baseline was 1.44 TWSTRS units higher (0.7 lower to 3.58 higher) in the BtB group compared to the BtA group</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>LOW <SUP>1, 2 </SUP>
</B>
</P>
<P>Due to study limitations and imprecision</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>There may be little or no difference in the overall cervical dystonia improvement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>
<B>Participants with adverse events</B>
<BR/>&#8470; of participants: 111<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.40</B>
<BR/>(1.00 to 1.96)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>47.3%</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>66.2%</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>18.9% more adverse events<BR/>(0 fewer to 45.4 more)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>LOW <SUP>3</SUP>
</B>
</P>
<P>Due to imprecision</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>There may be little or no difference in the risk of adverse events</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Subjective change as assessed by the patient at week 4 </B>
</P>
<P>assessed with: PGA<BR/>Scale (range, -4 to 4; more is worst)<BR/>&#8470; of participants: 138<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>1.6 PGA units decrease</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>1.4 PGA units decrease</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>The mean subjective change in the BtB group was 0.2 PGA units lower (0.17 lower to 0.57 higher) compared to the BtA group</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>LOW <SUP>2, 4</SUP>
</B>
</P>
<P>Due to study limitations and imprecision</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>There may be little or no difference in subjective assessment</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Cervical dystonia associated pain: change from baseline to week 2-4</B>
<BR/>assessed with TWSTRS pain sub-scale<BR/>Scale (range, 0 to 20; more is worst)<BR/>&#8470; of participants: 251<BR/>(3 RCTs)</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>2.63 TWSTRS units decrease</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>3.45 TWSTRS units decrease</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>The mean change was 0.83 TWSTRS units higher (1.75 lower to 0.09 higher) in the BtB group compared to the BtA group</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>LOW <SUP>2, 4</SUP>
</B>
</P>
<P>Due to study limitations and imprecision</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>There may be little or no difference in the risk of cervical dystonia-associated pain</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>
<B>Adverse events: sore throat/dry mouth</B>
<BR/>&#8470; of participants: 212<BR/>(2 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>
<B>RR 4.39</B>
<BR/>(2.43 to 7.91)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>10.5%<BR/>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>46.7%</P>
<P>(25.5 to 82.9)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>35.5% more</P>
<P>(15 more to 72.4 more)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>MODERATE<SUP> 2, 4</SUP>
</B>
</P>
<P>Due to study limitations and imprecision</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>BtB treatment probably increases the risk of sore throat/dry mouth</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>
<B>Adverse events: dysphagia</B>
<BR/>&#8470; of participants: 249<BR/>(3 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>
<B>RR 2.89</B>
<BR/>(0.80 to 10.41)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>10.2%<BR/>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>29.4%</P>
<P>(8.1 to 100.0)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>19.2% more </P>
<P>(2 fewer to 95.6 more)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>LOW <SUP>2, 4, 5</SUP>
</B>
</P>
<P>Due to study limitations, imprecision, and inconsistency</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>There may be little or no difference in the risk of dysphagia</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*<B>The risk in the intervention group</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).</P>
<P>
<BR/>
<B>BtA: </B>botulinum toxin type A; <B>BtB:</B> botulinum toxin type B; <B>CI:</B> confidence interval;<B> PGA:</B> Patient Global Assessment; <B>RCT:</B> randomised controlled trial; <B>RR:</B> risk ratio; <B>TWSTRS: </B>Toronto Western Spasmodic Torticollis Rating Scale</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>GRADE Working Group grades of evidence</B>
<BR/>
<B>High quality:</B> we are very confident that the true effect lies close to that of the estimate of the effect.<BR/>
<B>Moderate quality:</B> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<BR/>
<B>Low quality:</B> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<BR/>
<B>Very low quality:</B> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Serious imprecision: 95% CI includes both appreciable benefit and no effect. This means that we cannot conclusively state the equivalence of these two formulations.</P>
<P>
<SUP>2</SUP> Serious study limitations: the limitations in the studies assessing this outcome are serious and affect our confidence in the accuracy of the effect estimate.</P>
<P>
<SUP>3</SUP> Very serious imprecision: the total number of participants included was less than the number generated by a conventional sample size calculation for a single adequately powered equivalence trial. 95% CI includes both appreciable benefit and harm meaning that we cannot conclusively state the equivalence of these two formulations.</P>
<P>
<SUP>4</SUP> Serious imprecision: the total number of participants included was less than the number generated by a conventional sample size calculation for a single adequately powered equivalence trial.</P>
<P>
<SUP>5 </SUP>Serious inconsistency: high degree of heterogeneity expressed by I<SUP>2</SUP> and low overlap of 95% CI.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2016-10-09 11:44:02 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2016-10-03 21:27:44 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2016-06-08 01:39:31 +0100" MODIFIED_BY="[Empty name]">Glossary of terms</TITLE>
<TABLE COLS="2" ROWS="8">
<TR>
<TH>
<P>
<B>Term</B>
</P>
</TH>
<TH>
<P>
<B>Definition</B>
</P>
</TH>
</TR>
<TR>
<TH>
<P>
<B>BtA-non-responsive</B>
</P>
</TH>
<TD>
<P>People who do not experience the expected benefit from treatment with botulinum toxin type A</P>
</TD>
</TR>
<TR>
<TH>
<P>
<B>Cervical dystonia or spasmodic torticollis</B>
</P>
</TH>
<TD>
<P>A common movement disorder in which people have abnormal movements or postures of the head and neck that they cannot control. It is frequently accompanied by social embarrassment and pain.</P>
</TD>
</TR>
<TR>
<TH>
<P>
<B>Chemodenervation</B>
</P>
</TH>
<TD>
<P>The process by which botulinum toxin causes muscular paralysis. Although all the anatomical elements necessary for muscular control are intact (i.e. nerve, synapse and muscle), there is a chemical process that disables the transmission of the electrical signal from the nerve to the muscle.</P>
</TD>
</TR>
<TR>
<TH>
<P>
<B>Dysphagia</B>
</P>
</TH>
<TD>
<P>Discomfort or difficulty when swallowing</P>
</TD>
</TR>
<TR>
<TH>
<P>
<B>Electromyography</B>
</P>
</TH>
<TD>
<P>An examination that displays the electrical activity of muscles using pieces of metal attached to the skin or inserted into the muscle</P>
</TD>
</TR>
<TR>
<TH>
<P>
<B>Non-naive</B>
</P>
</TH>
<TD>
<P>People who have been treated in the past with botulinum toxin</P>
</TD>
</TR>
<TR>
<TH>
<P>
<B>Voluntary action</B>
</P>
</TH>
<TD>
<P>Movements that are normally under a person's control, that can be started and stopped at will</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2016-10-09 11:44:02 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2016-10-09 11:36:29 +0100" MODIFIED_BY="[Empty name]">Percentage of BtB-treated participants with adverse events of special interest: Comella 2005 versus Marques 2016 versus current review</TITLE>
<TABLE COLS="4" ROWS="3">
<TR>
<TH>
<P>Adverse event of special interest</P>
</TH>
<TH>
<P>
<LINK REF="STD-Comella-2005" TYPE="STUDY">Comella 2005</LINK>
</P>
</TH>
<TH>
<P>
<LINK REF="REF-Marques-2016" TYPE="REFERENCE">Marques 2016</LINK>
</P>
</TH>
<TH>
<P>Current review</P>
</TH>
</TR>
<TR>
<TH>
<P>Sore throat/dry mouth</P>
</TH>
<TD>
<P>48%</P>
</TD>
<TD>
<P>17%</P>
</TD>
<TD>
<P>47%</P>
</TD>
</TR>
<TR>
<TH>
<P>Dysphagia</P>
</TH>
<TD>
<P>80%</P>
</TD>
<TD>
<P>16%</P>
</TD>
<TD>
<P>29%</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<LINK REF="REF-Marques-2016" TYPE="REFERENCE">Marques 2016</LINK> is a Cochrane systematic review that studied efficacy and safety of BtB compared to placebo</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-10-03 23:31:57 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2016-10-03 23:31:57 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Botulinum toxin type A versus botulinum toxin type B</NAME>
<CONT_OUTCOME CHI2="0.34424855303093627" CI_END="0.701118447699465" CI_START="-3.5758291131855824" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.4373553327430588" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2016-09-29 17:05:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5573872706582493" P_Q="1.0" P_Z="0.1877140863983761" Q="0.0" RANDOM="YES" SCALE="7.37" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="120" TOTAL_2="111" UNITS="" WEIGHT="100.0" Z="1.3173716278064505">
<NAME>Overall cervical dystonia improvement as assessed with validated scales: change from baseline to week 4</NAME>
<GROUP_LABEL_1>BtA</GROUP_LABEL_1>
<GROUP_LABEL_2>BtB</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BtB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.8919940410209244" CI_START="-3.6919940410209215" EFFECT_SIZE="-0.8999999999999986" ESTIMABLE="YES" MEAN_1="9.3" MEAN_2="10.2" MODIFIED="2016-02-18 20:38:08 +0000" MODIFIED_BY="[Empty name]" ORDER="1057" SD_1="8.3" SD_2="8.4" SE="1.424512931382319" STUDY_ID="STD-Comella-2005" TOTAL_1="73" TOTAL_2="65" WEIGHT="58.664974404380025">
<FOOTNOTE>Change in total TWSTRS score at week 4. Botox 250 U; Myobloc 10000 U.</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="1.1261729270441387" CI_START="-5.526172927044137" EFFECT_SIZE="-2.1999999999999993" ESTIMABLE="YES" MEAN_1="8.8" MEAN_2="11.0" MODIFIED="2016-02-18 20:38:23 +0000" MODIFIED_BY="[Empty name]" ORDER="1058" SD_1="8.2268" SD_2="8.1388" SE="1.6970581874363844" STUDY_ID="STD-Pappert-2008" TOTAL_1="47" TOTAL_2="46" WEIGHT="41.335025595619975">
<FOOTNOTE>Adjusted mean change in total TWSTRS score at week 4. BtA 150 U; BtB 10000 U. SE -&gt; SD</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.6292480287267379" CI_END="0.7493273566628629" CI_START="-1.2699234378834552" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.2602980406102962" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2016-09-29 17:05:20 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7300633619998096" P_Q="1.0" P_Z="0.6133404437744696" Q="0.0" RANDOM="YES" SCALE="6.84" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="131" TOTAL_2="120" UNITS="" WEIGHT="100.0" Z="0.5053109660478309">
<NAME>Cervical dystonia associated severity: change from baseline to week 2-4 as assessed with validated scales</NAME>
<GROUP_LABEL_1>BtA</GROUP_LABEL_1>
<GROUP_LABEL_2>BtB</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BtB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.3575361689793544" CI_START="-1.3575361689793544" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="3.7" MEAN_2="3.7" MODIFIED="2016-08-28 22:31:17 +0100" MODIFIED_BY="[Empty name]" ORDER="51" SD_1="3.9" SD_2="4.2" SE="0.6926332216752075" STUDY_ID="STD-Comella-2005" TOTAL_1="73" TOTAL_2="65" WEIGHT="55.31179018916495"/>
<CONT_DATA CI_END="0.8653797088385362" CI_START="-2.2653797088385366" EFFECT_SIZE="-0.7000000000000002" ESTIMABLE="YES" MEAN_1="4.7" MEAN_2="5.4" MODIFIED="2016-08-28 23:22:09 +0100" MODIFIED_BY="[Empty name]" ORDER="52" SD_1="3.8" SD_2="3.9" SE="0.7986777926462179" STUDY_ID="STD-Pappert-2008" TOTAL_1="47" TOTAL_2="46" WEIGHT="41.59883168933215"/>
<CONT_DATA CI_END="6.744136259492892" CI_START="-4.744136259492892" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="2.0" MODIFIED="2016-08-29 10:13:44 +0100" MODIFIED_BY="[Empty name]" ORDER="50" SD_1="7.928" SD_2="5.087" SE="2.930735618002119" STUDY_ID="STD-Tintner-2005" TOTAL_1="11" TOTAL_2="9" WEIGHT="3.0893781215028913"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.6391724917167718" CI_END="0.8591266362544941" CI_START="-1.190358860611112" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.16561611217830896" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2016-09-29 17:05:26 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7264495975204501" P_Q="1.0" P_Z="0.7514226805239205" Q="0.0" RANDOM="YES" SCALE="15.4" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="131" TOTAL_2="120" UNITS="" WEIGHT="99.99999999999999" Z="0.31676400308805563">
<NAME>Cervical dystonia associated disability: change from baseline to week 2-4 as assessed with validated scales</NAME>
<GROUP_LABEL_1>BtA</GROUP_LABEL_1>
<GROUP_LABEL_2>BtB</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BtB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.3097856230127387" CI_START="-1.5097856230127389" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="2.5" MODIFIED="2016-08-28 23:30:24 +0100" MODIFIED_BY="[Empty name]" ORDER="56" SD_1="3.6" SD_2="4.7" SE="0.7192915962400064" STUDY_ID="STD-Comella-2005" TOTAL_1="73" TOTAL_2="65" WEIGHT="52.835223977010564"/>
<CONT_DATA CI_END="1.1448019322677114" CI_START="-1.9448019322677113" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="2.9" MODIFIED="2016-08-28 23:30:48 +0100" MODIFIED_BY="[Empty name]" ORDER="57" SD_1="3.9" SD_2="3.7" SE="0.7881787341261941" STUDY_ID="STD-Pappert-2008" TOTAL_1="47" TOTAL_2="46" WEIGHT="44.003183694211955"/>
<CONT_DATA CI_END="7.763176485319901" CI_START="-3.7631764853199012" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="4.0" MODIFIED="2016-08-29 10:17:48 +0100" MODIFIED_BY="[Empty name]" ORDER="58" SD_1="6.239" SD_2="6.78" SE="2.9404501974419435" STUDY_ID="STD-Tintner-2005" TOTAL_1="11" TOTAL_2="9" WEIGHT="3.161592328777472"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9564861326643792" CI_START="0.9984568552990856" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.397664835164835" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.2914767740211701" LOG_CI_START="-6.706968527292327E-4" LOG_EFFECT_SIZE="0.14540303858422043" METHOD="MH" MODIFIED="2016-10-03 22:06:20 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.051061230921551716" Q="0.0" RANDOM="YES" SCALE="2.24" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="55" WEIGHT="100.0" Z="1.9509648193447404">
<NAME>Proportion of participants with adverse events</NAME>
<GROUP_LABEL_1>BtB</GROUP_LABEL_1>
<GROUP_LABEL_2>BtA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BtB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9564861326643792" CI_START="0.9984568552990856" EFFECT_SIZE="1.397664835164835" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="26" LOG_CI_END="0.2914767740211701" LOG_CI_START="-6.706968527292327E-4" LOG_EFFECT_SIZE="0.14540303858422043" MODIFIED="2016-09-06 13:31:52 +0100" MODIFIED_BY="[Empty name]" ORDER="153" O_E="0.0" SE="0.17160887054463256" STUDY_ID="STD-Pappert-2008" TOTAL_1="56" TOTAL_2="55" VAR="0.029449604449604455" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.5676733998434991" CI_START="-0.16767339984349872" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2016-10-03 22:06:26 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.28635855861413306" Q="0.0" RANDOM="YES" SCALE="1.05" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="73" TOTAL_2="65" UNITS="" WEIGHT="100.0" Z="1.0661440209568165">
<NAME>Subjective change as assessed by the patient at week 4</NAME>
<GROUP_LABEL_1>BtA</GROUP_LABEL_1>
<GROUP_LABEL_2>BtB</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BtB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.5676733998434991" CI_START="-0.16767339984349872" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="1.4" MODIFIED="2016-06-15 15:40:41 +0100" MODIFIED_BY="[Empty name]" ORDER="154" SD_1="1.1" SD_2="1.1" SE="0.18759191635339206" STUDY_ID="STD-Comella-2005" TOTAL_1="73" TOTAL_2="65" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.839480190442318E-32" CI_END="0.601098254374726" CI_START="-0.2010982543747261" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.19999999999999993" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2016-10-03 22:06:31 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="1.0" P_Z="0.3284213160719669" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="73" TOTAL_2="65" UNITS="" WEIGHT="100.0" Z="0.9772986858770806">
<NAME>Subjective change as assessed by clinician at week 4</NAME>
<GROUP_LABEL_1>BtA</GROUP_LABEL_1>
<GROUP_LABEL_2>BtB</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BtB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.601098254374726" CI_START="-0.20109825437472606" EFFECT_SIZE="0.19999999999999996" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="1.8" MODIFIED="2016-06-15 15:43:00 +0100" MODIFIED_BY="[Empty name]" ORDER="155" SD_1="1.2" SD_2="1.2" SE="0.20464572693097313" STUDY_ID="STD-Comella-2005" TOTAL_1="73" TOTAL_2="65" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.15624463468140504" CI_END="0.09062960291106192" CI_START="-1.7494528948160388" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8294116459524885" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2016-10-03 22:06:31 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.9248513169958413" P_Q="1.0" P_Z="0.07724569220314316" Q="0.0" RANDOM="YES" SCALE="9.12" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="131" TOTAL_2="120" UNITS="" WEIGHT="99.99999999999999" Z="1.76689573041747">
<NAME>Cervical dystonia associated pain: change from baseline to week 2-4 as assessed with validated scales</NAME>
<GROUP_LABEL_1>BtA</GROUP_LABEL_1>
<GROUP_LABEL_2>BtB</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BtB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7041184539052228" CI_START="-2.3041184539052226" EFFECT_SIZE="-0.7999999999999998" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="4.0" MODIFIED="2016-08-28 23:26:03 +0100" MODIFIED_BY="[Empty name]" ORDER="53" SD_1="4.5" SD_2="4.5" SE="0.7674214759911493" STUDY_ID="STD-Comella-2005" TOTAL_1="73" TOTAL_2="65" WEIGHT="37.41541084388887"/>
<CONT_DATA CI_END="0.3864477832273234" CI_START="-1.9864477832273235" EFFECT_SIZE="-0.8" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="2.6" MODIFIED="2016-08-28 23:26:46 +0100" MODIFIED_BY="[Empty name]" ORDER="54" SD_1="2.6" SD_2="3.2" SE="0.6053416249410051" STUDY_ID="STD-Pappert-2008" TOTAL_1="47" TOTAL_2="46" WEIGHT="60.13361866007038"/>
<CONT_DATA CI_END="3.876764088222976" CI_START="-7.876764088222976" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="6.0" MODIFIED="2016-08-29 08:58:34 +0100" MODIFIED_BY="[Empty name]" ORDER="55" SD_1="5.44" SD_2="7.53" SE="2.998404120982906" STUDY_ID="STD-Tintner-2005" TOTAL_1="11" TOTAL_2="9" WEIGHT="2.4509704960407293"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.26055947423318393" CI_END="7.907292565016157" CI_START="2.43174792400085" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="4.385036177666656" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.8980278077264919" LOG_CI_START="0.3859185537876307" LOG_EFFECT_SIZE="0.6419731807570613" METHOD="MH" MODIFIED="2016-10-03 23:31:28 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.609736091006422" P_Q="1.0" P_Z="8.925119869290831E-7" Q="0.0" RANDOM="YES" SCALE="26.61" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="107" TOTAL_2="105" WEIGHT="100.0" Z="4.913968273944447">
<NAME>Adverse event: sore throat/dry mouth</NAME>
<GROUP_LABEL_1>BtB</GROUP_LABEL_1>
<GROUP_LABEL_2>BtA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BtB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.142714308132627" CI_START="1.8886454710130396" EFFECT_SIZE="3.9215686274509802" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="7" LOG_CI_END="0.9107691975856518" LOG_CI_START="0.27615044154643775" LOG_EFFECT_SIZE="0.5934598195660448" MODIFIED="2016-10-03 23:31:28 +0100" MODIFIED_BY="[Empty name]" ORDER="151" O_E="0.0" SE="0.3727781987109408" STUDY_ID="STD-Comella-2005" TOTAL_1="51" TOTAL_2="50" VAR="0.13896358543417367" WEIGHT="65.1177581682844">
<FOOTNOTE>Cases of newly-diagnosed sore throat/dry mouth at week 4 in comparison to baseline.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="14.65813139074591" CI_START="1.9906554338490197" EFFECT_SIZE="5.401785714285714" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="4" LOG_CI_END="1.1660786102497107" LOG_CI_START="0.29899609371486385" LOG_EFFECT_SIZE="0.7325373519822873" MODIFIED="2016-09-06 13:39:44 +0100" MODIFIED_BY="[Empty name]" ORDER="152" O_E="0.0" SE="0.5093285623402485" STUDY_ID="STD-Pappert-2008" TOTAL_1="56" TOTAL_2="55" VAR="0.25941558441558443" WEIGHT="34.882241831715604"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.796912934410418" CI_END="10.406818033531877" CI_START="0.8024678700427601" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.889833403726054" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="13" I2="74.34882219636796" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="1.0173179608532665" LOG_CI_START="-0.09557234726262706" LOG_EFFECT_SIZE="0.46087280679531967" METHOD="MH" MODIFIED="2016-10-03 23:31:57 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.020273214442787624" P_Q="1.0" P_Z="0.1045188832598703" Q="0.0" RANDOM="YES" SCALE="65.22" SORT_BY="YEAR" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.9458726366880651" TOTALS="YES" TOTAL_1="121" TOTAL_2="128" WEIGHT="100.0" Z="1.6233299835308597">
<NAME>Adverse event: dysphagia</NAME>
<GROUP_LABEL_1>BtB</GROUP_LABEL_1>
<GROUP_LABEL_2>BtA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BtB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2>
<DICH_DATA CI_END="25.66428009076448" CI_START="2.568508994105171" EFFECT_SIZE="8.119047619047619" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="3" LOG_CI_END="1.4093290863644212" LOG_CI_START="0.40968109082477355" LOG_EFFECT_SIZE="0.9095050885945972" MODIFIED="2016-10-03 23:31:57 +0100" MODIFIED_BY="[Empty name]" ORDER="1112" O_E="0.0" SE="0.5871981809173726" STUDY_ID="STD-Comella-2005" TOTAL_1="56" TOTAL_2="62" VAR="0.34480170367267143" WEIGHT="33.11031012429068">
<FOOTNOTE>Cases of newly-diagnosed dysphagia at week 4 in comparison to baseline.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="12.183256756916101" CI_START="0.7663320193745725" EFFECT_SIZE="3.0555555555555554" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0857633968762719" LOG_CI_START="-0.1155830280943962" LOG_EFFECT_SIZE="0.48509018439093776" MODIFIED="2016-09-06 13:40:26 +0100" MODIFIED_BY="[Empty name]" ORDER="1082" O_E="0.0" SE="0.705676836788482" STUDY_ID="STD-Tintner-2005" TOTAL_1="9" TOTAL_2="11" VAR="0.49797979797979786" WEIGHT="29.597642150071074"/>
<DICH_DATA CI_END="2.6550013399559913" CI_START="0.45982187209125974" EFFECT_SIZE="1.1049107142857142" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.4240647446021757" LOG_CI_START="-0.33741037473132635" LOG_EFFECT_SIZE="0.04332718493542468" MODIFIED="2016-09-06 13:40:43 +0100" MODIFIED_BY="[Empty name]" ORDER="1083" O_E="0.0" SE="0.4472942544591313" STUDY_ID="STD-Pappert-2008" TOTAL_1="56" TOTAL_2="55" VAR="0.20007215007215007" WEIGHT="37.29204772563824"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.65525559173229" CI_START="0.007418633742896445" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.14035087719298245" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.4241063320978338" LOG_CI_START="-2.1296760694589296" LOG_EFFECT_SIZE="-0.8527848686805478" METHOD="MH" MODIFIED="2016-09-29 17:06:31 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.19054043974308438" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="55" WEIGHT="100.0" Z="1.3089820245888653">
<NAME>Adverse event: injection site pain</NAME>
<GROUP_LABEL_1>BtB</GROUP_LABEL_1>
<GROUP_LABEL_2>BtA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BtB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BtA</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.65525559173229" CI_START="0.007418633742896445" EFFECT_SIZE="0.14035087719298245" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4241063320978338" LOG_CI_START="-2.1296760694589296" LOG_EFFECT_SIZE="-0.8527848686805478" MODIFIED="2016-09-06 13:41:49 +0100" MODIFIED_BY="[Empty name]" ORDER="150" O_E="0.0" SE="1.500104424101209" STUDY_ID="STD-Pappert-2008" TOTAL_1="56" TOTAL_2="55" VAR="2.25031328320802" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-10-07 00:13:40 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-10-07 00:13:40 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>BtA vs BtB in Cervical Dystonia Flow Diagram. </P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAloAAALmCAYAAACaUzrkAABfqElEQVR42uzdD2RXbeD//w9JkiQy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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2016-10-03 23:38:08 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA1IAAAGWCAMAAABFHkK+AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2016-10-03 23:38:08 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAe0AAAKjCAIAAAC/bMAtAAAog0lEQVR42u3dsY5cRdqH8ZaQEMEE
DnwFXMNEaEQEEfcE4QSWIPRdIC5hhXdD44gMsTteYQcO7N1sYa3zzXg+odmec7rPdNdbXW/V75GD
2Yb9e6hT9Zy3quvU2WwAANmZAAA54XEA4HEAAI8DAHgcAHgcAMDjAAAeBwDwOADwODDCANAI4HGA
ygEeB047ABxTAR4HAPA4AIDHgYPHwIdRYCyAx4F8A2DpB4DHAR4HeBzgcYDHgVVjwKZD8DgAgMeB
EwwAjQAeR9qrbiWBysHjSHq913w45i3NcACPI3HhqRsAPA4A4HFUuNhWEvY1i64CHgcyDYC7PxgL
4HEgt8epHDyONGsImoLHweNI7Cy2WlK5ZgGPg8cB8Dh4HACP41Qez7iBz6ZD8DiyXeyY/eNJn/if
/Z11FfA4hq70H/pPeRzgcfRv22rNYiyAx5Hjeq/58JBulPCJf2cVgMeR+aoTFsDjAAAeR281/taH
uX5zYwE8jnG70dbPWfqV81XA48CMxxP1KB4HjyO3c+PqcR4HeByZVJ56C7bdO+Bx5LzkReXlURqA
x9HhvSHLc0AuH3gcSD8GNAJ4HLnL52gVNn5OlifyweNIX36OfG4twOPg8dhKHwCPo6rHU/Z+/R88
jrz+Gvnq2ysJHgd4HOBxnNpfI1uMx8HjSHuxw3baJT1ZhcfB40hfj2cJz3VXA3gcndT7mgXgcdQQ
rjYBeByZLvndH3K9tQcAjyP2zQlxZb5eCvA4wj0et6PRyjvA41hUedliPF0RbcsKeBzI7fFpYSO5
QQEex9j9KWZ9PCJ56d5jUIDHYSUhR6XP4+BxZL3qESsJ9W0bV+kbFOBx5Kttj+kG9U9u0WkBHufx
8isJ0Se32E8C8DisJKyaSegh4HG4Q2RdVzEWwOMYvTPd/aFIv6p/uqzhAB5H656t8G1khSf+K9yN
AB7H6PX4lPO5fNcRPI40to2oQINObiFcgMcxr8IsTow7M13nB4+jh3o80e8cdGa6XgEeB3bV+y17
3P5x8Dhyl+Shb+0p69y43xngcSSWePHadvYTHQzgcfB48ACwogIeB4/v0GLQg51xNx6Ax5Hjqicy
V8QvuZRpOIDHAR4HeBw5PRu6h694L+Vx8DjyX/U8m0ki7hA8Dh5H7tp5qrhfJdG9wXAAj2NQj3Mi
wOPosx4vlekOseMiGr8wJAa+6oToTgweB9SJPA4ex2kueRa/RK+8Z3ykk8fB4/gfP2bxy+xJii3f
IardjI1f8LgekPI9yxnf4AzwOFqvx+PqxKQHWvm2ADyO1gvwk9x4srzBuc65kqYU4HEYAJvo5LhV
Jkvk4PHhr3rMaVYRdWIF2/I4eBwq0KxvtQ9NDm0KHgeP83imCjRuFTvvvkNP5ILHqTxTPQ6Ax1Gj
AlUnzraGWxp4HKix73DKs4rt9EfwOAI7U1Dy3k9as22u84HB40hZ0lYob3mcx8HjUJ5n9fgUvBak
g4HHEV71h04mUiTXnFrpeAadToC2CnAoxsHjQLdVswELHkfK+X7x2PpvGlKSg8cxrrlCzx8v/qah
Cq1hfRw8jmRFYs33AaVQOcDjSKbyvB5XNYPHUWli3v58P92+w+j1cbcH8LiSeXJ+U8apyZT2baXg
cUR5nAXSqZzHweMueXmP19wJE/2kaIp3X/A4eNxV39y9/OmqWltKrI+Dx5F+acKzkQCPg8fDVa5q
Bo/DrLxGPZ5xFTv0CwPwOPJVuOlUnuWV9nH3nowNAh5HDr8ElbdJjwjncfA4aigm7j01Wfanx73V
3rsvwOOI1VbxwnmpTmy5g3kqCjwO8Hgr7QweB6Lm+8N6vPj6VfRzs+Bx5KiXM1og9Jesdt6hZ5fA
49BZ7VcBeBy1VBvq3FzTiOij2A1h6ASDXvWIIjG6I9131rCb05X54HESDxFB9BJ29tao+WYJ8Dh4
fBShRLRG/V0lhrBBzeOjXvUM67YVnJhulcniOHgc6acR0fcegwI8DoSvG6TbrGKggcfR9MQ8+gmj
DvZix80h9GfoCmrblPeeiOToxim1S7KPCwoeR4seT7r6sfRDgy1f4S134HEMqvK83xbGeTzofRo8
Dh5H1VXsRL9zrtMZeRw8DvOJxZtEuv924xc8jtjCOYXKKzTFsDce8DjKu6/aGkX7ez9UzeBxYJfH
p+a/M6z2nlIqB48jRyWb9J3FEQfh8jh4HD2oPOk70tTj4HEkueRJviuL3pkedIewPg4eB+pJsM4p
vkG/szsEeBwhZlGE1rmr5foeAjyOQNuWrZfv7m4s+DuH/v48Dh5HvtWJ4k+mzGo37ncOfZUEj4PH
MbrHKyS3fyZMnXmV8Qse53Ee1/nB4+DxzB6fqhzTOAUsBOnP4PGBL3a2t9pvRYXuDkx0Iq5FFfA4
UGn2E/1tpCEMHgdSelw9Dh6Hrh/+LrrQWFcQPA4APA6gbtUc/SYQ8DjSXPK9n0guPMAMMfA4oDyv
du8BjwOIqscrfDcLHkcyuSR6lXu65LiRZcCCx11yq9jWKMDj4HHJ+zKjd6a78YDHqTzEApJT34nB
40h1yVOdlpU0Od3sBDwOIPbesPRXaHNdTj8AQoaWRgCPo161KFl5Cx6HslHyrrS4x/2NX/A4CDck
ucL3nNFvqACPg8d5nMfB44i75PGbKAZPniKf+Odx8DjQ1c1Yg+gP+gEA8DhUc5KXkydLH+BxlL3k
ez+RXDC54Cr2jhO4jGIe1wN4XHICjz/0vwU8Dh6XnMnj4HGMd9WtYksGjwPoaUYFHkdWC0jmcfA4
qFzydmDorhLvdQOPu+ROlw1PjrhtVHhDBXgcAMDjQKdTHw0CHkeIXApaRvJW8t5PCv7OOrZBrRMM
d9Xv/1xcXoMnV9tVYvyCx4eW+N1P4sw1ZvJUcVeJIWxQ8ziP83jJ5Pq7Sgxhg5rHR73q/yuXiOXm
wZPrXD7jF/oBAPA4gHVlPsDjQJpxtfeTY0bs1q1Cg+tv+gEQK/FSKl/aAGMI63I8DvA4eBwZr3rA
+38l8zh4HPWqxeJ77CTvEGvog0WGsEHN4zzO4yHJEftV7u9zN37B4zzO4yHJAI8j/qp7s3BwMsDj
AAAeBwAeR7dXPfJbOMkAjyPwkks+SXLx72Yr/FeAx8Hj4yYDPA4qp3KAx7H7qlvFrpscdwV1aSNa
P1CMS66RbH0cPA5O5HEeB4+DcE+UXHxdhcTB48Nf8oAFVsl7k4vkxyWDxwEAPA4A4HE8dGIuuc52
xvbXgnC/qe+2OY+jua654xPJFZq9/WQjZekHHgePj+hxKudxHgeP8ziP8ziPY+uqW8WOTHbQbjcj
pf2bpX4AAF1UZhoCALbkyOPI0UGzPC+eNNl5h1TO46jRNX3PKRl7b5Ytq5LHeZwTJaOLW46GGLnQ
kBy0q4THweOA+2XtZMy282TfIVq75FYS1LZY3zc8B4R2y8MUJ2LnPcXb05s8zuOY0llAMpXzOI8D
nc9+Gk/G7qZu/fd0wfhFMici96DWECaPkq1XgMdB5ZL3VPpFwr1k+SRzVs9zgsdHTJ49uaWUyoOS
sbedeRwt1hqSaz7PWWTHZFAy1rQzjwOjW4DHeZzHgaxTn4IuiEvG3nbmcfTcNSUDPI7EU0XJAI/j
BBIvJS/JGGHyan0cPM7j6GG88Dh4nMfB4zyOol3T+njc0I17C0GW9xtQOY8j8pLbVRKfvPRDs8nY
0TesjwPjlnI8Dh4HeJzHweNAAxPzFMnI2M76AQDsmvfs+ITHAYDHeRwt9U7Ju2flKZLB4wDCx7wB
W9uP1scBHudx8DjSVBmSqRw8jhrXe82HkovfIayPq3h4HLFF3DHdQLJifITx4ntOwF2Tx3mcx1G6
g4YeDiWZyntSuXUVNCrxsh1U8szQClhgTXQOX/aRsgSPg8eHSAZ4HDzO4wCPY+dVj9CW5B0T8xTJ
WLrNWx8HxlXAjk9aS0bSuRqPAzwOHkfCDpruOcN0yTzO4zyOSr2zrBAl77hDpEjG/XZu/2apH6gy
7FfJUXMBPA625XHwOHpUuafn6zyXnyUZM34MWHPjcSDTzbK4cH3PmX3myuMAj/M4j/P42P0y4twf
ybtn5far8DiPA8Dp/Oh9QMDg1dyOT1pLRu77jYZQZUgulRx3bnWiE7G7vBPzONSJoycP6Bcq53Hw
uDUKtDJtbVmVPD66yj35EpTsvW7gcVSqLxpft+1mrdkyC3gc6GoaROXgcYDHeRw8DlQYWqleqQEe
B4A+b8aT8w4BIKPEl37gcfRcZUi+H+uQLB7ncaTpnZLvx+74pLVk8Dj0Tsl7xNpyMlJPfXicx3mc
x9HF/UZDqDIkFzzvkMe7GSY8Dow+6SmuWuvjpyp64qbFxQ6ZcLUAkx7UKc+Lr+bpCqNXi847jEuG
epzHYcpvmQI9FOA8Dh7ncfR8k7A+jqOmivarTJabsXB39z4gAMDaWSCPAznGqrUgVzDokvH4oB00
3dHYjvPGCQdI429Y1XFVGZKB3H2Dx/VOyZXKuhTJSDyB0BBULrn4uFrzYTvJ2OoSoftVyp56z+Oj
3rozrPolTd6dcEx+XDJOUkh5DggAeJzHgVrDNe6ADuM33RXkcYQsJkiOWLEpO1YrJKNaOxdfyuPx
oXtnXJUhmcd5vGpl5prpnZIlg8fB45JnRleEAuKSEdrOQU+K8vjoKs/y/ZvvDNHlGJzsHweA1BIv
onIeB2Jn5c726uYK8jj4ZazkjHtsEGrbuDsEj+udkmOT7Vfh8UqVmWvW2syLx3mcx3mcxyu13ZoP
qZzK7bFRpe1Itj7eogobb1Kr2HWSgTp+0HH1IckAj7skqWa4bBudHPcWggrvN8COuVqzHU8nKCbx
RPUd4SrJcUDH8J5lHm+0xPA+ILUtKns8alC7ZkPV4+hgVu7GU1nlLbezflCmBRNJ3NLHqZKL7x9P
oZhubsNlb5ye5wQtJkjmcVS7gjyuyrA+vqlwHFLcbgfjl8d5vLwItIkuETQfD53pg8dHvx5OngM6
9mz0zb5MmitXxONTnq860+2jsPcDlcd1os6g7w7n8Yzfv/nOEKetdRq/zfN4SZUn3XfI4zyONX2j
2Vkgj+udPM7jyD0Gedyc0fp4jjOm6ySjQt/g8bbuqLl2gHlIp2bd7WAvVfPKcOsqOOTeI3mK35PA
4zy+fjp1ZBXI40PPE+POixg8mcp5/ATj2jUr5YKMvVNytVtm48lIOrp1glHu2GyrsEWDw9C+Qx4n
XCpHbokX6YQ8XtICGR/Kd95htd2BA873weP5bKgxUWGu5tklHudxgMdx4nYu+x4xHh96MjEFvN9A
Mo+bbZ/mF3blzOkkB9Vc1se7qcdbv/G4ZjwuWW2LpHNiHudxHudxrJr3NNvreLzRK13zd5Zc/HH/
KWZHY8bT2ayr8Pi4VxoAj/M4j6OtvmG/igEeNAvk8RFVbvUjNDlu15qnz044TOw7dKXViZLNAhF1
BXlcH2JblkRulfP46H2oeH+SnDoZsxPuKfIBseMlzOOFL0m6XzjF6m3SZHOIPsqd9p8t4HEjCsn6
RoXzm3x9yuPGaprfttRvLrmyE+OOYl/zIY/zOI/3OVYld9aTzTIn7+d0pVv2i13eVhLQ7F2Tx1VG
aPEeP6U6jX3keUlSlfM4EDtQnf7YzWy72bfC8vhRPT76Lb0qIx7n8W5WP8LvN0bdOBYAj+t1PI5d
V9qIwtL0OVGyLhfdAs47bHGItv/GkMnzlnWvILoc5m3WfzpuuzMvlZG5WuVkVCvGeRwYdK5WYQ5h
dsLjo1/sLC2ZdF9zruSM549vzf+Ywfq4uXOjlZF9FHWSU/dnrTF5HxCPt1wZsW01c+WdQ/B4yluO
hmhkfsSJkk9+77nbsQ1w6ypovU50mpU7MVauqNh3CJWROzGPg8ebv3UbTsg7h6hwXhB4fMTVj5rT
RsnMhbx3Yh23OY9HV0ap9zUnSoaqufb9xjUbpx5n2+jknp7nNLp53MyLyiWH/C1ByU5uqdYa1lXc
IcrXdJLb31uWOtkYDG1nHjenQ7IrGF0n6nLp+gaPl6zjUlRzyF7NTTH7Dp3GXnPElb1f8niObhRq
AfsOmQs1VV78rqnjqvQT1C/p9qsE/Y1xyVg5Epv+VV2z4y/2lOchIMl1Cq41H7aTjPQW0hBHWiDd
85yS6ySnOzWsWnnLHjzO4y3OFiWjszlExJNcPM7jQFfmanm8xH13UjyZx80WgQRW7aY1InYxsM9A
lVGFe49k5lozeR38BAv1uBFVPtmT6JKrmcs3SYG/Km+2VmXweN7kvOcdVnhqwTdJEbNAHm+3d1ab
0/F4neQUqx8ZR0oHs23r4332zqRnTEvG7nbOJfGgp/x4XJWBrHPnjKfNGN1T5JuyeVyVgWRz54zJ
Vj+msFVT6+MjVnNBHVRyB99Up/B4uudmE822eTxkLEU8Bdf+zgHJ2VVerdc5E4bHW1xR2f0hj4+Z
nPFMmOg3mVmE5PGB7tg83kE9Du3M465N7E67iOEkGWtUrp15HEh2J57C3sxXKvnPKKf4nqRKs+8Q
B5ZFkuskWwtCdK/j8UavcfR3WYQbnZz624KCjZO60q/2PCeP49gJnfcB5ToZKiI5+gSu1FVz+3tS
eby8CJqtjHDavtF+sj5W7U5sfbzFKx1dL7tMcFfrqR63rtK5xyv0mET7KFInp+vJFVaZctX+nuek
8hFni5J3T63aT642TBym6JysRi9G3GJliiekJWefq9V5P2euYjzFXY3Hh6tf2JbHa4Zn/74n9MBR
HufxVuZ0krtRuW/X65TnPN760kqKZJykb4y8Pt7BRWzZGzpBu1UzOusbGZMHfw4o2eKPUTdUv7f6
USE5l8c9tdDDpEFDNOjxLO/qltxNSU4Fd9sh4q4WlMzjrVdzKc5Ckryywm0/uWZrMI96fJRKP/qM
nrgdGpLzliPVnocgHx7n8bZGrORuel2F5BQHIcS9w6hsMo8fdRkyvvEWLNDCHaJ9jyd6+owjgNEt
sHuCElqX8DiPt1tlAB2cUuAoKx7v/xpbsUXfHqfyuKlD2WSCKFyPA+ksUMfj6pLwslJDmENI5pcp
7BtUkuHxZHIsnjzZi23/uJlrG3VPm8k8XnIe6nlOyRVq24jk3SEV/oqRb0XWx9vy+JTz/QaSQ5Oz
9I1ZFRS8T3SwftWsynl8OI9PTiWskqxvdDzeebxnlXuPBLJ7HDvmEM0mcwQQK4II1WZ5JHKqcoIF
NGij8yyFRgfJAI+PrvJ0O3klY307N36ySq6nFni8/FUpLvGy/Z5tq9kk9AmAoORETgSPp6lfot8j
QbjR70hz3qF5D4/zeI33SEjOOKNKdN5h3m+Sgv4TyibzeOtzZ+WMO3E3lX5eiQe1c6lkHm+336Ob
e7xnlzKuj/M4j0eVLUEPSQf5xb7D1F2aGbLciXXcFuuX6JMu7v4QV80NngzUvt9oCHNnyWWTp4Tv
WY4+/THXpMe6CoabQ0hOnRy9yzvpm2y91w05VJ6iTkxd26Y+0zhFpV/T5m0m83jh2aLGRF6PZ1yj
qGPwoFXTUsnU02j9gm7u8e3PyuvUJdbH45J53DwUmK/0dblkqwIaoh2VO1cIjXicyrOcdEYQ5Z3b
eKWPk2hx8O9mp8zrKu1/w8Hj/GK/iv0q9VojUaXC4wgp9of1i+Tsqx88zuM5bDtlOyKcuSSfSuVZ
nON8leEWKILGKo9Pyd/JEHFBiydXeJ7Tt/fh9xsN0aYFQq96Cr+kTk7dpbUGj/N4SP2iwVFN4lTO
4+O1oKfUJK+4GTeeXKc13B54HIVr/JJfs0henqtlOTM93WnJ4PEc2p2y7YSRPNmv0pHH2+9+PB5S
06lfwOM8zuNTxmsc8ZbOCk9IS66wmJDl6dZqRU/SMc7jnUv87icte9zqR51koPY9UkO05vEp/hsn
tuXxDkpa8HjUbLHxJiVcitnbn6eAnTCal8cRcuOJfvZ62OTUVbPn2ngcUcLVJkjqcWMwNJkghlv6
QB9rFKHPFkTsvErXzxMt5fH4iB63O7BCcuozGiMWr9Z8yOM8TuWHWCDF8+IdJE/OH0+4SJhF5Tye
YO6sTpTcgcfzDu32v13n8dbHasbfWXJ0BVotmRwy3XI0xDgen7wNuVZy3v4MHudxgwo83pEfvZ/T
lS41vXWZsveNXGd7IdHbSwiCXzaSnWMTfYfI+JJlHofeKdlRM4vhKXba8PigWow45jDROxglZxdu
zV84xYs6rY+rbQe690iuuUYxJVwfT+rxRCLi8bE87p3I1ZIzrqtUu/ckqnt4fJgW9EQG8nscW3OF
oLu75zmHs4DpJ5VTOXi8B49P5U4QTVRlJE2OXqOov/ox5vzSfpVx11WchYSeJhApzpmoMKgb/z6G
x9vtnc79AI93ObqdPz6Qx+v82nYHVtt32H5y0t304PHheqendSSf5A6Rcf+V93OOdBsMvtLRZREn
SsaOdm7/LVQ8nqMPTd5vYI2Cx3sZg8WTeXxEj+Mk07UsyWVvD9H7O3mcxxOsfvA46ptLpX9/9LX8
FioeH2j1w9M6fdSJGT3uDlGjmtQQqmaEanHYvZLR5zCDx0f0uB0aklvodQm06HnO4e6ESb5xcq5s
tTrRHcIqinrchfG+sdzJU6r9KhVWP3iGx3mcx833E69+JN13mOXESh5vt3fWWbEh3MpvMms5GUl7
II8PV9w5cTs6OfWavl0lGVXuUpmnwwSixl/Uwe2Bx43eAsWR5kXS/lznRNyWjyQMTSaIdq900l9b
cvQaRc3Vj0Q7Gkd+Fo/Hx53BtX8aZ+rkjMssNesSHudxKm+x30vuQOXVZoHt9+cpzxMAPF5+hhu3
M4FteTyvx6OHYYTEo+cQpZJ5vOQlydKSWU7jTJ2c8auCqYtdJTyOVq400Fl/zniHyHJiJY/r90C+
CrTCBCXR81wc0ahtk94hJKdOTn2SYvSOowQWomOVkWTJU6pzmGc9Ptl3CB6X7D0SFaatxd/PN9l3
yONFrseU5zyKpO8by5XM4/WLnmFXmXh8uDmdd/fUSZ5yrryDx3ncvkOg9syVx3m8XY9nfMIIqDZS
/rwlJH2Xi/Xxdpcp2q8FgPpVs5lrjaumIUaY0zk5RPKpbMvjPK7SL/a1W9D4kZw9uYJtPW8Vl8zj
Jbt+3s0qkiVPafdfBc1afM85osTz9nvJkqMr0JqtwePo3+NAxwXEmE+f8fiIHreeKLl+BZrrGa7J
eYejqTydxM1DJVd2ImpUZhqi/aqZuSTXTwaPo8URxVySwePI7fHJirDkFcluDzwOk1wk7nL2j/M4
yhdcLhOye7x4pe+cZB4PFK42AY/XT44u9u0ft/QBpKxLUlT61Ua35zl5vJURBfRR6UefP87jVN50
H3I4lOQOKv0K/8nOOxx0Hppij/Ds2lzxoSU5UXLG5zltjuTx1tdV6s/pIt5TITlXcrRoKlRRYwqN
x9ud2VU+C4kTJVebvKYbg1PAfpWCyTzedDeqeYeIWLqV3EdylvI8aGi3vwuTx8tP6zQLuilK4orQ
RDNXHseB19gdAj15PK4DV/gmiceRYxohWfJ9oQx+nv5k3+GwTkxUZVQYUZLTJRffAZL3aZ18FqLj
dvpQhbdVMZdktRSPI3HVTF6SO1v9qHaHaHZljMeH652V30srOVFyhLnMLysk83i7czr7VXDyuiTF
BKLaThgex4FX2iES6MDjGeeXiVTO4zk8PrV9zqfk7MmVzdW4c7wPaNDllLhVv0Tn7qPLjh10e9Cf
1eONTkWDDgByjZB9XSXp0zo8Pmi/b//sUO+llVzf41PCJ+Ym7+fk8cHnEJI7SB58DHqv23gzmuCD
lZM+8S85XXLG3a5GCo+rMiRLrlrxTJGL46GvQm22/uPx4TyeqHdKrp8c3Z/tvwq8R2qIguXAsGMV
/fVnHufxEatmwCzwJB4vftdJ9CQXj4/ocW9OkFzZ4xXmlyN7jMfb7T2DHxkhuYXkRHJoucCv8Kvy
eMmyKONuB+aSXK1qTtcaKZJ5PE3vVJJLTlomhz6DOkWeW5vlBHkeH87j3pwg2Zy4z0bgzYLdaNgZ
LjorIPQ6Hh+r03vbA8wCV9YliUaK93OO6PGp+fMOJ29OkHwKj4eOFDu7eLy53lnheyHgVE4s7nE7
u3i8cAfVkkA3Hp/sO0T7pZZ3MkjuqdKPqMftO4R1FfTQ/Ya9Q+S7arrvMb2nzkQMqLb6AR4frsff
3UUQep3K3nuCpoqSkyZPwQ9G7qh+2h/dpdonKJnHy1yP6CeDx+ydkqslx6m8TmvwOI+XvB4RNdew
vVNyZY/H7Xmv2Ro8jrb6EI9LrlyPd1Db8jjU45J5nMd5fBiPV9gdWGHXqr3Ykqdab52/+z/1Z/vH
B71taAcAPA4APA4A4HEAAI8DAHgcAHi8/6YBgDbg8UM8LlmyZMntJ/O4PiRZsmQe53HJkiVL5nEe
lyxZsmQed6UlS5bM49CHJEuWzOPjePztH28vry4vXlw8+uujzV82Z8/Ozp+ff/P3b978/qbZ5Pfv
3757d/n69cXLl4/+8Y/N1dXZq1fnb99+8/79mwFbQ3L25D/evr26vHxxcfHXR4/+stk8Ozt7fn7+
92+++f1Nu8kRY5DHD7weT397+vhvj6875f0/1531u39+12Dyv//99OXLx9dd5/6f6y71r399N1Rr
SM6e/NvTp397/HgueHMt339+12Jy0Bjk8UNa7bqUmO2Xd/9c/ztNJV/f8Gd7z90/1//OIK0hOXvy
dWm8L3hz/e80lRw3Bnn8wR6/ri/2ds3bP0u1Rv3k6ypgbwe6/bNUEfTUGpKzJ1/Xy+uCN0u1c/3k
uDH4MI9HvO9m9rdc/1fM/koHfDj7N85++PaPt0uTxNlp4+v/vD558vv3b+9O5X78cfP555tPPrn5
89VXm59+2p7c/fe/rztuDcnZk/94+3Zp0WN2GeQ/r0+fHDcGH+bxCi8DfKjHZ3+l9R/u/Ytm/+nl
1eXKrrljzlg5+d27y7u95NNPb674Dz9svv/+5ofPPls1s+umNSRnT766vHxI8PwaSOXkuDH4AI/f
/xe2bLgV8ucLgne8kW/p/7U3fP09YP2H6z1+8eJi5nreMnepz5+fnzz59euL2enbL7/cZH/88fbn
r16dd9wakrMnv7i4eJBtn5+fPjluDB7l8b1F8dLPa8S6t44u5fHdN4nZz283Tq3vnWfPzk6efLu9
aevPzz9vvvjiJvvbb7f/0dXVWcetITl78u1GwPV/np2dPjluDMZ6/JjVj/Wr1UX+ugf9jfP98i73
rvbJk2cLgS+/vIn8+uv5b1o6bg3J2ZPv+/TxnuDTJ8eNwRN7/H45vHtdpbjH93fEruvxjz66Cf71
15kOpB6XrB6vUI8XGYNl1sePr8dXFuYrVz+iPd7T+vjSH+vjkq2P11kfP34MltmvErqusuNr0pVf
wBaXewf7VW7/3LL+SQT7KCTbr1Jqv0rBMfgwj+/YOrJj58nun9fvV1lS9uyqy5Gbyne3Wgf7x3f3
IfvHJds/Hr1/vOAYfLDHR8PznL22huTsyZ7n5PFjPT45XyV/a0jOnux8FR4/1uO3tcb8N/IfJolP
Xj5pMPnDWWuPls9aezJUa0jOnnxdOy/tMLn+/OWTFpODxiCPH3g9puVTlWdX+hpJXjr7eHY9rvvW
kJw9eemU8NmV60aSI8Ygjx9+PSRLliy5hWQe14ckS5bM4zwuWbJkyTzO45IlS5bM4660ZMmSeRz6
kGTJknm8J48DQDvwuFpAsmTJ6nEelyxZsmQe53HJkiVL5nEelyxZsmQe14ckS5bM4zwuWbJkyTye
2+NL55a9f//myOSl8+He/C5ZclRyxv68dCrh72/GamceP/B6fDhH+PHyOcLfHZz89LenSy/Euu5S
S29OkSz5mOSM/fm3p0+XXsN2rfWl9/V02c48fkirebeO5J6SM/bnuLf2ZGxnHn+wx73rUrJ3t572
d457i2bGdj7E4yufE61j1dlf48gPd/+NW++9/vHHzeefbz755ObPV19tfvrJu+clZ0rO2J/j3mqf
sZ0P9/iDFvXjPH73kz9/PvLDvf9p795d3m3xTz+9ab0ffth8//3ND599tmqWNJt8eXW5sgPtmNlJ
lvyg5Iz9+ery8iHB86sr3bRzeY/fL29vf17z4d7/+95jYup4/PXri9mp0C+/3Px6H3+8/fmrV+cr
ky9eXMz0lVvm+tD5c8mSj03O2J9fXFw8yOPPz3tu58IeX3Ll/X9h6cOV//fTenz2Xdc//7z54oub
X/Xbb7f/0dXV2crk+XeKL/ehs2eSJR+bnLE/L73JfunPs7Oe2zlwfbyUVfeqdve/tjfngPXx2Zvq
l1/ehHz99fy3FmvX+md7z13udSPJko9Mztif7xv18Z7gntu5TD2+pPgDlL3y/17K4wXr8Y8+uvmd
f/115mKoxyWnq8cb78/d1ONF2rmwxwuW3nsFvX69vtr6+NIf6+OSM66Pt9yfe1ofP76dozy+VVAf
uT7+UNVW3q9y++eW9bv67aOQ3OZ+lRT9uYP9KgXbOWpd5b4rj9yvct/+u1fqa+4f33097B+XnGv/
eIr+3MH+8YLtfKDHH8T6OrdBPM8p2fOcnufs83lOHp+cryLZ+Sqn/p2dr1LP46lZcW7Zo+Vzy54c
nHxdEcx/b/5hKvfkpWTJ5ZMz9ufrqnxp78r15y+fDNTOPH7g9ZiWzxGeXdt6UPLS2cez63GSJRdJ
ztifl84fn10T77idefzw6yFZsmTJLSTzuD4kWbJkHudxyZIlS+ZxHpcsWbJkHnelJUuWzOPQhyRL
lszjPXkcANqBx9UCkiVLVo/zuGTJkiXzOI9LlixZMo/zuGTJkiXzuD4kWbJkHudxyZIlS+bx3B5f
Orfs/fs3kiWnS1464e/N78cmL51K+PubEZMj2pnHD7weH84Rfrx8jvB3kiUnSn7629OlV5pd62bp
3Tdrkn97+nTpNWzXilx6X0+vyUHtzOOHtFrcez0kS66fnPGtPRmT49qZxx/s8bj37EmW7C2avSbH
tfOxHl96cnR3YMHbxuzjqgd8uP49olvvvf7xx83nn28++eTmz1dfbX766fD3XkuWXD8541vtMybH
tXPJevxBCaU8fjfnz5/Xf3jY/ebdu8u7Y+bTT29a74cfNt9/f/PDZ5+tmudKltxI8uXV5Uq57Jj1
zyZfXV4+JHh+paKb5Lh2DvT4lkDv/hX3y/Y1tfPeMv8Aj+/9r579F16/vpidzP7yy80v/PHH25+/
enUuWXKzyRcvLmY8csucX86fr01+cXHxICc+P+85Oa6dK3n8vjdX/tOlf7Ogx3efIjb7+ey7rn/+
efPFFzc53367/Y+urs4kS242ef6t8Mt+OXu2NnnpTfZLf56d9Zwc18716vEdHi9SO+9dNnnQYsvu
D2fLoi+/vGnDr7+e/95JsuRmk+fNcpd7ilmZfN9Oj/cE95wc187tevx+pRzh8f1Nv7oy+uijm1/1
119nhtORNZdkyaHJ6nH1eHg9vvI/4LAvPw/z+NJK5dKf49dAJUuOS7Y+bn389Osq9z+PXlfZ2jlw
++eW9c9lSJbcSLL9KvarHO7x+/tPtn6e3a8y/6vP/cvHbCrf/Zdu7eTdPaKO2SMsWXKFZPvH6yTn
2D/eJZ4GlOx5Ts9z9v8855gen5zOIdn5KuuSna9Sp515/BCPT/9/8tyj5ZPnnkiWnCj5ulqc31Px
YZr/5OXhydcV7tI+kOvPXz4ZKzmonXn8wOsxLZ8EPbs6KVly48lL52LPrtU+KHnpLO/Z9eXukyPa
mccPvx6SJUuW3EIyj+tDkiVL5nEelyxZsmQe53HJkiVL5nFXWrJkyTwOfUiyZMk83pPHAaAdeBwA
ui46NQQA8DgAgMcBADwOADwOAOBxAACPAwDWehwAkJf/A0r6XNm6cOcIAAAAAElFTkSuQmCC
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2016-10-03 23:38:08 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Botulinum toxin type A versus botulinum toxin type B, outcome: 1.1 Overall cervical dystonia improvement as assessed with validated scales: change from baseline to week 4.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAyQAAADACAMAAADC6Vc/AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2016-02-19 23:04:17 +0000" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2016-10-07 00:36:13 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2016-10-07 00:26:54 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2016-01-03 20:18:49 +0000" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-10-07 00:26:54 +0100" MODIFIED_BY="[Empty name]">
<P>#1 MeSH descriptor: [Botulinum Toxins] explode all trees</P>
<P>#2 Botulinum Toxins, Type A</P>
<P>#3 (botul* near/2 tox*):ti,ab</P>
<P>#4 (botox or dysport or xeomin or myobloc or rimabotulinum* or abobotuli* or onabotulinum* or oculinum or purtox or CNBTX or Neuronox):ti,ab</P>
<P>#5 {or #1-#4}</P>
<P>#6 MeSH descriptor: [Dystonic Disorders] explode all trees</P>
<P>#7 MeSH descriptor: [Dystonia] explode all trees</P>
<P>#8 MeSH descriptor: [Torticollis] explode all trees</P>
<P>#9 MeSH descriptor: [Blepharospasm] explode all trees</P>
<P>#10 MeSH descriptor: [Meige Syndrome] explode all trees</P>
<P>#11 MeSH descriptor: [Hemifacial Spasm] explode all trees</P>
<P>#12 (cervic* near/2 dysto*):ti,ab</P>
<P>#13 blepharosp*:ti,ab</P>
<P>#14 (hem* near/2 spasm*):ti,ab</P>
<P>#15 (meige and (dysto* or syndrom*)):ti,ab</P>
<P>#16 (crani* near/2 dysto*):ti,ab</P>
<P>#17 (foca* near/2 dysto*):ti,ab</P>
<P>#18 (write* and (cramp* or dysto*)):ti,ab</P>
<P>#19 torticol*:ti,ab</P>
<P>#20 {or #6-#19}</P>
<P>#21 #5 and #20</P>
<P>#22 MeSH descriptor: [Animals] explode all trees</P>
<P>#23 MeSH descriptor: [Humans] explode all trees</P>
<P>#24 #22 not #23</P>
<P>#25 #21 not #24 in Trials</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2016-10-07 00:32:42 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2016-01-03 20:16:48 +0000" MODIFIED_BY="[Empty name]">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-10-07 00:32:42 +0100" MODIFIED_BY="[Empty name]">
<P>#1 randomized controlled trial.pt.</P>
<P>#2 controlled clinical trial.pt.</P>
<P>#3 randomized.ab.</P>
<P>#4 placebo.ab.</P>
<P>#5 clinical trials as topic.sh.</P>
<P>#6 randomly.ab.</P>
<P>#7 trial.ti.</P>
<P>#8 1 or 2 or 3 or 4 or 5 or 6 or 7</P>
<P>#9 exp botulinum toxins/</P>
<P>#10 exp botulinum toxins, type A/</P>
<P>#11 (botul$ adj2 tox$).ti,ab.</P>
<P>#12 (botox or dysport or xeomin or myobloc or rimabotulinum$ or abobotuli$ or onabotulinum$ or oculinum or purtox or CNBTX or Neuronox).ti,ab.</P>
<P>#13 9 or 10 or 11 or 12</P>
<P>#14 (cervic$ adj2 dysto$).ti,ab.</P>
<P>#15 blepharosp$.ti,ab.</P>
<P>#16 (hem$ adj2 spasm$).ti,ab.</P>
<P>#17 (meige and (dysto$ or syndrom$)).ti,ab.</P>
<P>#18 (crani$ adj2 dysto$).ti,ab.</P>
<P>#19 (foca$ adj2 dysto$).ti,ab.</P>
<P>#20 (write$ and (cramp$ or dysto$)).ti,ab.</P>
<P>#21 torticol$.ti,ab.</P>
<P>#22 exp dystonic disorders/</P>
<P>#23 exp dystonia/</P>
<P>#24 exp torticollis/</P>
<P>#25 exp blepharospasm/</P>
<P>#26 exp meige syndrome/</P>
<P>#27 exp hemifacial spasm/</P>
<P>#28 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27</P>
<P>#29 8 and 3 and 28</P>
<P>#30 exp animals/ not humans/</P>
<P>#31 29 not 30</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2016-10-07 00:36:13 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2016-10-05 23:01:44 +0100" MODIFIED_BY="[Empty name]">Embase search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-10-07 00:36:13 +0100" MODIFIED_BY="[Empty name]">
<P>#1 random$.tw.</P>
<P>#2 clinical trial:.mp.</P>
<P>#3 placebo$.mp.</P>
<P>#4 double-blind$.tw.</P>
<P>#5 1 or 2 or 3 or 4</P>
<P>#6 exp Hemifacial Spasm/</P>
<P>#7 exp Meige Syndrome/</P>
<P>#8 exp blepharospasm/</P>
<P>#9 exp torticollis/</P>
<P>#10 exp Dystonia/</P>
<P>#11 exp Dystonic Disorders/</P>
<P>#12 (cervic$ adj2 dysto$).ti,ab.</P>
<P>#13 blepharosp$.ti,ab.</P>
<P>#14 (hem$ adj2 spasm$).ti,ab.</P>
<P>#15 (meige and (dysto$ or syndrom$)).ti,ab.</P>
<P>#16 (crani$ adj2 dysto$).ti,ab.</P>
<P>#17 (foca$ adj2 dysto$).ti,ab.</P>
<P>#18 (write$ and (cramp$ or dysto$)).ti,ab.</P>
<P>#19 torticol$.ti,ab.</P>
<P>#20 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18</P>
<P>#21 exp Botulinum Toxins, Type A/</P>
<P>#22 exp Botulinum Toxins/</P>
<P>#23 (botul$ adj2 tox$).ti,ab.</P>
<P>#24 (botox or dysport or xeomin or myobloc or rimabotulinum$ or abobotuli$ or onabotulinum$ or oculinum or purtox or CNBTX or Neuronox).ti,ab.</P>
<P>#25 21 or 22 or 23 or 24</P>
<P>#26 19 and 20 and 25</P>
<P>#27 limit 26 to human</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2016-02-19 23:04:17 +0000" MODIFIED_BY="[Empty name]">
<EXTENSION ID="AFF_z1309131050199323179683584225320_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="z1309131050199323179683584225320">
<ADDRESS>
<DEPARTMENT>Clinical Pharmacology Unit</DEPARTMENT>
<ORGANISATION>Instituto de Medicina Molecular</ORGANISATION>
<ADDRESS_1>Avenida Professor Egas Moniz</ADDRESS_1>
<ADDRESS_2/>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION/>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_z1408111518211702342261129499685_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="z1408111518211702342261129499685">
<ADDRESS>
<DEPARTMENT>Clinical Pharmacology Unit</DEPARTMENT>
<ORGANISATION>Instituto de Medicina Molecular</ORGANISATION>
<ADDRESS_1>Av. Prof. Egas Moniz</ADDRESS_1>
<ADDRESS_2/>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION/>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_6005_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="6005">
<ADDRESS>
<DEPARTMENT>Clinical Pharmacology Unit</DEPARTMENT>
<ORGANISATION>Instituto de Medicina Molecular</ORGANISATION>
<ADDRESS_1>Avenida Professor Egas Moniz</ADDRESS_1>
<ADDRESS_2/>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION/>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_FDF5556E82E26AA201D6C2758D661DA8_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="FDF5556E82E26AA201D6C2758D661DA8">
<ADDRESS>
<DEPARTMENT>Clinical Pharmacology Unit</DEPARTMENT>
<ORGANISATION>Instituto de Medicina Molecular</ORGANISATION>
<ADDRESS_1>Avenida Professor Egas Moniz</ADDRESS_1>
<ADDRESS_2/>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION/>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_z1309131047147899672215461982225_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="z1309131047147899672215461982225">
<ADDRESS>
<DEPARTMENT>Clinical Pharmacology Unit</DEPARTMENT>
<ORGANISATION>Instituto de Medicina Molecular</ORGANISATION>
<ADDRESS_1>Av. Prof. Egas Moniz</ADDRESS_1>
<ADDRESS_2/>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION/>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_z1307091141448665579807736261374_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="z1307091141448665579807736261374">
<ADDRESS>
<DEPARTMENT>Clinical Pharmacology Unit</DEPARTMENT>
<ORGANISATION>Instituto de Medicina Molecular</ORGANISATION>
<ADDRESS_1>Av. Prof. Egas Moniz</ADDRESS_1>
<ADDRESS_2/>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION/>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;3 (all new) studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;3 studies included in qualitative synthesis&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;3 full-text articles assessed for eligibility&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;1599 records screened&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;1599 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;1646 records identified in total&lt;/p&gt;" WIDTH="199">
<FLOWCHARTBOX TEXT="&lt;p&gt;208 records identified through CENTRAL database search&lt;/p&gt;&lt;p&gt;182 records identified through MEDLINE database search&lt;/p&gt;&lt;p&gt;1256 records identified through Embase database search&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through other sources&lt;/p&gt;&lt;p&gt;&lt;/p&gt;"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;1596 records excluded&lt;/p&gt;"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;0 full-text articles excluded&lt;/p&gt;"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>